{"b6f77e50a5926b1b4ac50e374df5a368e9e02967": [["As an important antibacterial agent, quinolone has been widely concerned by human beings.", [["quinolone", "CHEMICAL", 37, 46], ["quinolone", "CHEMICAL", 37, 46], ["quinolone", "SIMPLE_CHEMICAL", 37, 46], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["an important antibacterial agent", "TREATMENT", 3, 35], ["quinolone", "TREATMENT", 37, 46]]], ["As a fully synthetic drug, quinolone drugs have also played a great role in the field of antibacterial and anticancer [1] [2] [3] .", [["anticancer", "ANATOMY", 107, 117], ["quinolone", "CHEMICAL", 27, 36], ["quinolone", "CHEMICAL", 27, 36], ["quinolone drugs", "SIMPLE_CHEMICAL", 27, 42], ["anticancer [1] [2] [3]", "SIMPLE_CHEMICAL", 107, 129], ["a fully synthetic drug", "TREATMENT", 3, 25], ["quinolone drugs", "TREATMENT", 27, 42], ["antibacterial and anticancer", "TREATMENT", 89, 117]]], ["Since the first synthetic quinolone drug was put into clinical practice in 1962, this family has a history of nearly 60 years, and it has indeed become a veteran role of antibacterial drugs [4] [5] [6] [7] [8] .", [["quinolone", "CHEMICAL", 26, 35], ["[4] [5] [6", "CHEMICAL", 190, 200], ["quinolone", "CHEMICAL", 26, 35], ["quinolone", "SIMPLE_CHEMICAL", 26, 35], ["[4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 190, 209], ["the first synthetic quinolone drug", "TREATMENT", 6, 40], ["antibacterial drugs", "TREATMENT", 170, 189]]], ["The most primitive discoveries often give people infinite enlightenment, guide future generations to design and synthesize based on this drug and have had very successful cases, but also stimulated experts to explore their molecular level mechanism of action [9] [10] [11] [12] [13] [14] .", [["people", "ORGANISM", 42, 48], ["[9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 259, 287], ["people", "SPECIES", 42, 48], ["most primitive", "OBSERVATION_MODIFIER", 4, 18]]], ["For the design and development of any pharmacy, relevant internal mechanism research is often indispensable [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .", [["[15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25]", "CHEMICAL", 108, 162], ["[15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25]", "SIMPLE_CHEMICAL", 108, 162]]], ["As of now, it is well known that the target of quinolone drugs is topoisomerase, and the target of antibacterial action is topoisomerase II.", [["quinolone", "CHEMICAL", 47, 56], ["quinolone", "CHEMICAL", 47, 56], ["quinolone", "SIMPLE_CHEMICAL", 47, 56], ["topoisomerase", "GENE_OR_GENE_PRODUCT", 66, 79], ["topoisomerase II", "GENE_OR_GENE_PRODUCT", 123, 139], ["topoisomerase", "PROTEIN", 66, 79], ["topoisomerase II", "PROTEIN", 123, 139], ["quinolone drugs", "TREATMENT", 47, 62], ["topoisomerase", "TREATMENT", 66, 79], ["antibacterial action", "TREATMENT", 99, 119]]], ["The main mechanism of its anticancer activity has recently been discovered as an inhibitor of topoisomerase I [5, 26, 27] .", [["anticancer", "ANATOMY", 26, 36], ["anticancer", "CANCER", 26, 36], ["topoisomerase I", "GENE_OR_GENE_PRODUCT", 94, 109], ["topoisomerase I", "PROTEIN", 94, 109], ["main", "OBSERVATION_MODIFIER", 4, 8], ["anticancer activity", "OBSERVATION", 26, 45]]], ["DNA topoisomerase plays an important role in the regulation of DNA transcription, replication and gene expression.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["topoisomerase", "GENE_OR_GENE_PRODUCT", 4, 17], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["DNA topoisomerase", "PROTEIN", 0, 17], ["DNA topoisomerase", "TREATMENT", 0, 17], ["DNA transcription", "TREATMENT", 63, 80]]], ["Studies have found that DNA topoisomerases in cancer cells exhibit high levels of expression independent of other factors.", [["cancer cells", "ANATOMY", 46, 58], ["cancer", "DISEASE", 46, 52], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["cancer cells", "CELL", 46, 58], ["DNA topoisomerases", "PROTEIN", 24, 42], ["cancer cells", "CELL_TYPE", 46, 58], ["Studies", "TEST", 0, 7], ["DNA topoisomerases in cancer cells", "PROBLEM", 24, 58], ["high levels of expression", "PROBLEM", 67, 92], ["high", "OBSERVATION_MODIFIER", 67, 71]]], ["Quinolone derivatives exhibit cytotoxicity by intercalating DNA and thus interfere with the DNA replication process, and have achieved initial success in drug design.", [["Quinolone", "CHEMICAL", 0, 9], ["Quinolone", "CHEMICAL", 0, 9], ["Quinolone derivatives", "SIMPLE_CHEMICAL", 0, 21], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["DNA", "CELLULAR_COMPONENT", 92, 95], ["Quinolone derivatives", "TREATMENT", 0, 21], ["cytotoxicity", "PROBLEM", 30, 42], ["intercalating DNA", "PROBLEM", 46, 63], ["the DNA replication process", "TREATMENT", 88, 115]]], ["For example, some anticancer agents based on topoisomerase I have been launched in the early 21st century.", [["anticancer", "ANATOMY", 18, 28], ["anticancer", "CANCER", 18, 28], ["topoisomerase I", "GENE_OR_GENE_PRODUCT", 45, 60], ["topoisomerase I", "PROTEIN", 45, 60], ["some anticancer agents", "TREATMENT", 13, 35], ["some", "OBSERVATION_MODIFIER", 13, 17], ["anticancer", "OBSERVATION", 18, 28]]], ["Belotecan hydrochloride, led by Chong KunDang, has shown outstanding advantages for the treatment of non-small cell lung cancer and ovarian cancer.", [["non-small cell lung cancer", "ANATOMY", 101, 127], ["ovarian cancer", "ANATOMY", 132, 146], ["Belotecan hydrochloride", "CHEMICAL", 0, 23], ["non-small cell lung cancer", "DISEASE", 101, 127], ["ovarian cancer", "DISEASE", 132, 146], ["Belotecan hydrochloride", "CHEMICAL", 0, 23], ["Belotecan", "SIMPLE_CHEMICAL", 0, 9], ["non-small cell lung cancer", "CANCER", 101, 127], ["ovarian cancer", "CANCER", 132, 146], ["Belotecan hydrochloride", "TREATMENT", 0, 23], ["the treatment", "TREATMENT", 84, 97], ["non-small cell lung cancer", "PROBLEM", 101, 127], ["ovarian cancer", "PROBLEM", 132, 146], ["non-small cell", "OBSERVATION", 101, 115], ["lung", "ANATOMY", 116, 120], ["cancer", "OBSERVATION", 121, 127], ["ovarian", "ANATOMY", 132, 139], ["cancer", "OBSERVATION", 140, 146]]], ["The latter irinotecan hydrochloride developed by Yakult and Pfizer has emerged in the fight against the small cell lung cancer, gastric cancer and solid cancer.", [["small cell lung cancer", "ANATOMY", 104, 126], ["gastric cancer", "ANATOMY", 128, 142], ["solid cancer", "ANATOMY", 147, 159], ["irinotecan hydrochloride", "CHEMICAL", 11, 35], ["Yakult", "CHEMICAL", 49, 55], ["Pfizer", "CHEMICAL", 60, 66], ["lung cancer", "DISEASE", 115, 126], ["gastric cancer", "DISEASE", 128, 142], ["solid cancer", "DISEASE", 147, 159], ["irinotecan hydrochloride", "CHEMICAL", 11, 35], ["irinotecan", "SIMPLE_CHEMICAL", 11, 21], ["Yakult", "SIMPLE_CHEMICAL", 49, 55], ["Pfizer", "SIMPLE_CHEMICAL", 60, 66], ["small cell lung cancer", "CANCER", 104, 126], ["gastric cancer", "CANCER", 128, 142], ["solid cancer", "CANCER", 147, 159], ["The latter irinotecan hydrochloride", "TREATMENT", 0, 35], ["the small cell lung cancer", "PROBLEM", 100, 126], ["gastric cancer", "PROBLEM", 128, 142], ["solid cancer", "PROBLEM", 147, 159], ["small cell", "OBSERVATION", 104, 114], ["lung", "ANATOMY", 115, 119], ["cancer", "OBSERVATION", 120, 126], ["gastric", "ANATOMY", 128, 135], ["cancer", "OBSERVATION", 136, 142], ["solid cancer", "OBSERVATION", 147, 159]]], ["Amaridine is another marketed anticancer drug targeted at topoisomerase II, which is used in the treatment of leukemia.", [["anticancer", "ANATOMY", 30, 40], ["leukemia", "ANATOMY", 110, 118], ["Amaridine", "CHEMICAL", 0, 9], ["topoisomerase II", "CHEMICAL", 58, 74], ["leukemia", "DISEASE", 110, 118], ["Amaridine", "CHEMICAL", 0, 9], ["Amaridine", "SIMPLE_CHEMICAL", 0, 9], ["anticancer", "CANCER", 30, 40], ["topoisomerase II", "GENE_OR_GENE_PRODUCT", 58, 74], ["leukemia", "CANCER", 110, 118], ["topoisomerase II", "PROTEIN", 58, 74], ["Amaridine", "TREATMENT", 0, 9], ["another marketed anticancer drug", "TREATMENT", 13, 45], ["leukemia", "PROBLEM", 110, 118], ["leukemia", "OBSERVATION", 110, 118]]], ["[28] [29] [30] [31] After the exploration of experts, quinolones exert their biological activities by inhibiting the formation of bacterial DNA topoisomerase.", [["quinolones", "CHEMICAL", 54, 64], ["quinolones", "CHEMICAL", 54, 64], ["[28] [29] [30] [31", "SIMPLE_CHEMICAL", 0, 18], ["quinolones", "SIMPLE_CHEMICAL", 54, 64], ["DNA", "CELLULAR_COMPONENT", 140, 143], ["topoisomerase", "GENE_OR_GENE_PRODUCT", 144, 157], ["bacterial DNA topoisomerase", "PROTEIN", 130, 157], ["the exploration", "TEST", 26, 41], ["quinolones", "TREATMENT", 54, 64], ["bacterial DNA topoisomerase", "PROBLEM", 130, 157], ["bacterial DNA", "OBSERVATION", 130, 143]]], ["The successful exploration of this mechanism provides the basis for the subsequent drug design.", [["successful", "OBSERVATION_MODIFIER", 4, 14], ["exploration", "OBSERVATION", 15, 26]]], ["Drug designers no longer hunted around like a headless chicken, and since then quinolone drug design has a real design center [32] [33] [34] .", [["quinolone", "CHEMICAL", 79, 88], ["quinolone", "CHEMICAL", 79, 88], ["chicken", "ORGANISM", 55, 62], ["quinolone", "SIMPLE_CHEMICAL", 79, 88], ["chicken", "SPECIES", 55, 62], ["chicken", "SPECIES", 55, 62]]]], "3e2d6d8e5ce07b4d7095145bd28b25874d53c719": [["Coronavirus disease (COVID-19) has emerged as a public health crisis of global proportions.", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 21, 29], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 21, 26]]], ["Despite rapidly growing knowledge of the clinical features of COVID-19, data about the pathophysiology of the disease are still scarce.", [["COVID-19", "CELL", 62, 70], ["COVID", "TEST", 62, 67], ["the disease", "PROBLEM", 106, 117], ["disease", "OBSERVATION", 110, 117]]], ["As a consequence, medical treatments are often empirical, based on drugs previously used for other conditions, case reports, or retrospective data.", [["medical treatments", "TREATMENT", 18, 36], ["drugs", "TREATMENT", 67, 72]]]], "71fb82eade9a66edd0d585f7217d67ebfa857a52": [["A key ingredient employed by MP is the deep neural network (DNN), which has emerged as an effective means to semi-autonomously implement many complex software systems.", [["neural network", "ANATOMY", 44, 58], ["MP", "GENE_OR_GENE_PRODUCT", 29, 31], ["neural network", "MULTI-TISSUE_STRUCTURE", 44, 58], ["deep", "ANATOMY_MODIFIER", 39, 43], ["neural", "ANATOMY", 44, 50]]], ["DNNs are artifacts produced by machine learning: a user provides examples of how a system should behave, and a machine learning algorithm generalizes these examples into a DNN capable of correctly handling inputs that it had not seen before.", [["DNNs", "SIMPLE_CHEMICAL", 0, 4], ["DNNs", "DNA", 0, 4], ["artifacts", "OBSERVATION", 9, 18]]], ["Systems with DNN components have obtained unprecedented results in fields such as image recognition [24] , game playing [33] , natural language processing [16] , computer networks [28] , and many others, often surpassing the results obtained by similar systems that have been carefully handcrafted.", [["DNN components", "PROTEIN", 13, 27]]], ["It seems evident that this trend will increase and intensify, and that DNN components will be deployed in various safety-critical systems [3, 19] .IntroductionDNNs are appealing in that (in some cases) they are easier to create than handcrafted software, while still achieving excellent results.", [["DNN components", "PROBLEM", 71, 85], ["IntroductionDNNs", "TREATMENT", 147, 163]]], ["Undesired behavior has been observed in many state-of-the-art DNNs.", [["Undesired behavior", "PROBLEM", 0, 18]]], ["For example, in many cases slight perturbations to correctly handled inputs can cause severe errors [26, 35] .", [["severe errors", "PROBLEM", 86, 99]]], ["Because many practices for improving the reliability of hand-crafted code have yet to be successfully applied to DNNs (e.g., code reviews, coding guidelines, etc.), it remains unclear how to overcome the opacity of DNNs, which may limit our ability to certify them before they are deployed.IntroductionTo mitigate this, the formal methods community has begun developing techniques for the formal verification of DNNs (e.g., [10, 17, 20, 37] ).", [["hand", "ANATOMY", 56, 60], ["DNNs", "DISEASE", 215, 219], ["hand", "ORGANISM_SUBDIVISION", 56, 60], ["DNNs", "GENE_OR_GENE_PRODUCT", 412, 416], ["the opacity of DNNs", "PROBLEM", 200, 219], ["opacity", "OBSERVATION", 204, 211]]], ["These techniques can automatically prove that a DNN always satisfies a prescribed property.", [["DNN", "DISEASE", 48, 51]]], ["Unfortunately, the DNN verification problem is computationally difficult (e.g., NP-complete, even for simple specifications and networks [20] ), and becomes exponentially more difficult as network sizes increase.", [["the DNN verification problem", "PROBLEM", 15, 43], ["NP", "TEST", 80, 82], ["sizes", "OBSERVATION_MODIFIER", 197, 202], ["increase", "OBSERVATION_MODIFIER", 203, 211]]], ["Thus, despite recent advances in DNN verification techniques, network sizes remain a severely limiting factor.IntroductionIn this work, we propose a technique by which the scalability of many existing verification techniques can be significantly increased.", [["DNN verification techniques", "TREATMENT", 33, 60], ["a severely limiting factor", "PROBLEM", 83, 109], ["a technique", "TREATMENT", 147, 158], ["verification techniques", "TREATMENT", 201, 224], ["sizes", "OBSERVATION_MODIFIER", 70, 75], ["severely", "OBSERVATION_MODIFIER", 85, 93], ["significantly", "OBSERVATION_MODIFIER", 232, 245], ["increased", "OBSERVATION_MODIFIER", 246, 255]]], ["The idea is to apply the well-established notion of abstraction and refinement [6] : replace a network N that is to be verified with a much smaller, abstract network,N , and then verify thisN .", [["thisN", "PROTEIN", 186, 191], ["a network N", "TREATMENT", 93, 104]]], ["BecauseN is smaller it can be verified more efficiently; and it is constructed in such a way that if it satisfies the specification, the original network N also satisfies it.", [["smaller", "OBSERVATION_MODIFIER", 12, 19]]], ["In the case thatN does not satisfy the specification, the verification procedure provides a counterexample x.", [["the verification procedure", "TREATMENT", 54, 80]]], ["This x may be a true counterexample demonstrating that the original network N violates the specification, or it may be spurious.", [["may be", "UNCERTAINTY", 112, 118], ["spurious", "OBSERVATION", 119, 127]]], ["If x is spurious, the networkN is refined to make it more accurate (and slightly larger), and then the process is repeated.", [["networkN", "DNA", 22, 30], ["spurious", "PROBLEM", 8, 16], ["spurious", "OBSERVATION", 8, 16], ["slightly", "OBSERVATION_MODIFIER", 72, 80], ["larger", "OBSERVATION_MODIFIER", 81, 87]]], ["This variant, known as counterexample-guided abstraction refinement (CEGAR) [6] , has been successfully applied in many verification contexts.IntroductionAs part of our technique we propose a method for abstracting and refining neural networks.", [["neural networks", "ANATOMY", 228, 243], ["neural networks", "MULTI-TISSUE_STRUCTURE", 228, 243], ["counterexample-guided abstraction refinement (CEGAR)", "TREATMENT", 23, 75], ["a method", "TREATMENT", 190, 198], ["neural networks", "OBSERVATION", 228, 243]]], ["Our basic abstraction step merges two neurons into one, thus reducing the overall number of neurons by one.", [["neurons", "ANATOMY", 38, 45], ["neurons", "ANATOMY", 92, 99], ["neurons", "CELL", 38, 45], ["neurons", "CELL", 92, 99]]], ["This basic step can be repeated numerous times, significantly reducing the network size.", [["size", "OBSERVATION_MODIFIER", 83, 87]]], ["Conversely, refinement is performed by splitting a previously merged neuron in two, increasing the network size but making it more closely resemble the original.", [["neuron", "ANATOMY", 69, 75], ["size", "OBSERVATION_MODIFIER", 107, 111]]], ["A key point is that not all pairs of neurons can be merged, as this could result in a network that is smaller but is not an over-approximation of the original.", [["neurons", "ANATOMY", 37, 44], ["neurons", "CELL", 37, 44], ["smaller", "OBSERVATION_MODIFIER", 102, 109]]], ["We resolve this by first transforming the original network into an equivalent network where each node belongs to one of four classes, determined by its edge weights and its effect on the network's output; merging neurons from the same class can then be done safely.", [["node", "ANATOMY", 97, 101], ["neurons", "ANATOMY", 213, 220], ["neurons", "CELL", 213, 220], ["the network's output", "TEST", 183, 203], ["node", "OBSERVATION", 97, 101]]], ["The actual choice of which neurons to merge or split is performed heuristically.", [["neurons", "ANATOMY", 27, 34], ["neurons", "CELL", 27, 34]]], ["We propose and discuss several possible heuristics.IntroductionFor evaluation purposes, we implemented our approach as a Python framework that wraps the Marabou verification tool [22] .", [["evaluation purposes", "TEST", 67, 86], ["a Python framework", "TREATMENT", 119, 137]]], ["Further, in most cases the properties in question could indeed be shown to hold or not hold for the original DNN by verifying a small, abstract version thereof.IntroductionTo summarize, our contributions are: (i) we propose a general framework for over-approximating and refining DNNs; (ii) we propose several heuristics for abstraction and refinement, to be used within our general framework; and (iii) we provide an implementation of our technique that integrates with the Marabou verification tool and use it for evaluation.", [["DNN", "CANCER", 109, 112], ["a small, abstract version thereof", "PROBLEM", 126, 159], ["refinement", "TREATMENT", 341, 351], ["our technique", "TREATMENT", 436, 449], ["evaluation", "TEST", 516, 526], ["small", "OBSERVATION_MODIFIER", 128, 133]]], ["2, we provide a brief background on neural networks and their verification.", [["neural networks", "ANATOMY", 36, 51], ["neural networks", "MULTI-TISSUE_STRUCTURE", 36, 51]]], ["3, we describe our general framework for abstracting an refining DNNs.", [["DNNs", "CANCER", 65, 69]]], ["4, we discuss how to apply these abstraction and refinement steps as part of a CEGAR procedure, followed by an evaluation in Sect.", [["refinement steps", "TREATMENT", 49, 65], ["a CEGAR procedure", "TREATMENT", 77, 94], ["an evaluation", "TEST", 108, 121]]], ["7.Neural NetworksA neural network consists of an input layer, an output layer, and one or more intermediate layers called hidden layers.", [["Neural", "ANATOMY", 2, 8], ["neural network", "ANATOMY", 19, 33], ["neural network", "MULTI-TISSUE_STRUCTURE", 19, 33], ["layers", "TISSUE", 129, 135], ["layer", "OBSERVATION_MODIFIER", 55, 60], ["output", "OBSERVATION_MODIFIER", 65, 71], ["layer", "OBSERVATION_MODIFIER", 72, 77], ["intermediate", "OBSERVATION_MODIFIER", 95, 107], ["layers", "OBSERVATION_MODIFIER", 108, 114]]], ["Each layer is a collection of nodes, called neurons.", [["nodes", "ANATOMY", 30, 35], ["neurons", "ANATOMY", 44, 51], ["nodes", "MULTI-TISSUE_STRUCTURE", 30, 35], ["neurons", "CELL", 44, 51], ["a collection of nodes", "PROBLEM", 14, 35], ["layer", "OBSERVATION_MODIFIER", 5, 10], ["collection", "OBSERVATION_MODIFIER", 16, 26], ["nodes", "OBSERVATION", 30, 35], ["neurons", "ANATOMY", 44, 51]]], ["Each neuron is connected to other neurons by one or more directed edges.", [["neuron", "ANATOMY", 5, 11], ["neurons", "ANATOMY", 34, 41], ["neurons", "CELL", 34, 41]]], ["In a feedforward neural network, the neurons in the first layer receive input data that sets their initial values.", [["neural network", "ANATOMY", 17, 31], ["neurons", "ANATOMY", 37, 44], ["neural network", "MULTI-TISSUE_STRUCTURE", 17, 31], ["neurons", "CELL", 37, 44], ["input data", "TEST", 72, 82]]], ["The remaining neurons calculate their values using the weighted values of the neurons that they are connected to through edges from the preceding layer (see Fig. 1 ).", [["neurons", "ANATOMY", 14, 21], ["neurons", "ANATOMY", 78, 85], ["neurons", "CELL", 14, 21], ["neurons", "CELL", 78, 85]]], ["The output layer provides the resulting value of the DNN for a given input.Neural NetworksThere are many types of DNNs, which may differ in the way their neuron values are computed.", [["Neural", "ANATOMY", 75, 81], ["neuron", "ANATOMY", 154, 160], ["DNNs", "GENE_OR_GENE_PRODUCT", 114, 118], ["neuron", "CELL", 154, 160], ["DNN", "PROTEIN", 53, 56], ["The output layer", "TEST", 0, 16], ["DNNs", "TREATMENT", 114, 118], ["output", "OBSERVATION_MODIFIER", 4, 10], ["layer", "OBSERVATION_MODIFIER", 11, 16], ["many", "OBSERVATION_MODIFIER", 100, 104], ["types", "OBSERVATION_MODIFIER", 105, 110], ["DNNs", "OBSERVATION", 114, 118]]], ["Typically, a neuron is evaluated by first computing a weighted sum of the preceding layer's neuron values according to the edge weights, and then applying an activation function to this weighted sum [13] .", [["neuron", "ANATOMY", 13, 19], ["neuron", "ANATOMY", 92, 98], ["the edge weights", "TEST", 119, 135]]], ["Thus, if the weighted sum computation yields a positive value, it is kept; and otherwise, it is replaced by zero.Neural NetworksMore formally, given a DNN N , we use n to denote the number of layers of N .", [["Neural", "ANATOMY", 113, 119], ["DNN N", "CHEMICAL", 151, 156], ["N", "CHEMICAL", 202, 203], ["a positive value", "PROBLEM", 45, 61], ["positive value", "OBSERVATION_MODIFIER", 47, 61]]], ["We denote the number of nodes of layer i by s i .", [["nodes", "OBSERVATION", 24, 29], ["layer", "OBSERVATION_MODIFIER", 33, 38]]], ["Layers 1 and n are the input and output layers, respectively.", [["output", "OBSERVATION_MODIFIER", 33, 39], ["layers", "OBSERVATION_MODIFIER", 40, 46]]], ["Layers 2, . . . , n \u2212 1 are the hidden layers.", [["layers", "TISSUE", 39, 45]]], ["We denote the value of the j-th node of layer i by v i,j , and denote the columnNeural NetworksEvaluating N is performed by calculating V n for a given input assignment V 1 .", [["V 1", "PROTEIN", 169, 172], ["node", "OBSERVATION", 32, 36]]], ["This is done by sequentially computing V i for i = 2, 3, . . . , n, each time using the values of V i\u22121 to compute weighted sums, and then applying the ReLU activation functions.", [["V i\u22121", "PROTEIN", 98, 103], ["ReLU", "PROTEIN", 152, 156]]], ["Specifically, layer i (for i > 1) is associated with a weight matrix W i of size s i \u00d7 s i\u22121 and a bias vector B i of size s i .", [["size", "OBSERVATION_MODIFIER", 118, 122]]], ["If i is a hidden layer, its values are given byNeural Networkswhere the ReLUs are applied element-wise; and the output layer is given by V n = W n V n\u22121 + B n (ReLUs are not applied).", [["ReLUs", "PROTEIN", 72, 77], ["ReLUs", "PROTEIN", 160, 165], ["byNeural", "TREATMENT", 45, 53], ["the output layer", "TEST", 108, 124], ["B n (ReLUs", "TREATMENT", 155, 165]]], ["Without loss of generality, in the rest of the paper we assume that all bias values are 0, and can be ignored.", [["loss of generality", "PROBLEM", 8, 26]]], ["This rule is applied repeatedly once for each layer, until V n is eventually computed.Neural NetworksWe will sometimes use the notation w(v i,j , v i+1,k ) to refer to the entry of W i+1 that represents the weight of the edge between neuron j of layer i and neuron k of layer i + 1.", [["Neural", "ANATOMY", 86, 92], ["neuron", "ANATOMY", 234, 240], ["neuron", "ANATOMY", 258, 264], ["W i+1", "DNA", 181, 186]]], ["We will also refer to such an edge as an outgoing edge for v i,j , and as an incoming edge for v i+1,k .Neural NetworksAs part of our abstraction framework, we will sometimes need to consider a suffix of a DNN, in which the first layers of the DNN are omitted.", [["Neural", "ANATOMY", 104, 110], ["DNN", "CANCER", 244, 247], ["DNN", "DNA", 244, 247], ["a DNN", "TREATMENT", 204, 209]]], ["For 1 < i < n, we use N [i] to denote the DNN comprised of layers i, i + 1, . . . , n of the original network.", [["DNN", "PROTEIN", 42, 45]]], ["The sizes and weights of the remaining layers are unchanged, and layer i of N is treated as the input layer of N [i] .", [["N", "CHEMICAL", 76, 77], ["sizes", "OBSERVATION_MODIFIER", 4, 9], ["weights", "OBSERVATION_MODIFIER", 14, 21], ["remaining", "OBSERVATION_MODIFIER", 29, 38], ["layers", "OBSERVATION_MODIFIER", 39, 45], ["unchanged", "OBSERVATION_MODIFIER", 50, 59], ["layer", "OBSERVATION_MODIFIER", 65, 70]]], ["Figure 2 depicts a small neural network.", [["neural network", "ANATOMY", 25, 39], ["neural network", "MULTI-TISSUE_STRUCTURE", 25, 39], ["a small neural network", "PROBLEM", 17, 39], ["small", "OBSERVATION_MODIFIER", 19, 24], ["neural network", "OBSERVATION", 25, 39]]], ["The network has n = 3 layers, of sizes s 1 = 1, s 2 = 2 and s 3 = 1.", [["sizes s", "TEST", 33, 40]]], ["Its weights are w(v 1,1 , v 2,1 ) = 1, w(v 1,1 , v 2,2 ) = \u22121, w(v 2,1 , v 3,1 ) = 1 and w(v 2,2 , v 3,1 ) = 2.", [["v 2,2 , v 3,1 ) = 2", "SIMPLE_CHEMICAL", 91, 110], ["Its weights", "TEST", 0, 11], ["v", "TEST", 18, 19], ["v", "TEST", 49, 50], ["v", "TEST", 65, 66], ["v", "TEST", 73, 74], ["v", "TEST", 91, 92], ["v", "TEST", 99, 100]]], ["For input v 1,1 = 3, node v 2,1 evaluates to 3 and node v 2,2 evaluates to 0, due to the ReLU activation function.", [["ReLU", "GENE_OR_GENE_PRODUCT", 89, 93], ["ReLU", "PROTEIN", 89, 93], ["input v", "TEST", 4, 11], ["node v", "TEST", 21, 27], ["node v", "TEST", 51, 57], ["node", "ANATOMY", 21, 25], ["node", "ANATOMY", 51, 55]]], ["The output node v 3,1 then evaluates to 3.Neural Network VerificationDNN verification amounts to answering the following question: given a DNN N , which maps input vector x to output vector y, and predicates P and Q, does there exist an input x 0 such that P (x 0 ) and Q(N (x 0 )) both hold?", [["Neural", "ANATOMY", 42, 48], ["P", "DNA", 208, 209], ["The output node v", "TEST", 0, 17], ["output", "OBSERVATION_MODIFIER", 4, 10], ["node", "OBSERVATION", 11, 15]]], ["In other words, the verification process determines whether there exists a particular input that meets the input criterion P , and that is mapped to an output that meets the output criterion Q. We refer to N, P, Q as the verification query.", [["P", "DNA", 123, 124]]], ["Different verification approaches may differ in (i) the kinds of neural networks they allow (specifically, the kinds of activation functions in use); (ii) the kinds of input properties; and (iii) the kinds of output properties.", [["neural networks", "ANATOMY", 65, 80], ["neural networks", "MULTI-TISSUE_STRUCTURE", 65, 80], ["neural networks", "OBSERVATION", 65, 80], ["output properties", "OBSERVATION", 209, 226]]], ["For simplicity, we focus on networks that employ the ReLU activation function.", [["ReLU", "GENE_OR_GENE_PRODUCT", 53, 57], ["ReLU", "PROTEIN", 53, 57]]], ["In addition, our input properties will be conjunctions of linear constraints on the input values.", [["the input values", "TEST", 80, 96]]], ["Many properties of interest, including those with arbitrary Boolean structure and involving multiple neurons, can be reduced into the above single-output setting by adding a few neurons that encode the Boolean structure [20, 32] ; see Fig. 3 for an example.", [["neurons", "ANATOMY", 101, 108], ["neurons", "ANATOMY", 178, 185], ["neurons", "CELL", 101, 108], ["neurons", "CELL", 178, 185]]], ["The number of neurons to be added is typically negligible when compared to the size of the DNN.", [["neurons", "ANATOMY", 14, 21], ["neurons", "CELL", 14, 21], ["DNN", "CANCER", 91, 94], ["neurons", "CELL_TYPE", 14, 21], ["negligible", "OBSERVATION_MODIFIER", 47, 57]]], ["In particular, this is true for the ACAS Xu family of benchmarks [20] , and also for adversarial robustness queries that use the L \u221e or the L 1 norm as a distance metric [5, 14, 21] .", [["L \u221e", "PROTEIN", 129, 132]]], ["Additionally, other piecewise-linear activation functions, such as max-pooling layers, can also be encoded using ReLUs [5] .Neural Network VerificationSeveral techniques have been proposed for solving the aforementioned verification problem in recent years (Sect.", [["linear activation functions", "PROBLEM", 30, 57]]], ["Our abstraction technique is designed to be compatible with most of these techniques, by simplifying the network being verified, as we describe next.Network Abstraction and RefinementBecause the complexity of verifying a neural network is strongly connected to its size [20] , our goal is to transform a verification query \u03d5 1 = N, P, Q into query \u03d5 2 = N , P, Q , such that the abstract networkN is significantly smaller than N (notice that properties P and Q remain unchanged).", [["neural network", "ANATOMY", 221, 235], ["neural network", "MULTI-TISSUE_STRUCTURE", 221, 235], ["Our abstraction technique", "TEST", 0, 25], ["these techniques", "TEST", 68, 84], ["a verification query", "TEST", 302, 322]]], ["More specifically, since our DNNs have a single output, we can regard N (x) andN (x) as real values for every input x.", [["DNNs", "CANCER", 29, 33], ["DNNs", "DNA", 29, 33]]], ["To guarantee that \u03d5 2 over-approximates \u03d5 1 , we will make sure that for every x, N (x) \u2264N (x); and Fig. 3 .", [["N", "CHEMICAL", 82, 83], ["N", "CHEMICAL", 89, 90]]], ["For the network on the left hand side, suppose we wish to examine the property y2 > y1 \u2228 y2 > y3, which is a property that involves multiple outputs and includes a disjunction.", [["left hand", "ANATOMY", 23, 32], ["left", "ANATOMY_MODIFIER", 23, 27]]], ["We do this (right hand side network) by adding two neurons, t1 and t2, such that t1 = ReLU(y2 \u2212 y1) and t2 = ReLU(y2 \u2212 y3).", [["right hand", "ANATOMY", 12, 22], ["neurons", "ANATOMY", 51, 58], ["neurons", "CELL", 51, 58], ["y2 \u2212 y3", "GENE_OR_GENE_PRODUCT", 114, 121], ["t1", "TEST", 81, 83], ["ReLU", "TEST", 86, 90]]], ["Finally, we add a neuron z1 such that z1 = t1 + t2.", [["neuron", "ANATOMY", 18, 24], ["t1", "DNA", 43, 45]]], ["It holds that z1 > 0 if and only if t1 > 0 \u2228 t2 > 0.", [["t1", "TEST", 36, 38]]], ["Thus, we have reduced the complex property into an equivalent property in the desired form.Network Abstraction and Refinementfor all x and so \u03d5 1 is also UNSAT.", [["UNSAT", "PROTEIN", 154, 159]]], ["We now propose a framework for generating variousN s with this property.AbstractionWe seek to define an abstraction operator that removes a single neuron from the network, by merging it with another neuron.", [["neuron", "ANATOMY", 147, 153], ["neuron", "ANATOMY", 199, 205], ["neuron", "CELL", 199, 205], ["generating variousN s", "TREATMENT", 31, 52]]], ["To do this, we will first transform N into an equivalent network, whose neurons have properties that will facilitate their merging.", [["neurons", "ANATOMY", 72, 79], ["neurons", "CELL", 72, 79]]], ["First, each hidden neuron v i,j of our transformed network will be classified as either a pos neuron or a neg neuron.", [["pos neuron", "ANATOMY", 90, 100], ["neg neuron", "ANATOMY", 106, 116]]], ["A neuron is pos if all the weights on its outgoing edges are positive, and is neg if all those weights are negative.", [["neuron", "ANATOMY", 2, 8], ["neuron", "CELL", 2, 8], ["positive", "OBSERVATION", 61, 69], ["negative", "OBSERVATION", 107, 115]]], ["Second, orthogonally to the pos/neg classification, each hidden neuron will also be classified as either an inc neuron or a dec neuron.Abstractionincreases the output.", [["neuron", "ANATOMY", 64, 70], ["inc neuron", "ANATOMY", 108, 118], ["dec neuron", "ANATOMY", 124, 134], ["dec neuron", "CELL", 124, 134], ["output", "OBSERVATION_MODIFIER", 160, 166]]], ["We first describe this transformation (an illustration of which appears in Fig. 4 ), and later we explain how it fits into our abstraction framework.AbstractionOur first step is to transform N into a new network, N , in which every hidden neuron is classified as pos or neg.", [["neuron", "ANATOMY", 239, 245], ["neuron", "CELL", 239, 245], ["this transformation", "PROBLEM", 18, 37]]], ["This transformation is done by replacing each hidden neuron v ij with two neurons, v + i,j and v \u2212 i,j , which are respectively pos and neg.", [["neurons", "ANATOMY", 74, 81], ["neurons", "CELL", 74, 81], ["v + i", "GENE_OR_GENE_PRODUCT", 83, 88], ["v \u2212 i", "GENE_OR_GENE_PRODUCT", 95, 100], ["This transformation", "PROBLEM", 0, 19], ["ij", "ANATOMY", 62, 64], ["neurons", "ANATOMY", 74, 81]]], ["Both v + i,j an v \u2212 i,j retain a copy of all incoming edges of the original v i,j ; however, v + i,j retains just the outgoing edges with positive weights, and v \u2212 i,j retains just those with negative weights.", [["v + i", "GENE_OR_GENE_PRODUCT", 93, 98], ["positive weights", "OBSERVATION", 138, 154]]], ["Outgoing edges with negative weights are removed from v + i,j by setting their weights to 0, and the same is done for outgoing edges with positive weights for v \u2212 i,j .", [["negative", "OBSERVATION", 20, 28]]], ["This operation is performed once for every hidden neuron of N , resulting in a network N that is roughly double the size of N .", [["neuron", "ANATOMY", 50, 56], ["N", "CHEMICAL", 124, 125], ["This operation", "TREATMENT", 0, 14], ["size", "OBSERVATION_MODIFIER", 116, 120]]], ["Classifying neurons as pos/neg and inc/dec.", [["neurons", "ANATOMY", 12, 19], ["neurons", "CELL", 12, 19], ["neg", "GENE_OR_GENE_PRODUCT", 27, 30], ["inc", "GENE_OR_GENE_PRODUCT", 35, 38], ["pos/neg and inc/dec", "DNA", 23, 42]]], ["In the initial network (left), the neurons of the second hidden layer are already classified: + and \u2212 superscripts indicate pos and neg neurons, respectively; the I superscript and green background indicate inc, and the D superscript and red background indicate dec.", [["neurons", "ANATOMY", 35, 42], ["neg neurons", "ANATOMY", 132, 143], ["neurons", "CELL", 35, 42], ["pos and neg neurons", "CELL_TYPE", 124, 143], ["the D superscript", "TREATMENT", 216, 233], ["left", "ANATOMY_MODIFIER", 24, 28], ["neurons", "ANATOMY", 136, 143], ["inc", "OBSERVATION", 207, 210]]], ["Classifying node v1,1 is done by first splitting it into two nodes v + 1,1 and v \u2212 1,1 (middle).", [["node", "ANATOMY", 12, 16], ["node", "MULTI-TISSUE_STRUCTURE", 12, 16], ["v \u2212 1,1", "GENE_OR_GENE_PRODUCT", 79, 86], ["v1,1", "DNA", 17, 21], ["nodes v", "TEST", 61, 68], ["node", "OBSERVATION", 12, 16], ["nodes", "OBSERVATION", 61, 66], ["middle", "ANATOMY_MODIFIER", 88, 94]]], ["Both nodes have identical incoming edges, but the outgoing edges of v1,1 are partitioned between them, according to the sign of each edge's weight.", [["nodes", "ANATOMY", 5, 10], ["nodes", "MULTI-TISSUE_STRUCTURE", 5, 10], ["v1,1", "GENE_OR_GENE_PRODUCT", 68, 72], ["v1,1", "DNA", 68, 72], ["nodes", "OBSERVATION", 5, 10], ["incoming", "OBSERVATION_MODIFIER", 26, 34], ["edges", "OBSERVATION_MODIFIER", 35, 40]]], ["In the last network (right), v + 1,1 is split once more, into an inc node with outgoing edges only to other inc nodes, and a dec node with outgoing edges only to other dec nodes.", [["inc node", "ANATOMY", 65, 73], ["inc nodes", "ANATOMY", 108, 117], ["dec node", "ANATOMY", 125, 133], ["dec nodes", "ANATOMY", 168, 177], ["v + 1,1", "GENE_OR_GENE_PRODUCT", 29, 36], ["inc nodes", "MULTI-TISSUE_STRUCTURE", 108, 117], ["dec nodes", "MULTI-TISSUE_STRUCTURE", 168, 177], ["an inc node", "PROBLEM", 62, 73], ["other inc nodes", "PROBLEM", 102, 117], ["a dec node", "PROBLEM", 123, 133], ["other dec nodes", "PROBLEM", 162, 177], ["right", "ANATOMY_MODIFIER", 21, 26], ["inc", "OBSERVATION_MODIFIER", 65, 68], ["node", "OBSERVATION", 69, 73], ["edges", "OBSERVATION_MODIFIER", 88, 93], ["inc", "OBSERVATION_MODIFIER", 108, 111], ["nodes", "OBSERVATION", 112, 117], ["node", "OBSERVATION", 129, 133], ["nodes", "OBSERVATION", 172, 177]]], ["Node v1,1 is thus transformed into three nodes, each of which can finally be classified as inc or dec.", [["nodes", "ANATOMY", 41, 46], ["Node v1,1", "DNA", 0, 9], ["nodes", "OBSERVATION", 41, 46]]], ["Notice that in the worst case, each node is split into four nodes, although for v1,1 three nodes were enough.AbstractionOur second step is to alter N further, into a new network N , where every hidden neuron is either inc or dec (in addition to already being pos or neg).", [["node", "ANATOMY", 36, 40], ["nodes", "ANATOMY", 60, 65], ["nodes", "ANATOMY", 91, 96], ["neuron", "ANATOMY", 201, 207], ["node", "MULTI-TISSUE_STRUCTURE", 36, 40], ["v1,1 three nodes", "PROBLEM", 80, 96], ["node", "OBSERVATION", 36, 40], ["split", "OBSERVATION_MODIFIER", 44, 49], ["four", "OBSERVATION_MODIFIER", 55, 59], ["nodes", "OBSERVATION", 60, 65], ["nodes", "OBSERVATION", 91, 96]]], ["Generating N from N is performed by traversing the layers of N backwards, each time handling a single layer and possibly doubling its number of neurons: -Initial step: the output layer has a single neuron, y.", [["neurons", "ANATOMY", 144, 151], ["neuron", "ANATOMY", 198, 204], ["neurons", "CELL", 144, 151]]], ["This neuron is an inc node, because increasing its value will increase the network's output value.Abstraction-Iterative step: observe layer i, and suppose the nodes of layer i + 1 have already been partitioned into inc and dec nodes.", [["neuron", "ANATOMY", 5, 11], ["inc node", "ANATOMY", 18, 26], ["dec nodes", "ANATOMY", 223, 232], ["neuron", "CELL", 5, 11], ["inc node", "MULTI-TISSUE_STRUCTURE", 18, 26], ["i + 1", "GENE_OR_GENE_PRODUCT", 174, 179], ["dec nodes", "MULTI-TISSUE_STRUCTURE", 223, 232], ["an inc node", "PROBLEM", 15, 26], ["increasing its value", "PROBLEM", 36, 56], ["the network's output value", "TEST", 71, 97], ["inc", "OBSERVATION_MODIFIER", 18, 21], ["node", "OBSERVATION", 22, 26], ["nodes", "OBSERVATION", 159, 164], ["dec nodes", "OBSERVATION", 223, 232]]], ["Observe a neuron v + i,j in layer i which is marked pos (the case for neg is symmetrical).", [["neuron", "ANATOMY", 10, 16], ["marked", "OBSERVATION_MODIFIER", 45, 51]]], ["We replace v + i,j with two neurons v +,I i,j and v +,D i,j , which are inc and dec, respectively.", [["neurons", "ANATOMY", 28, 35], ["v + i", "GENE_OR_GENE_PRODUCT", 11, 16]]], ["Both new neurons retain a copy of all incoming edges of v + i,j ; however, v +,I i,j retains only outgoing edges that lead to inc nodes, and v +,D i,j retains only outgoing edges that lead to dec nodes.", [["neurons", "ANATOMY", 9, 16], ["inc nodes", "ANATOMY", 126, 135], ["dec nodes", "ANATOMY", 192, 201], ["neurons", "CELL", 9, 16], ["dec nodes", "MULTI-TISSUE_STRUCTURE", 192, 201], ["inc nodes", "PROBLEM", 126, 135], ["dec nodes", "PROBLEM", 192, 201], ["inc", "OBSERVATION_MODIFIER", 126, 129], ["nodes", "OBSERVATION", 130, 135], ["nodes", "OBSERVATION", 196, 201]]], ["We perform this step for each neuron in layer i, resulting in neurons that are each classified as either inc or dec.AbstractionTo understand the intuition behind this classification, recall that by our assumption all hidden nodes use the ReLU activation function, which is monotonically increasing.", [["neuron", "ANATOMY", 30, 36], ["neurons", "ANATOMY", 62, 69], ["neuron", "CELL", 30, 36], ["neurons", "CELL", 62, 69], ["nodes", "MULTI-TISSUE_STRUCTURE", 224, 229], ["nodes", "OBSERVATION", 224, 229], ["monotonically", "OBSERVATION_MODIFIER", 273, 286], ["increasing", "OBSERVATION_MODIFIER", 287, 297]]], ["Because v + i,j is pos, all its outgoing edges have positive weights, and so if its assignment was to increase (decrease), the assignments of all nodes to which it is connected in the following layer would also increase (decrease).", [["v + i", "GENE_OR_GENE_PRODUCT", 8, 13], ["positive weights", "PROBLEM", 52, 68], ["all nodes", "PROBLEM", 142, 151], ["positive", "OBSERVATION", 52, 60], ["nodes", "OBSERVATION", 146, 151], ["increase", "OBSERVATION_MODIFIER", 211, 219]]], ["Thus, we split v + i,j in two, and make sure one copy, v +,I i,j , is only connected to nodes that need to increase (inc nodes), and that the other copy, v +,D i,j , is only connected to nodes that need to decrease (dec nodes).", [["inc nodes", "MULTI-TISSUE_STRUCTURE", 117, 126], ["dec nodes", "MULTI-TISSUE_STRUCTURE", 216, 225], ["nodes", "OBSERVATION", 88, 93], ["increase", "OBSERVATION_MODIFIER", 107, 115], ["nodes", "OBSERVATION", 187, 192], ["decrease", "OBSERVATION_MODIFIER", 206, 214], ["nodes", "OBSERVATION", 220, 225]]], ["This ensures that v +,I i,j is itself inc,Abstractionremain pos nodes, because their outgoing edges all have positive weights.AbstractionWhen this procedure terminates, N is equivalent to N , and so also to N ; and N is roughly double the size of N , and roughly four times the size of N .", [["N", "CHEMICAL", 169, 170], ["N", "CHEMICAL", 188, 189], ["N", "CHEMICAL", 207, 208], ["N", "CHEMICAL", 215, 216], ["N", "CHEMICAL", 247, 248], ["N", "CHEMICAL", 286, 287], ["Abstractionremain pos nodes", "PROBLEM", 42, 69], ["positive weights", "PROBLEM", 109, 125], ["this procedure", "TREATMENT", 142, 156], ["pos nodes", "OBSERVATION", 60, 69], ["positive", "OBSERVATION", 109, 117], ["size", "OBSERVATION_MODIFIER", 239, 243], ["size", "OBSERVATION_MODIFIER", 278, 282]]], ["Both transformation steps are only performed for hidden neurons, whereas the input and output neurons remain unchanged.", [["neurons", "ANATOMY", 56, 63], ["output neurons", "ANATOMY", 87, 101], ["neurons", "CELL", 56, 63], ["neurons", "CELL", 94, 101], ["hidden neurons", "PROBLEM", 49, 63], ["output neurons", "TEST", 87, 101], ["transformation steps", "OBSERVATION", 5, 25], ["unchanged", "OBSERVATION_MODIFIER", 109, 118]]], ["This is summarized by the following lemma: Lemma 1.", [["Lemma", "OBSERVATION", 43, 48]]], ["Any DNN N can be transformed into an equivalent network N where each hidden neuron is pos or neg, and also inc or dec, by increasing its number of neurons by a factor of at most 4.AbstractionUsing Lemma 1, we can assume without loss of generality that the DNN nodes in our input query \u03d5 1 are each marked as pos/neg and as inc/dec.", [["neuron", "ANATOMY", 76, 82], ["neurons", "ANATOMY", 147, 154], ["DNN nodes", "ANATOMY", 256, 265], ["neurons", "CELL", 147, 154], ["DNN nodes", "MULTI-TISSUE_STRUCTURE", 256, 265], ["\u03d5 1", "GENE_OR_GENE_PRODUCT", 285, 288], ["DNN nodes", "DNA", 256, 265], ["\u03d5 1", "DNA", 285, 288], ["pos/neg and as inc/dec", "DNA", 308, 330], ["loss of generality", "PROBLEM", 228, 246], ["the DNN nodes", "PROBLEM", 252, 265], ["nodes", "OBSERVATION", 260, 265]]], ["We do this by specifying an abstract operator that merges a pair of neurons in the network (thus reducing network size by one), and can be applied multiple times.", [["neurons", "ANATOMY", 68, 75], ["neurons", "CELL", 68, 75], ["network", "MULTI-TISSUE_STRUCTURE", 106, 113], ["size", "OBSERVATION_MODIFIER", 114, 118]]], ["The only restrictions are that the two neurons being merged need to be from the same hidden layer, and must share the same pos/neg and inc/dec attributes.", [["neurons", "ANATOMY", 39, 46], ["neurons", "CELL", 39, 46]]], ["Consequently, applying abstract to saturation will result in a network with at most 4 neurons in each hidden layer, which over-approximates the original network.", [["neurons", "ANATOMY", 86, 93], ["neurons", "CELL", 86, 93]]], ["This, of course, would be an immense reduction in the number of neurons for most reasonable input networks.AbstractionThe abstract operator's behavior depends on the attributes of the neurons being merged.", [["neurons", "ANATOMY", 64, 71], ["neurons", "ANATOMY", 184, 191], ["neurons", "CELL", 64, 71], ["input networks", "MULTI-TISSUE_STRUCTURE", 92, 106], ["neurons", "CELL", 184, 191], ["an immense reduction", "TREATMENT", 26, 46]]], ["Let v i,j , v i,k be two hidden neurons of layer i, both classified as pos, inc .", [["neurons", "ANATOMY", 32, 39], ["Let v i", "GENE_OR_GENE_PRODUCT", 0, 7], ["neurons", "CELL", 32, 39], ["pos", "OBSERVATION", 71, 74]]], ["Because layer i is hidden, we know that layers i + 1 and i \u2212 1 are defined.", [["i + 1", "GENE_OR_GENE_PRODUCT", 47, 52], ["i \u2212 1", "GENE_OR_GENE_PRODUCT", 57, 62]]], ["Let v i\u22121,p and v i+1,q denote arbitrary neurons in the preceding and succeeding layer, respectively.", [["neurons", "ANATOMY", 41, 48], ["Let v i\u22121", "GENE_OR_GENE_PRODUCT", 0, 9], ["v i+1", "GENE_OR_GENE_PRODUCT", 16, 21], ["neurons", "CELL", 41, 48], ["Let v", "TEST", 0, 5]]], ["We construct a networkN that is identical to N , except that: (i) nodes v i,j and v i,k are removed and replaced with a new single node, v i,t ; and (ii) all edges that touched nodes v i,j or v i,k are removed, and other edges are untouched.", [["nodes", "OBSERVATION", 66, 71], ["new", "OBSERVATION_MODIFIER", 120, 123], ["node", "OBSERVATION", 131, 135], ["nodes", "OBSERVATION", 177, 182], ["removed", "OBSERVATION", 202, 209], ["edges", "OBSERVATION_MODIFIER", 221, 226], ["untouched", "OBSERVATION", 231, 240]]], ["Finally, we add new incoming and outgoing edges for the new node v i,t as follows:Abstractionwherew represents the weights in the new networkN .", [["new", "OBSERVATION_MODIFIER", 56, 59], ["node", "OBSERVATION", 60, 64]]], ["An illustrative example appears in Fig. 5 .", [["Fig", "OBSERVATION", 35, 38]]], ["Intuitively, this definition of abstract seeks to ensure that the new node v i,t always contributes more to the network's output than the two original nodes v i,j and v i,k -so that the new network produces a larger output than the original for every input.", [["the new node v", "PROBLEM", 62, 76], ["new", "OBSERVATION_MODIFIER", 66, 69], ["node", "OBSERVATION", 70, 74], ["nodes", "OBSERVATION", 151, 156], ["larger", "OBSERVATION_MODIFIER", 209, 215], ["output", "OBSERVATION_MODIFIER", 216, 222]]], ["By the way we defined the incoming edges of the new neuron v i,t , we are guaranteed that for every input x passed into both N andN , the value assigned to v i,t inN is greater than the values assigned to both v i,j and v i,k in the original network.", [["N", "CHEMICAL", 125, 126]]], ["This works to our advantage, because v i,j and v i,k were both inc-so increasing their values increases the output value.", [["the output value", "TEST", 104, 120]]], ["By our definition of the outgoing edges, the values of any inc nodes in layer i + 1 increase inN compared to N , and those of any dec nodes decrease.", [["inc nodes", "ANATOMY", 59, 68], ["dec nodes", "ANATOMY", 130, 139], ["dec nodes", "MULTI-TISSUE_STRUCTURE", 130, 139], ["the values", "TEST", 41, 51], ["any inc nodes", "PROBLEM", 55, 68], ["any dec nodes decrease", "PROBLEM", 126, 148], ["inc", "OBSERVATION_MODIFIER", 59, 62], ["nodes", "OBSERVATION", 63, 68], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["nodes", "OBSERVATION", 134, 139], ["decrease", "OBSERVATION_MODIFIER", 140, 148]]], ["By definition, this means that the network's overall output increases.AbstractionThe abstraction operation for the neg, inc case is identical to the one described above.", [["The abstraction operation", "TREATMENT", 81, 106]]], ["For the remaining two cases, i.e. pos, dec and neg, dec , the max operator in the definition is replaced with a min operator.AbstractionThe next lemma (proof omitted due to lack of space) justifies the use of our abstraction step, and can be applied once per each application of abstract: Lemma 2.", [["a min operator", "TREATMENT", 110, 124], ["our abstraction step", "TREATMENT", 209, 229]]], ["LetN be derived from N by a single application of abstract.", [["LetN", "GENE_OR_GENE_PRODUCT", 0, 4], ["LetN", "PROTEIN", 0, 4]]], ["For every x, it holds thatN (x) \u2265 N (x).RefinementThe aforementioned abstract operator reduces network size by merging neurons, but at the cost of accuracy: whereas for some input x 0 the original network returns N (x 0 ) = 3, the over-approximation networkN created by abstract might returnN (x 0 ) = 5.", [["neurons", "ANATOMY", 119, 126], ["thatN", "CHEMICAL", 22, 27], ["N", "CHEMICAL", 34, 35], ["network", "MULTI-TISSUE_STRUCTURE", 95, 102], ["neurons", "CELL", 119, 126], ["some input", "PROBLEM", 169, 179], ["size", "OBSERVATION_MODIFIER", 103, 107]]], ["Next (middle), abstract merges v1 and v2 into a single node.", [["node", "ANATOMY", 55, 59], ["node", "MULTI-TISSUE_STRUCTURE", 55, 59], ["v1", "DNA", 31, 33], ["middle", "ANATOMY_MODIFIER", 6, 12], ["single", "OBSERVATION_MODIFIER", 48, 54], ["node", "OBSERVATION", 55, 59]]], ["For the edge between x1 and the new abstract node we pick the weight 4, which is the maximal weight among edges from x1 to v1 and v2.", [["node", "ANATOMY", 45, 49], ["x1", "DNA", 21, 23], ["v1", "DNA", 123, 125], ["new", "OBSERVATION_MODIFIER", 32, 35], ["abstract node", "OBSERVATION", 36, 49]]], ["Likewise, the edge between x2 and the abstract node has weight \u22121.", [["node", "ANATOMY", 47, 51], ["node", "MULTI-TISSUE_STRUCTURE", 47, 51], ["x2", "DNA", 27, 29], ["weight", "TEST", 56, 62], ["edge", "OBSERVATION_MODIFIER", 14, 18], ["node", "OBSERVATION", 47, 51]]], ["The outgoing edge from the abstract node to y has weight 8, which is the sum of the weights of edges from v1 and v2 to y.", [["node", "ANATOMY", 36, 40], ["weight", "TEST", 50, 56], ["abstract node", "OBSERVATION", 27, 40], ["edges", "ANATOMY_MODIFIER", 95, 100]]], ["Next, abstract is applied again to merge v3 with the abstract node, and the weights are adjusted accordingly (right).", [["node", "ANATOMY", 62, 66], ["node", "MULTI-TISSUE_STRUCTURE", 62, 66], ["the weights", "TEST", 72, 83], ["abstract node", "OBSERVATION", 53, 66], ["right", "ANATOMY_MODIFIER", 110, 115]]], ["With every abstraction, the value of y (given as a formula at the bottom of each DNN, where R represents the ReLU operator) increases.", [["DNN", "PROTEIN", 81, 84]]], ["For example, to see thatRefinement, which holds because ReLU is a monotonically increasing function and x1 and x2 are non-negative (being, themselves, the output of ReLU nodes).RefinementN (x) \u2264 10, and this will be enough.", [["ReLU nodes", "MULTI-TISSUE_STRUCTURE", 165, 175], ["ReLU", "PROTEIN", 56, 60], ["x1", "DNA", 104, 106], ["x2", "DNA", 111, 113], ["a monotonically increasing function", "PROBLEM", 64, 99], ["nodes", "OBSERVATION", 170, 175]]], ["However, if our goal is to prove that it is never the case that N (x) > 4, the over-approximation is inadequate: it is possible that the property holds for N , but becauseN (x 0 ) = 5 > 4, our verification procedure will return x 0 as a spurious counterexample (a counterexample for N that is not a counterexample for N ).", [["N", "CHEMICAL", 156, 157], ["our verification procedure", "TREATMENT", 189, 215]]], ["In order to handle this situation, we define a refinement operator, refine, that is the inverse of abstract: it trans-formsN into yet another over-approximation,N , with the property that for every x, N (x) \u2264N (x) \u2264N (x).", [["N", "CHEMICAL", 201, 202], ["N", "CHEMICAL", 208, 209], ["N", "CHEMICAL", 215, 216]]], ["IfN (x 0 ) = 3.5, it might be a suitable overapproximation for showing that never N (x) > 4.", [["N", "CHEMICAL", 82, 83], ["IfN", "TEST", 0, 3]]], ["4 we explain how to use abstract and refine as part of a CEGAR-based verification scheme.", [["a CEGAR", "TREATMENT", 55, 62]]], ["Recall that abstract merges together a couple of neurons that share the same attributes.", [["neurons", "ANATOMY", 49, 56], ["neurons", "CELL", 49, 56]]], ["After a series of applications of abstract, each hidden layer i of the resulting network can be regarded as a partitioning of hidden layer i of the original network, where each partition contains original, concrete neurons that share the same attributes.", [["neurons", "ANATOMY", 215, 222], ["neurons", "CELL", 215, 222], ["concrete neurons", "CELL_TYPE", 206, 222]]], ["In the abstract network, each partition is represented by a single, abstract neuron.", [["neuron", "ANATOMY", 77, 83], ["neuron", "CELL", 77, 83]]], ["The weights on the incoming and outgoing edges of this abstract neuron are determined according to the definition of the abstract operator.", [["neuron", "ANATOMY", 64, 70], ["neuron", "CELL", 64, 70]]], ["For example, in the case of an abstract neuronv that represents a set of concrete neurons {v 1 , . . . , v n } all with attributes pos, inc , the weight of each incoming edge tov is given b\u0233Refinementwhere u represents a neuron that has not been abstracted yet, and w is the weight function of the original network.", [["neurons", "ANATOMY", 82, 89], ["neuron", "ANATOMY", 221, 227], ["neuronv", "CANCER", 40, 47], ["an abstract neuronv", "PROBLEM", 28, 47]]], ["The key point here is that the order of abstract operations that merged v 1 , . . . , v n does not matter-but rather, only the fact that they are now grouped together determines the abstract network's weights.", [["abstract operations", "TREATMENT", 40, 59]]], ["The following corollary, which is a direct result of Lemma 2, establishes this connection between sequences of abstract applications and partitions: Corollary 1.", [["Lemma 2", "PROBLEM", 53, 60]]], ["Let N be a DNN where each hidden neuron is labeled as pos/neg and inc/dec, and let P be a partitioning of the hidden neurons of N , that only groups together hidden neurons from the same layer that share the same labels.", [["neuron", "ANATOMY", 33, 39], ["neurons", "ANATOMY", 117, 124], ["neurons", "ANATOMY", 165, 172], ["Let N", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNN", "CANCER", 11, 14], ["neg", "GENE_OR_GENE_PRODUCT", 58, 61], ["let P", "GENE_OR_GENE_PRODUCT", 79, 84], ["neurons", "CELL", 117, 124], ["neurons", "CELL", 165, 172], ["DNN", "DNA", 11, 14], ["P", "DNA", 83, 84]]], ["Then N and P give rise to an abstract neural networkN , which is obtained by performing a series of abstract operations that group together neurons according to the partitions of P. ThisN is an over-approximation of N .RefinementWe now define a refine operation that is, in a sense, the inverse of abstract. refine takes as input a DNNN that was generated from N via a sequence of abstract operations, and splits a neuron fromN in two.", [["neural", "ANATOMY", 38, 44], ["neurons", "ANATOMY", 140, 147], ["neuron", "ANATOMY", 415, 421], ["neurons", "CELL", 140, 147], ["N and P", "PROTEIN", 5, 12], ["DNNN", "PROTEIN", 332, 336], ["fromN", "PROTEIN", 422, 427], ["abstract operations", "TREATMENT", 100, 119], ["a refine operation", "TREATMENT", 243, 261], ["abstract operations", "TREATMENT", 381, 400]]], ["Formally, the operator receives the original network N , the partitioning P, and a finer partition P that is obtained from P by splitting a single class in two.", [["P", "DNA", 74, 75], ["P", "DNA", 99, 100], ["P", "DNA", 123, 124]]], ["The operator then returns a new abstract network,N , that is the abstraction of N according to P .RefinementDue to Corollary 1, and becauseN returned by refine corresponds to a partition P of the hidden neurons of N , it is straightforward to show thatN is indeed an over-approximation of N .", [["neurons", "ANATOMY", 203, 210], ["neurons", "CELL", 203, 210], ["P", "DNA", 95, 96], ["P", "DNA", 187, 188]]], ["LetN be an abstraction of N , and letN be a network obtained fromN by applying a single refine step.", [["N", "CHEMICAL", 26, 27], ["LetN", "GENE_OR_GENE_PRODUCT", 0, 4], ["letN", "GENE_OR_GENE_PRODUCT", 34, 38], ["fromN", "SIMPLE_CHEMICAL", 61, 66], ["fromN", "PROTEIN", 61, 66], ["abstraction", "OBSERVATION", 11, 22]]], ["Then for every input x it holds thatThe second part of the inequality,N (x) \u2265 N (x) holds becauseN is an over-approximation of N (Corollary 1).", [["N", "CHEMICAL", 70, 71], ["N", "CHEMICAL", 78, 79]]], ["The first part of the inequality,N (x) \u2265 N (x), follows from the fact thatN (x) can be obtained fromN (x) by a single application of abstract.Lemma 3.", [["N (x) \u2265 N (x)", "TEST", 33, 46]]], ["LetN be an abstraction of N , and letN be a network obtained fromN by applying a single refine step.", [["N", "CHEMICAL", 26, 27], ["LetN", "GENE_OR_GENE_PRODUCT", 0, 4], ["letN", "GENE_OR_GENE_PRODUCT", 34, 38], ["fromN", "SIMPLE_CHEMICAL", 61, 66], ["fromN", "PROTEIN", 61, 66], ["abstraction", "OBSERVATION", 11, 22]]], ["Then for every input x it holds thatIn practice, in order to support the refinement of an abstract DNN, we maintain the current partitioning, i.e. the mapping from concrete neurons to the abstract neurons that represent them.", [["neurons", "ANATOMY", 173, 180], ["neurons", "ANATOMY", 197, 204], ["DNN", "CANCER", 99, 102], ["neurons", "CELL", 173, 180], ["neurons", "CELL", 197, 204], ["DNN", "PROTEIN", 99, 102], ["concrete neurons", "CELL_TYPE", 164, 180], ["the mapping", "TEST", 147, 158]]], ["4), we adjust the mapping and use it to compute the weights of the edges that touch the affected neuron.A CEGAR-Based ApproachIn Sect.", [["neuron", "ANATOMY", 97, 103], ["neuron", "CELL", 97, 103], ["the mapping", "TREATMENT", 14, 25]]], ["3 we defined the abstract operator that reduces network size at the cost of reducing network accuracy, and its inverse refine operator that increases network size and restores accuracy.", [["network", "MULTI-TISSUE_STRUCTURE", 48, 55], ["network", "MULTI-TISSUE_STRUCTURE", 85, 92], ["network", "MULTI-TISSUE_STRUCTURE", 150, 157], ["size", "OBSERVATION_MODIFIER", 56, 60], ["size", "OBSERVATION_MODIFIER", 158, 162]]], ["Together with a black-box verification procedure Verify that can dispatch queries of the form \u03d5 = N, P, Q , these components now allow us to design an abstraction-refinement algorithm for DNN verification, given as Algorithm 1 (we assume that all hidden neurons in the input network have already been marked pos/neg and inc/dec).Algorithm 1.", [["neurons", "ANATOMY", 254, 261], ["neurons", "CELL", 254, 261], ["input network", "MULTI-TISSUE_STRUCTURE", 269, 282], ["a black-box verification procedure", "TREATMENT", 14, 48], ["an abstraction", "TEST", 148, 162], ["refinement algorithm", "TEST", 163, 183], ["DNN verification", "TEST", 188, 204]]], ["Abstraction-based DNN Verification(N, P, Q)1: Use abstract to generate an initial over-approximationN of N 2: if Verify(N, P, Q) is UNSAT then 3:Algorithm 1.", [["Abstraction", "TEST", 0, 11]]], ["Abstraction-based DNN Verification(N, P, Q)return UNSAT 4: else 5:Algorithm 1.", [["Abstraction", "TEST", 0, 11]]], ["Abstraction-based DNN Verification(N, P, Q)Extract counterexample c 6:Algorithm 1.", [["Abstraction", "TEST", 0, 11], ["Verification", "TEST", 22, 34]]], ["Abstraction-based DNN Verification(N, P, Q)if c is a counterexample for N then 7:Algorithm 1.", [["Abstraction", "TEST", 0, 11]]], ["Abstraction-based DNN Verification(N, P, Q)return SAT 8: else 9:Algorithm 1.", [["Abstraction", "TEST", 0, 11]]], ["Abstraction-based DNN Verification(N, P, Q)Use refine to refineN intoN 10:N \u2190N 11:Algorithm 1.", [["Abstraction", "TEST", 0, 11]]], ["Abstraction-based DNN Verification(N, P, Q)Goto step 2 12:Algorithm 1.", [["Abstraction", "TEST", 0, 11], ["Verification", "TEST", 22, 34]]], ["Abstraction-based DNN Verification(N, P, Q)end if 13: end if BecauseN is obtained via applications of abstract and refine, the soundness of the underlying Verify procedure, together with Lemmas 2 and 3, guarantees the soundness of Algorithm 1.", [["Abstraction", "TEST", 0, 11], ["procedure", "TREATMENT", 162, 171]]], ["Because no additional abstract operations are performed beyond Step 1, after finitely many refine stepsN will become identical to N , at which point no spurious counterexample will be found, and the algorithm will terminate with either SAT or UNSAT.", [["additional abstract operations", "TREATMENT", 11, 41], ["spurious counterexample", "PROBLEM", 152, 175]]], ["Of course, termination is only guaranteed when the underlying Verify procedure is guaranteed to terminate.Algorithm 1.", [["the underlying Verify procedure", "TREATMENT", 47, 78]]], ["Abstraction-based DNN Verification(N, P, Q)There are two steps in the algorithm that we intentionally left ambiguous:Algorithm 1.", [["Abstraction", "TEST", 0, 11]]], ["Abstraction-based DNN Verification(N, P, Q)Step 1, where the initial over-approximation is computed, and Step 9, where the current abstraction is refined due to the discovery of a spurious counterexample.", [["Abstraction", "TEST", 0, 11], ["a spurious counterexample", "PROBLEM", 178, 203]]], ["The motivation was to make Algorithm 1 general, and allow it to be customized by plugging in different heuristics for performing Steps 1 and 9, which may depend on the problem at hand.", [["hand", "ORGANISM_SUBDIVISION", 179, 183], ["plugging", "PROBLEM", 81, 89], ["plugging", "OBSERVATION", 81, 89]]], ["As previously discussed, abstract can merge together any pair of hidden neurons from a given layer that share the same attributes.", [["neurons", "ANATOMY", 72, 79], ["neurons", "CELL", 72, 79], ["hidden neurons", "CELL_TYPE", 65, 79], ["hidden neurons", "PROBLEM", 65, 79]]], ["Since there are four possible attribute combinations, this will result in each hidden layer of the network having four neurons or fewer.", [["neurons", "ANATOMY", 119, 126], ["neurons", "CELL", 119, 126]]], ["The downside is that, in some case, these networks might be too coarse, and might require multiple rounds of refinement before a SAT or UNSAT answer can be reached.Generating an Initial AbstractionA different heuristic for producing abstractions that may require fewer refinement steps is as follows.", [["a SAT", "TEST", 127, 132]]], ["Another point that is addressed by Algorithm 2, besides how many rounds of abstraction should be performed, is which pair of neurons should be merged in every application of abstract.", [["neurons", "ANATOMY", 125, 132], ["neurons", "CELL", 125, 132]]], ["Since any pair of neurons that we pick will result in the same reduction in network size, our strategy is to prefer neurons that will result in a more accurate approximation.", [["neurons", "ANATOMY", 18, 25], ["neurons", "ANATOMY", 116, 123], ["neurons", "CELL", 18, 25], ["network", "MULTI-TISSUE_STRUCTURE", 76, 83], ["neurons", "CELL", 116, 123], ["size", "OBSERVATION_MODIFIER", 84, 88]]], ["Inaccuracies are caused by the max and min operators within the abstract operator: e.g., in the case of max , every pair of incoming edges with weights a, b are replaced by a single edge with weight max (a, b).", [["weight max", "TEST", 192, 202]]], ["Our strategy here is to merge the pair of neurons for which the maximal value of |a \u2212 b| (over all incoming edges with weights a and b) is minimal.", [["neurons", "ANATOMY", 42, 49], ["neurons", "CELL", 42, 49], ["neurons", "ANATOMY", 42, 49], ["minimal", "OBSERVATION_MODIFIER", 139, 146]]], ["Intuitively, this leads to max (a, b) being close to both a and b-which, in turn, leads to an over-approximation network that is smaller than the original, but is close to it weight-wise.", [["smaller", "OBSERVATION_MODIFIER", 129, 136]]], ["Still, if this step happens to become a bottleneck, it is possible to adjust the algorithm to heuristically sample just some of the pairs, and pick the best pair among those considered-without harming the algorithm's soundness.Algorithm 2.", [["the algorithm", "TREATMENT", 77, 90]]], ["Indicator-Guided Abstraction(N, P, Q, X)As a small example, consider the network depicted on the left hand side of Fig. 5 .", [["left hand", "ANATOMY", 97, 106], ["Guided Abstraction", "TEST", 10, 28], ["left", "ANATOMY_MODIFIER", 97, 101]]], ["This network has three pairs of neurons that can be merged using abstract (any subset of {v 1 , v 2 , v 3 }).", [["neurons", "ANATOMY", 32, 39], ["neurons", "CELL", 32, 39]]], ["Consider the pair v 1 , v 2 : the maximal value of |a \u2212 b| for these neurons is max (|1 \u2212 4)|, |(\u22122) \u2212 (\u22121)|) = 3.", [["neurons", "ANATOMY", 69, 76], ["neurons", "CELL", 69, 76], ["the pair v", "TEST", 9, 19], ["the maximal value", "TEST", 30, 47], ["these neurons", "TEST", 63, 76]]], ["For pair v 1 , v 3 , the maximal value is 1; and for pair v 2 , v 3 the maximal value is 2.", [["v 3", "GENE_OR_GENE_PRODUCT", 15, 18], ["v 3", "GENE_OR_GENE_PRODUCT", 64, 67], ["pair v", "TEST", 4, 10], ["the maximal value", "TEST", 21, 38], ["pair v", "TEST", 53, 59], ["the maximal value", "TEST", 68, 85]]], ["According to the strategy described in Algorithm 2, we would first choose to apply abstract on the pair with the minimal maximal value, i.e. on the pair v 1 , v 3 .Performing the Refinement StepA refinement step is performed when a spurious counterexample x has been found, indicating that the abstract network is too coarse.", [["v 3", "GENE_OR_GENE_PRODUCT", 159, 162], ["a spurious counterexample x", "PROBLEM", 230, 257]]], ["In other words, our abstraction steps, and specifically the max and min operators that were used to select edge weights for the abstract neurons, have resulted in the abstract network's output being too great for input x, and we now need to reduce it.", [["neurons", "ANATOMY", 137, 144], ["neurons", "CELL", 137, 144], ["the abstract network's output", "PROBLEM", 163, 192]]], ["Thus, our refinement strategies are aimed at applying refine in a way that will result in a significant reduction to the abstract network's output.", [["a significant reduction", "PROBLEM", 90, 113]]], ["We note that there may be multiple options for applying refine, on different nodes, such that any of them would remove the spurious counterexample x from the abstract network.", [["different nodes", "PROBLEM", 67, 82], ["may be", "UNCERTAINTY", 19, 25], ["multiple", "OBSERVATION_MODIFIER", 26, 34], ["nodes", "OBSERVATION", 77, 82]]], ["In addition, it is not guaranteed that it is possible to remove x with a single application of refine, and multiple consecutive applications may be required.Performing the Refinement StepOne heuristic approach for refinement follows the well-studied notion of counterexample-guided abstraction refinement [6] .", [["multiple consecutive applications", "TREATMENT", 107, 140]]], ["Intuitively, a neuron pair v,v for which the difference |v(x) \u2212v(x)| is significant makes a good candidate for a refinement operation that will split v away fromv.Performing the Refinement StepIn addition to considering v(x) andv(x), we propose to also consider the weights of the incoming edges of v andv.", [["neuron", "ANATOMY", 15, 21], ["v andv", "GENE_OR_GENE_PRODUCT", 299, 305], ["a refinement operation", "TREATMENT", 111, 133]]], ["When these weights differ significantly, this could indicate thatv is too coarse an approximation for v, and should be refined.", [["these weights", "TEST", 5, 18]]], ["We argue that by combining these two criteria-edge weight difference between v andv, which is a property of the current abstraction, together with the difference between v(x) andv(x), which is a property of the specific input x, we can identify abstract neurons that have contributed significantly to x being a spurious counterexample.Performing the Refinement StepThe refinement heuristic is formally defined in Algorithm 3.", [["neurons", "ANATOMY", 254, 261], ["neurons", "CELL", 254, 261], ["abstract neurons", "PROBLEM", 245, 261]]], ["The algorithm traverses the original neurons, looks for the edge weight times assignment value that has changed the most as a result of the current abstraction, and then performs refinement on the neuron at the end of that edge.", [["neurons", "ANATOMY", 37, 44], ["neuron", "ANATOMY", 197, 203], ["neurons", "CELL", 37, 44]]], ["As was the case with Algorithm 2, if considering all possible nodes turns out to be too costly, it is possible to adjust the algorithm to explore only some of the nodes, and pick the best one among those considered-without jeopardizing the algorithm's soundness.", [["nodes", "MULTI-TISSUE_STRUCTURE", 62, 67], ["Algorithm", "TEST", 21, 30], ["nodes", "PROBLEM", 62, 67], ["the algorithm", "TEST", 121, 134], ["nodes", "OBSERVATION", 62, 67], ["nodes", "OBSERVATION", 163, 168]]], ["(N,N , x) 1: bestNeuron \u2190 \u22a5, m \u2190 0 2: for each concrete neuron vi,j of N mapped into abstract neuronv i,j ofN do 3:Algorithm 3.", [["(N,N , x) 1", "CHEMICAL", 0, 11]]], ["Counterexample-Guided RefinementAs an example, let us use Algorithm 3 to choose a refinement step for the right hand side network of Fig. 5 , for a spurious counterexample x 1 , x 2 = 1, 0 .", [["right hand", "ANATOMY", 106, 116], ["a refinement step", "TREATMENT", 80, 97], ["a spurious counterexample", "PROBLEM", 146, 171], ["right", "ANATOMY_MODIFIER", 106, 111]]], ["For this input, the original neurons' evaluation is v 1 = 1, v 2 = 4 and v 3 = 2, whereas the abstract neuron that represents them evaluates to 4.", [["neurons", "ANATOMY", 29, 36], ["neurons", "CELL", 29, 36], ["the original neurons' evaluation", "TEST", 16, 48]]], ["Suppose v 1 is considered first.", [["v 1", "GENE_OR_GENE_PRODUCT", 8, 11]]], ["Thus, the largest value m computed for v 1 is |w(Algorithm 3.", [["largest", "OBSERVATION_MODIFIER", 10, 17]]], ["Counterexample-Guided RefinementThis value of m is larger than the one computed for v 2 (0) and for v 3 (4), and so v 1 is selected for the refinement step.", [["v 1", "GENE_OR_GENE_PRODUCT", 116, 119], ["larger", "OBSERVATION_MODIFIER", 51, 57]]], ["After this step is performed, v 2 and v 3 are still mapped to a single abstract neuron, whereas v 1 is mapped to a separate neuron in the abstract network.Implementation and EvaluationOur implementation of the abstraction-refinement framework includes modules that read a DNN in the NNet format [19] and a property to be verified, create an initial abstract DNN as described in Sect.", [["neuron", "ANATOMY", 80, 86], ["neuron", "ANATOMY", 124, 130], ["v 2", "GENE_OR_GENE_PRODUCT", 30, 33], ["v 3", "GENE_OR_GENE_PRODUCT", 38, 41], ["v 1", "GENE_OR_GENE_PRODUCT", 96, 99], ["DNN", "CANCER", 358, 361], ["DNN", "DNA", 272, 275], ["DNN", "DNA", 358, 361], ["the abstraction", "TEST", 206, 221]]], ["ACAS Xu is a system designed to produce horizontal turning advisories for an unmanned aircraft (the ownship), with the purpose of preventing a collision with another nearby aircraft (the intruder ).", [["horizontal turning advisories", "TREATMENT", 40, 69]]], ["The ACAS Xu system receive as input sensor readings, indicating the location of the intruder relative to the ownship, the speeds of the two aircraft, and their directions (see Fig. 6 ).", [["input sensor readings", "TEST", 30, 51], ["ACAS", "OBSERVATION", 4, 8]]], ["Based on these readings, it selects one of 45 DNNs, to which the readings are then passed as input.", [["these readings", "TEST", 9, 23]]], ["The selected DNN then assigns scores to five output neurons, each representing a possible turning advisory: strong left, weak left, strong right, weak right, or clear-of-conflict (the latter indicating that it is safe to continue along the current trajectory).", [["neurons", "ANATOMY", 52, 59], ["neurons", "CELL", 52, 59], ["DNN", "DNA", 13, 16], ["left", "ANATOMY_MODIFIER", 115, 119], ["weak", "OBSERVATION", 121, 125], ["left", "ANATOMY_MODIFIER", 126, 130], ["right", "ANATOMY_MODIFIER", 139, 144], ["weak", "OBSERVATION", 146, 150], ["right", "ANATOMY_MODIFIER", 151, 156], ["clear", "OBSERVATION", 161, 166]]], ["The neuron with the lowest score represents the selected advisory.", [["neuron", "ANATOMY", 4, 10], ["neuron", "CELL", 4, 10]]], ["We verified several properties of these DNNs based on the list of properties that appeared in [20] -specifically focusing on properties that ensure that the DNNs always advise clear-of-conflict for distant intruders, and that they are robust to (i.e., do not change their advisories in the presence of) small input perturbations.Implementation and EvaluationEach of the ACAS Xu DNNs has 300 hidden nodes spread across 6 hidden layers, leading to 1200 neurons when the transformation from Sect.", [["nodes", "ANATOMY", 398, 403], ["neurons", "ANATOMY", 451, 458], ["nodes", "MULTI-TISSUE_STRUCTURE", 398, 403], ["neurons", "CELL", 451, 458], ["ACAS Xu DNNs", "DNA", 370, 382], ["these DNNs", "TREATMENT", 34, 44], ["small input perturbations", "PROBLEM", 303, 328], ["hidden nodes spread", "PROBLEM", 391, 410], ["nodes", "OBSERVATION", 398, 403]]], ["In our experiments we set out to check whether the abstraction-based approach could indeed prove properties of the ACAS Xu networks on abstract networks that had significantly fewer neurons than the original ones.", [["neurons", "ANATOMY", 182, 189], ["neurons", "CELL", 182, 189], ["ACAS Xu networks", "DNA", 115, 131], ["the abstraction", "PROBLEM", 47, 62], ["significantly fewer neurons", "PROBLEM", 162, 189]]], ["In addition, we wished to compare the proposed approaches for generating initial abstractions (the abstraction to saturation approach versus the indicator-guided abstraction described in Algorithm 2), in order to identify an optimal configuration for our tool.", [["generating initial abstractions", "PROBLEM", 62, 93], ["saturation approach", "TEST", 114, 133]]], ["Figure 7 depicts a comparison of the two approaches for generating initial abstractions: the abstraction to saturation scheme (x axis), and the indicatorguided abstraction scheme described in Algorithm 2 (y axis).", [["the indicatorguided abstraction scheme", "PROBLEM", 140, 178]]], ["Each experiment included running our tool twice on the same benchmark (network and property), with an identical configuration except for the initial abstraction being used.", [["the initial abstraction", "PROBLEM", 137, 160]]], ["The plot depicts the total time (log-scale, in seconds, with a 20-h timeout) spent by Marabou solving verification queries as part of the abstraction-refinement procedure.", [["The plot", "TEST", 0, 8], ["refinement procedure", "TREATMENT", 150, 170]]], ["This is perhaps due to the fact that, although it might entail additional rounds of refinement, the abstraction to saturation approach tends to produce coarse verification queries that are easily solved by Marabou, resulting in an overall improved performance.", [["saturation approach", "TEST", 115, 134], ["coarse verification queries", "PROBLEM", 152, 179], ["perhaps due to", "UNCERTAINTY", 8, 22], ["overall", "OBSERVATION_MODIFIER", 231, 238], ["improved", "OBSERVATION_MODIFIER", 239, 247]]], ["We thus conclude that, at least in the ACAS Xu case, the abstraction to saturation approach is superior to that of indicator-guided abstraction.Implementation and EvaluationThis experiment also confirms that properties can indeed be proved on abstract networks that are significantly smaller than the original-i.e., despite the initial 4x increase in network size due to the preprocessing phase, the final abstract network on which our abstraction-enhanced approach could solve the query was usually substantially smaller than the original network.", [["saturation approach", "TREATMENT", 72, 91], ["Evaluation", "TEST", 163, 173], ["significantly", "OBSERVATION_MODIFIER", 270, 283], ["smaller", "OBSERVATION_MODIFIER", 284, 291], ["size", "OBSERVATION_MODIFIER", 359, 363], ["substantially", "OBSERVATION_MODIFIER", 500, 513], ["smaller", "OBSERVATION_MODIFIER", 514, 521]]], ["Specifically, among the abstraction to saturation experiments that terminated, the final network on which the property was shown to be SAT or UNSAT had an average size of 268.8 nodes, compared to the original 310-a 13% reduction.", [["saturation experiments", "TEST", 39, 61], ["SAT", "TEST", 135, 138], ["a 13% reduction", "TREATMENT", 213, 228], ["average", "OBSERVATION_MODIFIER", 155, 162], ["size", "OBSERVATION_MODIFIER", 163, 167], ["268.8 nodes", "OBSERVATION", 171, 182]]], ["Because DNN verification becomes exponentially more difficult as the network size increases, this reduction is highly beneficial.", [["network", "MULTI-TISSUE_STRUCTURE", 69, 76], ["DNN", "DNA", 8, 11], ["this reduction", "TREATMENT", 93, 107], ["size", "OBSERVATION_MODIFIER", 77, 81]]], ["Next, we compared our abstraction-enhanced Marabou (in abstraction to saturation mode) to the vanilla version.", [["vanilla version", "OBSERVATION", 94, 109]]], ["The plot in Fig. 8 compares the total query solving time of vanilla Marabou (y axis) to that of our approach (x axis).", [["vanilla Marabou (y axis)", "TREATMENT", 60, 84]]], ["Interestingly, the average size of the abstract networks for which our tool was able to solve the query was 385 nodes-which is an increase compared to the original 310 nodes.", [["average", "OBSERVATION_MODIFIER", 19, 26], ["size", "OBSERVATION_MODIFIER", 27, 31], ["nodes", "OBSERVATION", 112, 117], ["increase", "OBSERVATION_MODIFIER", 130, 138], ["nodes", "OBSERVATION", 168, 173]]], ["However, the improved runtimes demonstrate that although these networks were slightly larger, they were still much easier to verify, presumably because many of the network's original neurons remained abstracted away.", [["neurons", "ANATOMY", 183, 190], ["neurons", "CELL", 183, 190], ["slightly", "OBSERVATION_MODIFIER", 77, 85], ["larger", "OBSERVATION_MODIFIER", 86, 92]]], ["Finally, we used our abstraction-enhanced Marabou to verify adversarial robustness properties [35] .", [["our abstraction", "TEST", 17, 32]]], ["Intuitively, an adversarial robustness property states that slight input perturbations cannot cause sudden spikes in the network's output.", [["slight input perturbations", "PROBLEM", 60, 86], ["sudden spikes in the network's output", "PROBLEM", 100, 137], ["slight", "OBSERVATION_MODIFIER", 60, 66]]], ["This is desirable because such sudden spikes can lead to misclassification of inputs.", [["such sudden spikes", "PROBLEM", 26, 44]]], ["Unlike the ACAS Xu domain-specific properties [20] , whose formulation required input from human experts, adversarial robustness is a universal property, desirable for every DNN.", [["human", "ORGANISM", 91, 96], ["DNN", "CANCER", 174, 177], ["ACAS Xu domain", "PROTEIN", 11, 25], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96]]], ["Consequently it is easier to formulate, and has received much attention (e.g., [2, 10, 20, 36] ).Implementation and EvaluationIn order to formulate adversarial robustness properties for the ACAS Xu networks, we randomly sampled the ACAS Xu DNNs to identify input points where the selected output advisory, indicated by an output neuron y i , received a much lower score than the second-best advisory, y j (recall that the advisory with the lowest score is selected).", [["ACAS Xu DNNs", "DNA", 232, 244]]], ["Or, more formally:Implementation and EvaluationIf this query is SAT then there exists an input x whose distance to x 0 is at most \u03b4, but for which the network assigns a better (lower) score to advisory y j than to y i .", [["Evaluation", "TEST", 37, 47]]], ["Because we select point x 0 such that y i is initially much smaller than y j , we expect the query to be UNSAT for small values of \u03b4.Implementation and EvaluationFor each of the 45 ACAS Xu networks, we created robustness queries for 20 distinct input points-producing a total of 900 verification queries (we arbitrarily set \u03b4 = 0.1).", [["Evaluation", "TEST", 152, 162]]], ["For each of these queries we compared the runtime of vanilla Marabou to that of our abstraction-enhanced version (with a 20-h timeout).", [["vanilla", "SPECIES", 53, 60]]], ["This impressive 99% improvement in performance highlights the usefulness of our approach also in the context of adversarial robustness.", [["adversarial robustness", "PROBLEM", 112, 134], ["adversarial robustness", "OBSERVATION", 112, 134]]], ["In addition, over the solved benchmarks, the average size of the abstract networks for which our tool was able to solve the query was 104.4 nodes, versus 310 nodes in each of the original networks-a 66% reduction in size.", [["nodes", "PROBLEM", 140, 145], ["310 nodes", "PROBLEM", 154, 163], ["a 66% reduction in size", "TREATMENT", 197, 220], ["average", "OBSERVATION_MODIFIER", 45, 52], ["size", "OBSERVATION_MODIFIER", 53, 57], ["nodes", "OBSERVATION", 140, 145], ["nodes", "OBSERVATION", 158, 163], ["reduction", "OBSERVATION_MODIFIER", 203, 212], ["size", "OBSERVATION_MODIFIER", 216, 220]]], ["This reinforces our statement that, in many cases, DNNs contain a great deal of unneeded neurons, which can safely be removed by the abstraction process for the purpose of verification.Related WorkIn recent years, multiple schemes have been proposed for the verification of neural networks.", [["neurons", "ANATOMY", 89, 96], ["neural networks", "ANATOMY", 274, 289], ["DNNs", "SIMPLE_CHEMICAL", 51, 55], ["neurons", "CELL", 89, 96], ["neural networks", "MULTI-TISSUE_STRUCTURE", 274, 289], ["unneeded neurons", "CELL_TYPE", 80, 96], ["neural networks", "OBSERVATION", 274, 289]]], ["These include SMT-based approaches, such as Marabou [22, 23] , Reluplex [20] , DLV [17] and others; approaches based on formulating the problem as a mixed integer linear programming instance (e.g., [4, 7, 8, 36] ); approaches that use sophisticated symbolic interval propagation [37] , or abstract interpretation [10] ; and others (e.g., [1, 18, 25, 27, 30, 38, 39] ).", [["abstract interpretation", "TEST", 289, 312]]], ["These approaches have been applied in a variety of tasks, such as measuring adversarial robustness [2, 17] , neural network simplification [11] , neural network modification [12] , and many others (e.g., [23, 34] ).", [["neural", "ANATOMY", 109, 115], ["neural", "ANATOMY", 146, 152], ["neural network simplification", "TREATMENT", 109, 138], ["neural network modification", "TREATMENT", 146, 173]]], ["Incomplete solvers could also be used and might afford better performance, but this could result in our approach also becoming incomplete.Related WorkSome existing DNN verification techniques incorporate abstraction elements.", [["DNN", "DNA", 164, 167]]], ["In [31] , the authors use abstraction to over-approximate the Sigmoid activation function with a collection of rectangles.", [["Sigmoid", "ANATOMY", 62, 69]]], ["If the abstract verification query they produce is UNSAT, then so is the original.", [["the abstract verification", "TEST", 3, 28]]], ["When a spurious counterexample is found, an arbitrary refinement step is performed.", [["an arbitrary refinement step", "TEST", 41, 69]]], ["The authors report limited scalability, tackling only networks with a few dozen neurons.", [["neurons", "ANATOMY", 80, 87], ["neurons", "CELL", 80, 87]]], ["Abstraction techniques also appear in the AI2 approach [10] , but there it is the input property and reachable regions that are over-approximated, as opposed to the DNN itself.", [["DNN", "CANCER", 165, 168], ["DNN", "PROTEIN", 165, 168], ["Abstraction techniques", "TREATMENT", 0, 22]]], ["Combining this kind of input-focused abstraction with our network-focused abstraction is an interesting avenue for future work.ConclusionWith deep neural networks becoming widespread and with their forthcoming integration into safety-critical systems, there is an urgent need for scalable techniques to verify and reason about them.", [["neural networks", "ANATOMY", 147, 162], ["neural networks", "MULTI-TISSUE_STRUCTURE", 147, 162], ["scalable techniques", "TREATMENT", 280, 299], ["deep", "ANATOMY_MODIFIER", 142, 146], ["neural", "ANATOMY", 147, 153]]], ["However, the size of these networks poses a serious challenge.", [["a serious challenge", "TREATMENT", 42, 61], ["size", "OBSERVATION_MODIFIER", 13, 17], ["serious", "OBSERVATION_MODIFIER", 44, 51]]], ["Abstraction-based techniques can mitigate this difficulty, by replacing networks with smaller versions thereof to be verified, without compromising the soundness of the verification procedure.", [["the verification procedure", "TREATMENT", 165, 191]]], ["The abstraction-based approach we have proposed here can provide a significant reduction in network size, thus boosting the performance of existing verification technology.ConclusionIn the future, we plan to continue this work along several axes.", [["The abstraction-based approach", "TREATMENT", 0, 30], ["a significant reduction in network size", "PROBLEM", 65, 104], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["reduction", "OBSERVATION_MODIFIER", 79, 88], ["size", "OBSERVATION_MODIFIER", 100, 104]]], ["First, we intend to investigate refinement heuristics that can split an abstract neuron into two arbitrary sized neurons.", [["neuron", "ANATOMY", 81, 87], ["neurons", "ANATOMY", 113, 120], ["neurons", "CELL", 113, 120], ["neurons", "ANATOMY", 113, 120]]], ["In addition, we will investigate abstraction schemes for networks that use additional activation functions, beyond ReLUs.", [["ReLUs", "PROTEIN", 115, 120], ["abstraction schemes", "TREATMENT", 33, 52], ["additional activation functions", "TREATMENT", 75, 106]]], ["Finally, we plan to make our abstraction scheme parallelizable, allowing users to use multiple worker nodes to explore different combinations of abstraction and refinement steps, hopefully leading to faster convergence.", [["multiple worker nodes", "TREATMENT", 86, 107]]]], "PMC7135326": [["IntroductionEmergency physicians play a significant role in the evaluation, diagnosis, and treatment of viral respiratory illnesses.", [["respiratory", "ANATOMY", 110, 121], ["viral respiratory illnesses", "DISEASE", 104, 131], ["the evaluation", "TEST", 60, 74], ["viral respiratory illnesses", "PROBLEM", 104, 131], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["respiratory illnesses", "OBSERVATION", 110, 131]]], ["Fever, headache, cough, and complaints related to the throat are among the 10 most commonly cited reasons for patient presentation to United States (US) emergency departments (EDs) 1, 2, 3.", [["throat", "ANATOMY", 54, 60], ["Fever", "DISEASE", 0, 5], ["headache", "DISEASE", 7, 15], ["cough", "DISEASE", 17, 22], ["throat", "ORGANISM_SUBDIVISION", 54, 60], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["Fever", "PROBLEM", 0, 5], ["headache", "PROBLEM", 7, 15], ["cough", "PROBLEM", 17, 22], ["complaints", "PROBLEM", 28, 38], ["headache", "OBSERVATION", 7, 15], ["cough", "OBSERVATION", 17, 22], ["throat", "ANATOMY", 54, 60]]], ["From 2007 to 2009, approximately 1.3 million individuals experiencing the symptoms mentioned were assigned a formal diagnosis of influenza by an emergency physician 1, 2, 3, 4.", [["influenza", "DISEASE", 129, 138], ["the symptoms", "PROBLEM", 70, 82], ["influenza", "PROBLEM", 129, 138]]], ["Each year, nearly 220,000 patients require hospitalization secondary to influenza; an infection with a mortality rate of 1.4 deaths per 100,000 laboratory-confirmed cases 5, 6.IntroductionInfluenza A, B, and C, named for their respective viral surface proteins, are single-stranded ribonucleic acid viruses belonging to the Orthomyxoviridae family 7, 8, 9.", [["surface", "ANATOMY", 244, 251], ["influenza", "DISEASE", 72, 81], ["infection", "DISEASE", 86, 95], ["deaths", "DISEASE", 125, 131], ["ribonucleic acid", "CHEMICAL", 282, 298], ["patients", "ORGANISM", 26, 34], ["Influenza A", "ORGANISM", 188, 199], ["B", "GENE_OR_GENE_PRODUCT", 201, 202], ["C", "GENE_OR_GENE_PRODUCT", 208, 209], ["viral surface proteins", "PROTEIN", 238, 260], ["Orthomyxoviridae family 7, 8, 9", "PROTEIN", 324, 355], ["patients", "SPECIES", 26, 34], ["influenza", "PROBLEM", 72, 81], ["an infection", "PROBLEM", 83, 95], ["a mortality rate", "TEST", 101, 117], ["IntroductionInfluenza A", "TEST", 176, 199], ["their respective viral surface proteins", "TEST", 221, 260], ["stranded ribonucleic acid viruses", "PROBLEM", 273, 306], ["influenza", "OBSERVATION", 72, 81], ["infection", "OBSERVATION", 86, 95]]], ["While all of the influenza viruses possess the capability for human infectivity, influenza types B and C are primarily responsible for the majority of illness observed in the human population 8, 9.", [["illness", "DISEASE", 151, 158], ["influenza viruses", "ORGANISM", 17, 34], ["human", "ORGANISM", 62, 67], ["influenza types B", "ORGANISM", 81, 98], ["C", "GENE_OR_GENE_PRODUCT", 103, 104], ["human", "ORGANISM", 175, 180], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 175, 180], ["the influenza viruses", "PROBLEM", 13, 34], ["human infectivity", "PROBLEM", 62, 79], ["influenza types B and C", "PROBLEM", 81, 104], ["illness", "PROBLEM", 151, 158]]], ["Of the influenza viruses, only influenza A (commonly affecting birds, horses, swine, and dogs) is characterized by subtype based on the composition and morphology of its envelope glycoproteins 7, 8.IntroductionInfluenza viruses are unique in their ability to generate antigenic variability.", [["influenza viruses", "DISEASE", 7, 24], ["influenza A", "DISEASE", 31, 42], ["Influenza viruses", "DISEASE", 210, 227], ["influenza viruses", "ORGANISM", 7, 24], ["influenza A", "ORGANISM", 31, 42], ["horses", "ORGANISM_SUBDIVISION", 70, 76], ["dogs", "ORGANISM", 89, 93], ["Influenza viruses", "ORGANISM", 210, 227], ["envelope glycoproteins 7, 8", "PROTEIN", 170, 197], ["horses", "SPECIES", 70, 76], ["swine", "SPECIES", 78, 83], ["dogs", "SPECIES", 89, 93], ["horses", "SPECIES", 70, 76], ["swine", "SPECIES", 78, 83], ["the influenza viruses", "PROBLEM", 3, 24], ["influenza A", "PROBLEM", 31, 42], ["IntroductionInfluenza viruses", "PROBLEM", 198, 227], ["influenza viruses", "OBSERVATION", 7, 24], ["antigenic variability", "OBSERVATION", 268, 289]]], ["Minor (antigenic drift) and major (antigenic shift) genomic changes are responsible for several historical and recent influenza epidemics and pandemics 7, 8, 9.", [["influenza epidemics", "DISEASE", 118, 137], ["pandemics", "DISEASE", 142, 151], ["Minor (antigenic drift", "PROBLEM", 0, 22], ["genomic changes", "PROBLEM", 52, 67], ["recent influenza epidemics", "PROBLEM", 111, 137], ["pandemics", "PROBLEM", 142, 151], ["antigenic drift", "OBSERVATION", 7, 22], ["influenza", "OBSERVATION", 118, 127]]], ["Given the socioeconomic cost associated with influenza infection (annual direct costs of care estimated as $4.6 billion, with approximately $7 billion lost to sick days/productivity), primary prevention remains a significant public health concern (10).", [["influenza infection", "DISEASE", 45, 64], ["influenza infection", "PROBLEM", 45, 64], ["significant", "OBSERVATION_MODIFIER", 213, 224]]], ["Risk factors predisposing to a severe clinical course include extremes of age, numerous medical comorbidities, and pregnancy; therefore, the Centers for Disease Control and Prevention (CDC) has published recommendations for influenza vaccination, as detailed in Table 111, 12.Signs of Influenza ::: DiscussionSigns and symptoms of influenza commonly begin after a 1- to 2-day incubation period and are highly variable 7, 8, 9, 10.", [["Influenza", "DISEASE", 285, 294], ["influenza", "DISEASE", 331, 340], ["Risk factors", "PROBLEM", 0, 12], ["a severe clinical course", "PROBLEM", 29, 53], ["numerous medical comorbidities", "PROBLEM", 79, 109], ["pregnancy", "PROBLEM", 115, 124], ["Disease Control", "TREATMENT", 153, 168], ["influenza vaccination", "TREATMENT", 224, 245], ["Influenza", "PROBLEM", 285, 294], ["symptoms", "PROBLEM", 319, 327], ["influenza", "PROBLEM", 331, 340], ["Influenza", "OBSERVATION", 285, 294]]], ["The majority of adolescent and adult patients present with complaints of fever, headache, myalgias, malaise, anorexia, rhinorrhea, pharyngitis, cough, and chest discomfort 9, 10.", [["chest", "ANATOMY", 155, 160], ["fever", "DISEASE", 73, 78], ["headache", "DISEASE", 80, 88], ["myalgias", "DISEASE", 90, 98], ["anorexia", "DISEASE", 109, 117], ["rhinorrhea", "DISEASE", 119, 129], ["pharyngitis", "DISEASE", 131, 142], ["cough", "DISEASE", 144, 149], ["chest discomfort", "DISEASE", 155, 171], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["fever", "PROBLEM", 73, 78], ["headache", "PROBLEM", 80, 88], ["myalgias", "PROBLEM", 90, 98], ["malaise", "PROBLEM", 100, 107], ["anorexia", "PROBLEM", 109, 117], ["rhinorrhea", "PROBLEM", 119, 129], ["pharyngitis", "PROBLEM", 131, 142], ["cough", "PROBLEM", 144, 149], ["chest discomfort", "PROBLEM", 155, 171], ["fever", "OBSERVATION", 73, 78], ["myalgias", "ANATOMY", 90, 98], ["anorexia", "OBSERVATION", 109, 117], ["rhinorrhea", "OBSERVATION", 119, 129], ["pharyngitis", "OBSERVATION", 131, 142], ["cough", "OBSERVATION", 144, 149], ["chest", "ANATOMY", 155, 160]]], ["Abdominal pain, nausea, and emesis are also commonly reported among the pediatric population (15).", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal pain", "DISEASE", 0, 14], ["nausea", "DISEASE", 16, 22], ["emesis", "DISEASE", 28, 34], ["Abdominal pain", "PROBLEM", 0, 14], ["nausea", "PROBLEM", 16, 22], ["emesis", "PROBLEM", 28, 34], ["pain", "OBSERVATION", 10, 14], ["nausea", "OBSERVATION", 16, 22], ["emesis", "OBSERVATION", 28, 34]]], ["At the extremes of age, influenza can manifest as malaise, lethargy, or altered mental status 9, 13.Signs of Influenza ::: DiscussionWhile symptoms of influenza may be caused by a number of respiratory viruses (respiratory syncytial virus, parainfluenza virus, adenovirus, rhinovirus, and coronavirus), in the setting of a local outbreak, the accuracy of clinical diagnoses in healthy adolescent and adult patients approximates 80%\u201390% 9, 23, 24.", [["influenza", "DISEASE", 24, 33], ["lethargy", "DISEASE", 59, 67], ["Influenza", "DISEASE", 109, 118], ["influenza", "DISEASE", 151, 160], ["respiratory viruses", "DISEASE", 190, 209], ["respiratory syncytial virus, parainfluenza virus, adenovirus, rhinovirus, and coronavirus", "DISEASE", 211, 300], ["respiratory viruses", "ORGANISM", 190, 209], ["respiratory syncytial virus", "ORGANISM", 211, 238], ["parainfluenza virus", "ORGANISM", 240, 259], ["adenovirus", "ORGANISM", 261, 271], ["rhinovirus", "ORGANISM", 273, 283], ["patients", "ORGANISM", 406, 414], ["respiratory syncytial virus", "SPECIES", 211, 238], ["parainfluenza virus", "SPECIES", 240, 259], ["patients", "SPECIES", 406, 414], ["respiratory syncytial virus", "SPECIES", 211, 238], ["parainfluenza virus", "SPECIES", 240, 259], ["influenza", "PROBLEM", 24, 33], ["malaise", "PROBLEM", 50, 57], ["lethargy", "PROBLEM", 59, 67], ["altered mental status", "PROBLEM", 72, 93], ["Influenza", "PROBLEM", 109, 118], ["symptoms", "PROBLEM", 139, 147], ["influenza", "PROBLEM", 151, 160], ["respiratory viruses", "PROBLEM", 190, 209], ["respiratory syncytial virus", "PROBLEM", 211, 238], ["parainfluenza virus", "PROBLEM", 240, 259], ["adenovirus", "PROBLEM", 261, 271], ["rhinovirus", "PROBLEM", 273, 283], ["coronavirus", "PROBLEM", 289, 300], ["a local outbreak", "PROBLEM", 321, 337], ["Influenza", "OBSERVATION", 109, 118], ["influenza", "OBSERVATION", 151, 160], ["respiratory viruses", "OBSERVATION", 190, 209], ["local", "OBSERVATION_MODIFIER", 323, 328], ["outbreak", "OBSERVATION", 329, 337]]], ["It is recommended that confirmatory testing be performed in all populations at high risk for complications secondary to infection (see Table 1) and in closed settings in which an influenza outbreak is suspected (e.g., long-term care facilities, inpatient treatment centers) 9, 25.Signs of Influenza ::: DiscussionMethods for influenza detection include antigen detection (rapid influenza diagnostic tests [RIDTs]), direct immunofluorescence, reverse transcription polymerase chain reaction (RT-PCR), viral culture, and serology 9, 26.", [["infection", "DISEASE", 120, 129], ["influenza", "DISEASE", 179, 188], ["Influenza", "DISEASE", 289, 298], ["confirmatory testing", "TEST", 23, 43], ["complications", "PROBLEM", 93, 106], ["infection", "PROBLEM", 120, 129], ["an influenza outbreak", "PROBLEM", 176, 197], ["Influenza", "PROBLEM", 289, 298], ["influenza detection", "TEST", 325, 344], ["antigen detection", "TEST", 353, 370], ["rapid influenza diagnostic tests", "TEST", 372, 404], ["direct immunofluorescence", "TEST", 415, 440], ["reverse transcription polymerase chain reaction", "PROBLEM", 442, 489], ["RT-PCR", "TEST", 491, 497], ["viral culture", "TEST", 500, 513], ["serology", "TEST", 519, 527], ["infection", "OBSERVATION", 120, 129], ["Influenza", "OBSERVATION", 289, 298]]], ["Ideally, samples should be obtained within 4\u20135 days after the onset of symptoms, before the decline in viral replication and shedding (9).", [["samples", "ANATOMY", 9, 16], ["symptoms", "PROBLEM", 71, 79], ["the decline", "PROBLEM", 88, 99], ["viral replication", "TREATMENT", 103, 120], ["viral replication", "OBSERVATION", 103, 120]]], ["The majority of RIDTs provide results within approximately 15 min, with a reported sensitivity of 50%\u201370% and specificity > 90% 9, 26.", [["RIDTs", "CANCER", 16, 21], ["specificity", "TEST", 110, 121]]], ["Positive and negative predictive values of RIDTs should be interpreted with respect to the local prevalence of influenza infection and patient presentation.", [["influenza infection", "DISEASE", 111, 130], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["influenza infection", "PROBLEM", 111, 130], ["negative", "OBSERVATION_MODIFIER", 13, 21], ["predictive values", "OBSERVATION_MODIFIER", 22, 39], ["influenza", "OBSERVATION", 111, 120]]], ["False negatives are likely to occur at the height of the influenza season, when prevalence is high.", [["influenza", "DISEASE", 57, 66], ["False negatives", "PROBLEM", 0, 15], ["high", "OBSERVATION_MODIFIER", 94, 98]]], ["If diagnosis is likely to alter clinical decision making, the CDC recommends confirmation of a negative RIDT with RT-PCR (27).Signs of Influenza ::: DiscussionDirect immunofluorescence testing, RT-PCR, and viral culture require clinical laboratory handling, with processing time ranging from 1\u20138 h (direct immunofluorescence and RT-PCR) to 3\u201310 days (rapid viral culture and traditional viral culture) 9, 26.", [["Influenza", "DISEASE", 135, 144], ["RT-PCR", "TEST", 114, 120], ["Influenza", "PROBLEM", 135, 144], ["immunofluorescence testing", "TEST", 166, 192], ["RT-PCR", "TEST", 194, 200], ["viral culture", "TEST", 206, 219], ["direct immunofluorescence", "TEST", 299, 324], ["RT-PCR", "TEST", 329, 335], ["rapid viral culture", "TEST", 351, 370], ["traditional viral culture", "TEST", 375, 400], ["Influenza", "OBSERVATION", 135, 144]]], ["While individual sensitivities of the 26 Food and Drug Administration\u2013approved RT-PCR assays vary, several studies have demonstrated the superiority of RT-PCR in the detection of influenza viruses, making it the gold standard for diagnostic evaluation 28, 29, 30.", [["influenza viruses", "DISEASE", 179, 196], ["Drug Administration\u2013approved RT-PCR assays", "TEST", 50, 92], ["several studies", "TEST", 99, 114], ["RT-PCR", "TEST", 152, 158], ["influenza viruses", "PROBLEM", 179, 196], ["diagnostic evaluation", "TEST", 230, 251], ["influenza viruses", "OBSERVATION", 179, 196]]], ["Serologic testing allows for the retrospective confirmation of influenza infection, rendering it of little diagnostic utility in the emergency setting (9).Treatment RecommendationsIn the majority of immunocompetent individuals, influenza is self-resolving and does not require treatment (9).", [["influenza infection", "DISEASE", 63, 82], ["influenza", "DISEASE", 228, 237], ["individuals", "ORGANISM", 215, 226], ["Serologic testing", "TEST", 0, 17], ["the retrospective confirmation", "TEST", 29, 59], ["influenza infection", "PROBLEM", 63, 82], ["Treatment", "TREATMENT", 155, 164], ["immunocompetent individuals", "PROBLEM", 199, 226], ["influenza", "PROBLEM", 228, 237], ["treatment", "TREATMENT", 277, 286], ["influenza", "OBSERVATION", 63, 72]]], ["In persons who are at high risk for influenza complications, however, initiation of antiviral therapy can significantly reduce morbidity and mortality 9, 30.", [["influenza complications", "DISEASE", 36, 59], ["persons", "ORGANISM", 3, 10], ["persons", "SPECIES", 3, 10], ["influenza complications", "PROBLEM", 36, 59], ["antiviral therapy", "TREATMENT", 84, 101], ["influenza", "OBSERVATION", 36, 45]]], ["Populations in which antiviral treatment is recommended are detailed in Table 1(31).", [["antiviral treatment", "TREATMENT", 21, 40], ["antiviral treatment", "OBSERVATION", 21, 40]]], ["Double-blinded, placebo-controlled studies of influenza antiviral agents reported a mean reduction in febrile influenza illness of 1\u20131.6 days compared with placebo when therapy was initiated within 48 h of symptom onset 32, 33, 34, 35.", [["influenza illness", "DISEASE", 110, 127], ["placebo", "TREATMENT", 16, 23], ["influenza antiviral agents", "TREATMENT", 46, 72], ["febrile influenza illness", "PROBLEM", 102, 127], ["placebo", "TREATMENT", 156, 163], ["therapy", "TREATMENT", 169, 176], ["symptom onset", "TEST", 206, 219], ["febrile influenza", "OBSERVATION", 102, 119]]], ["For patients at risk of influenza complications presenting within 48 h of symptom onset, the CDC recommends treatment during the 2016\u20132017 influenza season as detailed in Table 3(36).Treatment RecommendationsTwo antiviral classes are commonly utilized in the treatment of influenza.", [["influenza complications", "DISEASE", 24, 47], ["influenza", "DISEASE", 139, 148], ["influenza", "DISEASE", 272, 281], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["influenza complications", "PROBLEM", 24, 47], ["symptom onset", "PROBLEM", 74, 87], ["treatment", "TREATMENT", 108, 117], ["Treatment", "TREATMENT", 183, 192], ["Two antiviral classes", "TREATMENT", 208, 229], ["influenza", "PROBLEM", 272, 281], ["influenza", "OBSERVATION", 24, 33], ["influenza", "OBSERVATION", 272, 281]]], ["The neuraminidase inhibitors oseltamivir (Tamiflu\u00a9), zanamivir (Relenza\u00a9), and peramivir (Rapivab\u00a9) inhibit viral aggregation and release of infectious nucleic acids to nearby host cells, therefore limiting infection 9, 36.", [["cells", "ANATOMY", 181, 186], ["oseltamivir", "CHEMICAL", 29, 40], ["Tamiflu\u00a9", "CHEMICAL", 42, 50], ["zanamivir", "CHEMICAL", 53, 62], ["Relenza\u00a9", "CHEMICAL", 64, 72], ["peramivir", "CHEMICAL", 79, 88], ["Rapivab\u00a9", "CHEMICAL", 90, 98], ["viral aggregation", "DISEASE", 108, 125], ["nucleic acids", "CHEMICAL", 152, 165], ["infection", "DISEASE", 207, 216], ["oseltamivir", "CHEMICAL", 29, 40], ["Tamiflu\u00a9", "CHEMICAL", 42, 50], ["zanamivir", "CHEMICAL", 53, 62], ["Relenza\u00a9", "CHEMICAL", 64, 72], ["peramivir", "CHEMICAL", 79, 88], ["Rapivab\u00a9", "CHEMICAL", 90, 98], ["oseltamivir", "SIMPLE_CHEMICAL", 29, 40], ["Tamiflu\u00a9", "SIMPLE_CHEMICAL", 42, 50], ["zanamivir", "SIMPLE_CHEMICAL", 53, 62], ["Relenza\u00a9", "SIMPLE_CHEMICAL", 64, 72], ["peramivir", "SIMPLE_CHEMICAL", 79, 88], ["Rapivab\u00a9", "SIMPLE_CHEMICAL", 90, 98], ["host cells", "CELL", 176, 186], ["nearby host cells", "CELL_TYPE", 169, 186], ["The neuraminidase inhibitors", "TREATMENT", 0, 28], ["oseltamivir (Tamiflu\u00a9)", "TREATMENT", 29, 51], ["zanamivir (Relenza\u00a9)", "TREATMENT", 53, 73], ["peramivir (Rapivab\u00a9)", "TREATMENT", 79, 99], ["viral aggregation", "PROBLEM", 108, 125], ["infectious nucleic acids", "TREATMENT", 141, 165], ["limiting infection", "PROBLEM", 198, 216], ["infection", "OBSERVATION", 207, 216]]], ["Amantadine (Symmetrel\u00a9) and rimantadine (Flumadine\u00a9), M2 inhibitors, are responsible for halting viral replication by inhibiting the release of infectious viral nucleic acids into host cells 9, 36.", [["cells", "ANATOMY", 185, 190], ["Amantadine", "CHEMICAL", 0, 10], ["Symmetrel\u00a9", "CHEMICAL", 12, 22], ["rimantadine", "CHEMICAL", 28, 39], ["Flumadine\u00a9", "CHEMICAL", 41, 51], ["nucleic acids", "CHEMICAL", 161, 174], ["Amantadine", "CHEMICAL", 0, 10], ["Symmetrel\u00a9", "CHEMICAL", 12, 22], ["rimantadine", "CHEMICAL", 28, 39], ["Flumadine\u00a9", "CHEMICAL", 41, 51], ["Amantadine", "SIMPLE_CHEMICAL", 0, 10], ["Symmetrel\u00a9", "SIMPLE_CHEMICAL", 12, 22], ["rimantadine", "SIMPLE_CHEMICAL", 28, 39], ["Flumadine\u00a9", "SIMPLE_CHEMICAL", 41, 51], ["M2", "GENE_OR_GENE_PRODUCT", 54, 56], ["host cells", "CELL", 180, 190], ["host cells", "CELL_TYPE", 180, 190], ["Amantadine (Symmetrel\u00a9)", "TREATMENT", 0, 23], ["rimantadine (Flumadine\u00a9)", "TREATMENT", 28, 52], ["M2 inhibitors", "TREATMENT", 54, 67], ["halting viral replication", "TREATMENT", 89, 114], ["infectious viral nucleic acids", "TEST", 144, 174]]], ["Although amantadine and rimantidine have previously been utilized in the treatment of influenza, the CDC does not recommend their use for the 2016\u20132017 influenza season because of viral resistance (36).Chemoprophylaxis RecommendationsIndividuals to be considered for chemoprophylaxis include family and close contacts of persons with suspected or confirmed cases of influenza at high risk for complications secondary to influenza infection, but have not been vaccinated against influenza strains circulating at the time of exposure 37, 38.", [["amantadine", "CHEMICAL", 9, 19], ["rimantidine", "CHEMICAL", 24, 35], ["influenza", "DISEASE", 86, 95], ["influenza", "DISEASE", 152, 161], ["influenza", "DISEASE", 366, 375], ["influenza infection", "DISEASE", 420, 439], ["amantadine", "CHEMICAL", 9, 19], ["rimantidine", "CHEMICAL", 24, 35], ["amantadine", "SIMPLE_CHEMICAL", 9, 19], ["rimantidine", "SIMPLE_CHEMICAL", 24, 35], ["persons", "ORGANISM", 321, 328], ["persons", "SPECIES", 321, 328], ["amantadine", "TREATMENT", 9, 19], ["rimantidine", "TREATMENT", 24, 35], ["influenza", "PROBLEM", 86, 95], ["viral resistance", "PROBLEM", 180, 196], ["Chemoprophylaxis", "TREATMENT", 202, 218], ["chemoprophylaxis", "TREATMENT", 267, 283], ["influenza", "PROBLEM", 366, 375], ["complications", "PROBLEM", 393, 406], ["influenza infection", "PROBLEM", 420, 439], ["influenza strains", "PROBLEM", 478, 495], ["viral resistance", "OBSERVATION", 180, 196], ["influenza", "OBSERVATION", 420, 429]]], ["In randomized, placebo-controlled trials, oseltamivir and zanamivir were efficacious in the prevention of influenza among persons administered chemoprophylaxis after exposure to a household member of close contact with laboratory confirmed influenza (oseltamivir 68%\u201389%, zanamivir 72%\u201382%) 37, 38, 39, 40, 41.", [["oseltamivir", "CHEMICAL", 42, 53], ["zanamivir", "CHEMICAL", 58, 67], ["influenza", "DISEASE", 106, 115], ["influenza", "DISEASE", 240, 249], ["oseltamivir", "CHEMICAL", 251, 262], ["zanamivir", "CHEMICAL", 272, 281], ["oseltamivir", "CHEMICAL", 42, 53], ["zanamivir", "CHEMICAL", 58, 67], ["oseltamivir", "CHEMICAL", 251, 262], ["zanamivir", "CHEMICAL", 272, 281], ["oseltamivir", "SIMPLE_CHEMICAL", 42, 53], ["zanamivir", "SIMPLE_CHEMICAL", 58, 67], ["persons", "ORGANISM", 122, 129], ["persons", "SPECIES", 122, 129], ["placebo-controlled trials", "TREATMENT", 15, 40], ["oseltamivir", "TREATMENT", 42, 53], ["zanamivir", "TREATMENT", 58, 67], ["influenza", "PROBLEM", 106, 115], ["chemoprophylaxis", "TREATMENT", 143, 159], ["influenza", "PROBLEM", 240, 249], ["oseltamivir", "TREATMENT", 251, 262], ["zanamivir", "TREATMENT", 272, 281]]], ["Chemoprophylaxis should continue for no longer than 10 days after the most recent exposure (see Table 3 for chemoprophylaxis recommendations) (42).ED Approach ::: Mimics of InfluenzaIdentifying individuals infected with the influenza viruses, specifically those at risk for adverse outcomes secondary to infection, is paramount in limiting the morbidity and mortality associated with influenza.", [["influenza viruses", "DISEASE", 224, 241], ["infection", "DISEASE", 304, 313], ["influenza", "DISEASE", 384, 393], ["Chemoprophylaxis", "TREATMENT", 0, 16], ["chemoprophylaxis recommendations", "TREATMENT", 108, 140], ["InfluenzaIdentifying individuals", "PROBLEM", 173, 205], ["the influenza viruses", "PROBLEM", 220, 241], ["adverse outcomes", "PROBLEM", 274, 290], ["infection", "PROBLEM", 304, 313], ["influenza", "PROBLEM", 384, 393], ["influenza viruses", "OBSERVATION", 224, 241], ["infection", "OBSERVATION", 304, 313]]], ["Due to the extensive variability of influenza symptoms, and that the influenza virus circulates concurrently with other respiratory viruses, the emergency physician must be acutely aware of influenza mimics and their evaluation and treatment 97, 98.1.The assessment of a patient presenting with fever, headache, chills, myalgias, sore throat, and influenza-like symptoms (or in the case of the pediatric patient: decreased appetite, decreased per os tolerance, or decreased urinary output) begins with evaluation of airway, breathing, and circulation (3).", [["urinary", "ANATOMY", 474, 481], ["airway", "ANATOMY", 516, 522], ["influenza symptoms", "DISEASE", 36, 54], ["influenza virus", "DISEASE", 69, 84], ["respiratory viruses", "DISEASE", 120, 139], ["influenza", "DISEASE", 190, 199], ["fever", "DISEASE", 295, 300], ["headache", "DISEASE", 302, 310], ["chills", "DISEASE", 312, 318], ["myalgias", "DISEASE", 320, 328], ["sore throat", "DISEASE", 330, 341], ["influenza-like symptoms", "DISEASE", 347, 370], ["influenza virus", "ORGANISM", 69, 84], ["patient", "ORGANISM", 271, 278], ["patient", "ORGANISM", 404, 411], ["urinary", "ORGANISM_SUBDIVISION", 474, 481], ["airway", "MULTI-TISSUE_STRUCTURE", 516, 522], ["patient", "SPECIES", 271, 278], ["patient", "SPECIES", 404, 411], ["influenza virus", "SPECIES", 69, 84], ["influenza symptoms", "PROBLEM", 36, 54], ["the influenza virus circulates", "PROBLEM", 65, 95], ["other respiratory viruses", "PROBLEM", 114, 139], ["influenza mimics", "PROBLEM", 190, 206], ["their evaluation", "TEST", 211, 227], ["treatment", "TREATMENT", 232, 241], ["The assessment", "TEST", 251, 265], ["fever", "PROBLEM", 295, 300], ["headache", "PROBLEM", 302, 310], ["chills", "PROBLEM", 312, 318], ["myalgias", "PROBLEM", 320, 328], ["sore throat", "PROBLEM", 330, 341], ["influenza", "PROBLEM", 347, 356], ["like symptoms", "PROBLEM", 357, 370], ["decreased appetite", "PROBLEM", 413, 431], ["decreased urinary output", "PROBLEM", 464, 488], ["evaluation of airway", "TEST", 502, 522], ["influenza", "OBSERVATION", 36, 45], ["respiratory viruses", "OBSERVATION", 120, 139], ["sore throat", "ANATOMY", 330, 341], ["influenza", "OBSERVATION", 347, 356], ["airway", "ANATOMY", 516, 522]]], ["A definitive airway should be obtained in all toxic-appearing patients with signs of impending airway compromise including stridor, \u201chot potato voice,\u201d trismus, seated in the tripod position, or in those presenting with an inability to protect their airway (altered mental status) (70).", [["airway", "ANATOMY", 13, 19], ["airway", "ANATOMY", 95, 101], ["airway", "ANATOMY", 250, 256], ["stridor", "DISEASE", 123, 130], ["trismus", "DISEASE", 152, 159], ["airway", "MULTI-TISSUE_STRUCTURE", 13, 19], ["patients", "ORGANISM", 62, 70], ["airway", "MULTI-TISSUE_STRUCTURE", 95, 101], ["airway", "MULTI-TISSUE_STRUCTURE", 250, 256], ["patients", "SPECIES", 62, 70], ["potato", "SPECIES", 137, 143], ["potato", "SPECIES", 137, 143], ["impending airway compromise", "PROBLEM", 85, 112], ["stridor", "PROBLEM", 123, 130], ["hot potato voice", "PROBLEM", 133, 149], ["\u201d trismus", "PROBLEM", 150, 159], ["airway", "ANATOMY", 13, 19], ["airway", "ANATOMY", 95, 101], ["compromise", "OBSERVATION", 102, 112], ["stridor", "OBSERVATION", 123, 130], ["trismus", "OBSERVATION", 152, 159], ["airway", "ANATOMY", 250, 256]]], ["An assessment of systemic inflammatory response syndrome criteria should be performed, and diagnostic testing ordered as appropriate, given the physician's clinical suspicion regarding the etiology of the systemic illness.", [["systemic illness", "DISEASE", 205, 221], ["An assessment", "TEST", 0, 13], ["systemic inflammatory response syndrome criteria", "PROBLEM", 17, 65], ["diagnostic testing", "TEST", 91, 109], ["the systemic illness", "PROBLEM", 201, 221], ["systemic", "OBSERVATION_MODIFIER", 17, 25], ["inflammatory", "OBSERVATION", 26, 38], ["systemic", "OBSERVATION_MODIFIER", 205, 213], ["illness", "OBSERVATION", 214, 221]]], ["Potential studies include a complete blood count, serum electrolytes, urinalysis, chest x-ray study, blood cultures, and lactate.", [["blood", "ANATOMY", 37, 42], ["serum", "ANATOMY", 50, 55], ["blood", "ANATOMY", 101, 106], ["lactate", "CHEMICAL", 121, 128], ["lactate", "CHEMICAL", 121, 128], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["lactate", "SIMPLE_CHEMICAL", 121, 128], ["Potential studies", "TEST", 0, 17], ["a complete blood count", "TEST", 26, 48], ["serum electrolytes", "TEST", 50, 68], ["urinalysis", "TEST", 70, 80], ["chest x-ray study", "TEST", 82, 99], ["blood cultures", "TEST", 101, 115], ["lactate", "TEST", 121, 128], ["chest", "ANATOMY", 82, 87]]], ["If sepsis is suspected, the provider should initiate fluid resuscitation to improve peripheral perfusion and administer broad-spectrum antimicrobials 44, 45, 46, 98.2.After initial resuscitation and stabilization of the toxic-appearing patient, a focused history and examination allows for the development of a differential diagnosis based on targeted questioning regarding immunization status, medical comorbidities, daily medication use, sexual practices, and recent travel (e.g., high-risk areas for mosquito-borne illness, such as Southeast Asia, Africa, South/Central America).", [["fluid", "ANATOMY", 53, 58], ["sepsis", "DISEASE", 3, 9], ["mosquito-borne illness", "DISEASE", 503, 525], ["fluid", "ORGANISM_SUBSTANCE", 53, 58], ["peripheral", "TISSUE", 84, 94], ["patient", "ORGANISM", 236, 243], ["patient", "SPECIES", 236, 243], ["sepsis", "PROBLEM", 3, 9], ["fluid resuscitation", "TREATMENT", 53, 72], ["peripheral perfusion", "TEST", 84, 104], ["broad-spectrum antimicrobials", "TREATMENT", 120, 149], ["initial resuscitation", "TREATMENT", 173, 194], ["examination", "TEST", 267, 278], ["immunization status", "TREATMENT", 374, 393], ["medical comorbidities", "PROBLEM", 395, 416], ["sexual practices", "TREATMENT", 440, 456], ["sepsis", "OBSERVATION", 3, 9], ["toxic", "OBSERVATION_MODIFIER", 220, 225], ["Central", "ANATOMY_MODIFIER", 565, 572]]], ["A determination regarding the requirement for adjunct testing and advanced imaging (point-of-care blood glucose, respiratory viral panel, serology, peripheral smear, head noncontrast computed tomography [CT], abdomen/pelvis CT) can then be made.3.In the nontoxic, immunocompetent adolescent or adult patient, the clinical diagnosis of influenza is accurate in up to 90% of cases 23, 24, 97.", [["blood", "ANATOMY", 98, 103], ["peripheral smear", "ANATOMY", 148, 164], ["head", "ANATOMY", 166, 170], ["abdomen", "ANATOMY", 209, 216], ["pelvis", "ANATOMY", 217, 223], ["influenza", "DISEASE", 335, 344], ["glucose", "CHEMICAL", 104, 111], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["glucose", "SIMPLE_CHEMICAL", 104, 111], ["head", "ORGANISM_SUBDIVISION", 166, 170], ["abdomen", "ORGAN", 209, 216], ["patient", "ORGANISM", 300, 307], ["patient", "SPECIES", 300, 307], ["adjunct testing", "TEST", 46, 61], ["advanced imaging", "TEST", 66, 82], ["blood glucose", "TEST", 98, 111], ["respiratory viral panel", "TEST", 113, 136], ["serology", "TEST", 138, 146], ["peripheral smear", "TEST", 148, 164], ["head noncontrast computed tomography", "TEST", 166, 202], ["CT], abdomen/pelvis CT", "TEST", 204, 226], ["influenza", "PROBLEM", 335, 344], ["abdomen", "ANATOMY", 209, 216], ["pelvis", "ANATOMY", 217, 223], ["nontoxic", "OBSERVATION_MODIFIER", 254, 262]]], ["Patients, or caregivers of patients older than 1 month of age, presenting for evaluation and treatment within 48 h of symptoms onset should be counseled about the benefits (reduced duration of illness up to 1.6 days), and common side effects (gastrointestinal upset) of antiviral therapy 31, 32, 33, 35.4.In patients at high risk for complications secondary to influenza infection (e.g., elderly [50 years and older], immunosuppressed, health care workers, pregnant females; detailed in Table 3), confirmatory testing for influenza should be performed.", [["gastrointestinal", "ANATOMY", 243, 259], ["illness", "DISEASE", 193, 200], ["influenza infection", "DISEASE", 361, 380], ["influenza", "DISEASE", 522, 531], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 27, 35], ["gastrointestinal", "ORGANISM_SUBDIVISION", 243, 259], ["patients", "ORGANISM", 308, 316], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 308, 316], ["evaluation", "TEST", 78, 88], ["treatment", "TREATMENT", 93, 102], ["symptoms", "PROBLEM", 118, 126], ["illness", "PROBLEM", 193, 200], ["common side effects", "PROBLEM", 222, 241], ["antiviral therapy", "TREATMENT", 270, 287], ["complications", "PROBLEM", 334, 347], ["influenza infection", "PROBLEM", 361, 380], ["confirmatory testing", "TEST", 497, 517], ["influenza", "PROBLEM", 522, 531], ["gastrointestinal", "ANATOMY", 243, 259], ["influenza", "OBSERVATION", 361, 370]]], ["RIDT has a sensitivity of 50%\u201370% and specificity > 90%, and testing should be interpreted in terms of the community prevalence of influenza infection 9, 26.", [["influenza infection", "DISEASE", 131, 150], ["a sensitivity", "TEST", 9, 22], ["specificity", "TEST", 38, 49], ["testing", "TEST", 61, 68], ["influenza infection", "PROBLEM", 131, 150], ["influenza", "OBSERVATION", 131, 140]]], ["The utility of performing direct immunofluorescence and RT-PCR testing in the ED may be limited by required laboratory processing times (1\u20138 h) 9, 26.", [["direct immunofluorescence", "TEST", 26, 51], ["RT-PCR testing", "TEST", 56, 70]]], ["RT-PCR is recognized as the gold standard for the definitive diagnosis of influenza 28, 29, 30, 97.", [["influenza", "DISEASE", 74, 83], ["RT-PCR", "TEST", 0, 6], ["influenza", "PROBLEM", 74, 83]]]], "d1a6f4541047ea26f5e109500362b5ea767ccbfe": [["IntroductionIn March 2020, the Centers for Disease Control and Prevention (CDC) highlighted people living with HIV (PLWH) as a population that may be at heightened risk for severe physical health illness from the new coronavirus disease known as COVID-19 compared to the general population [1] .", [["HIV", "DISEASE", 111, 114], ["PLWH", "DISEASE", 116, 120], ["physical health illness", "DISEASE", 180, 203], ["coronavirus disease", "DISEASE", 217, 236], ["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98], ["HIV", "SPECIES", 111, 114], ["HIV", "SPECIES", 111, 114], ["Disease Control", "TREATMENT", 43, 58], ["severe physical health illness", "PROBLEM", 173, 203], ["the new coronavirus disease", "PROBLEM", 209, 236], ["COVID", "TEST", 246, 251], ["new", "OBSERVATION_MODIFIER", 213, 216], ["coronavirus disease", "OBSERVATION", 217, 236]]], ["This risk in PLWH is predicated on potential interactions between COVID-19, HIV, and other risk factors for COVID-19 complications such as diabetes and hypertension that are common in PLWH, potential interference with care and treatments, and high rates of socially-produced burdens in the form of violence, stigma, discrimination, isolation, and hate experienced by PLWH [1, 2] .", [["diabetes", "DISEASE", 139, 147], ["hypertension", "DISEASE", 152, 164], ["PLWH", "DISEASE", 184, 188], ["violence", "DISEASE", 298, 306], ["PLWH", "CANCER", 13, 17], ["COVID-19", "GENE_OR_GENE_PRODUCT", 66, 74], ["HIV", "ORGANISM", 76, 79], ["HIV", "SPECIES", 76, 79], ["COVID", "TEST", 66, 71], ["HIV", "PROBLEM", 76, 79], ["COVID-19 complications", "PROBLEM", 108, 130], ["diabetes", "PROBLEM", 139, 147], ["hypertension", "PROBLEM", 152, 164], ["treatments", "TREATMENT", 227, 237], ["stigma", "PROBLEM", 308, 314], ["PLWH", "OBSERVATION", 13, 17], ["hypertension", "OBSERVATION", 152, 164]]], ["As such, a syndemic framework provides a meaningful and robust paradigm to understand the impact of COVID-19 disease in PLWH and to develop health programming services for PLWH in light of the COVID-19 pandemic.IntroductionA syndemic is defined as two or more epidemics interacting synergistically to produce an increased burden of disease in a population [3] .", [["PLWH", "DISEASE", 120, 124], ["PLWH", "DISEASE", 172, 176], ["PLWH", "CANCER", 120, 124], ["COVID-19 disease in PLWH", "PROBLEM", 100, 124], ["the COVID", "TEST", 189, 198], ["pandemic", "PROBLEM", 202, 210], ["an increased burden of disease", "PROBLEM", 309, 339], ["increased", "OBSERVATION_MODIFIER", 312, 321], ["burden", "OBSERVATION_MODIFIER", 322, 328], ["disease", "OBSERVATION", 332, 339]]], ["In this perspective, infection with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), the virus responsible for COVID-19, is assumed to function in tandem with a myriad of health challenges faced by PLWH, including HIV itself, chronic non-communicable diseases, mental health burden, substance abuse, and other infections, all of which are catalyzed by biological, behavioral, psychosocial and structural drivers of disease as posited by Halkitis et al. [4, 5] .", [["infection", "DISEASE", 21, 30], ["acute respiratory syndrome coronavirus", "DISEASE", 43, 81], ["PLWH", "DISEASE", 211, 215], ["HIV itself", "DISEASE", 227, 237], ["chronic non-communicable diseases", "DISEASE", 239, 272], ["substance abuse", "DISEASE", 296, 311], ["infections", "DISEASE", 323, 333], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 36, 83], ["SARS-Cov-2", "ORGANISM", 85, 95], ["PLWH", "CANCER", 211, 215], ["HIV", "SPECIES", 227, 230], ["severe acute respiratory syndrome coronavirus", "SPECIES", 36, 81], ["SARS-Cov-2", "SPECIES", 85, 95], ["HIV", "SPECIES", 227, 230], ["infection", "PROBLEM", 21, 30], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 36, 81], ["SARS", "TEST", 85, 89], ["Cov", "TEST", 90, 93], ["the virus", "PROBLEM", 98, 107], ["COVID", "TEST", 124, 129], ["HIV itself", "PROBLEM", 227, 237], ["chronic non-communicable diseases", "PROBLEM", 239, 272], ["mental health burden", "PROBLEM", 274, 294], ["other infections", "PROBLEM", 317, 333], ["disease", "PROBLEM", 428, 435], ["infection", "OBSERVATION", 21, 30], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["respiratory syndrome", "OBSERVATION", 49, 69], ["chronic", "OBSERVATION_MODIFIER", 239, 246], ["non-communicable diseases", "OBSERVATION", 247, 272], ["infections", "OBSERVATION", 323, 333]]], ["Such synergies are even greater in older PLWH, who also are at higher risk for COVID-19-related mortality [6] [7] [8] .", [["PLWH", "CANCER", 41, 45], ["COVID", "TEST", 79, 84]]], ["Over the last two decades, the extant literature has provided ample evidence to support the veracity of a syndemic framework along the developmental continuum [4, 5, 9, 10] and across time [11] , which is notably a biopsychosocial perspective of health and disease [12, 13] .IntroductionTo understand the manifestation of COVID-19 in the lives of PLWH, it must be viewed alongside HIV and other health conditions that already exist in this population.IntroductionThese mutually reinforcing health conditions constitute a syndemic for PLWH [4, 14, 15] .", [["PLWH", "DISEASE", 534, 538], ["PLWH", "CANCER", 347, 351], ["HIV", "ORGANISM", 381, 384], ["HIV", "SPECIES", 381, 384], ["HIV", "SPECIES", 381, 384], ["a syndemic framework", "PROBLEM", 104, 124]]], ["Here, we discuss how HIV and medical comorbidities, including the co-occurrence of a broad range of diseases [16] , may function synergistically to fuel COVID-19 disease in a syndemic [17] .", [["HIV and medical comorbidities", "DISEASE", 21, 50], ["HIV", "ORGANISM", 21, 24], ["HIV", "SPECIES", 21, 24], ["HIV and medical comorbidities", "PROBLEM", 21, 50]]], ["Moreover, we address the drivers of such syndemics, namely the social and economic inequalities, including but not limited to socially produced psychological conditions (i.e., psychosocial burdens) and healthcare access.Comorbidities and COVID-19 in People Living with HIVEffective antiretroviral therapy (ART) has prolonged the lifespan of PLWH.", [["syndemics", "DISEASE", 41, 50], ["PLWH", "DISEASE", 341, 345], ["People", "ORGANISM", 250, 256], ["PLWH", "CANCER", 341, 345], ["People", "SPECIES", 250, 256], ["Comorbidities", "PROBLEM", 220, 233], ["COVID", "TEST", 238, 243], ["HIVEffective antiretroviral therapy", "TREATMENT", 269, 304], ["PLWH", "OBSERVATION", 341, 345]]], ["In the United States, 1.2 million people are living with HIV.", [["HIV", "DISEASE", 57, 60], ["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 57, 60], ["HIV", "PROBLEM", 57, 60]]], ["Of these, more than 50% are 50 + years of age, and many physical complications related to long-term ART use and aging have arisen [18] [19] [20] [21] .", [["[18] [19] [20] [21]", "SIMPLE_CHEMICAL", 130, 149], ["many physical complications", "PROBLEM", 51, 78], ["long-term ART use", "TREATMENT", 90, 107]]], ["Older PLWH, in particular, have a higher risk of non-communicable comorbidities, including diabetes, hypertension, cardiovascular disease, and chronic lung disease than uninfected individuals of similar age [22] [23] [24] [25] .", [["cardiovascular", "ANATOMY", 115, 129], ["lung", "ANATOMY", 151, 155], ["diabetes", "DISEASE", 91, 99], ["hypertension", "DISEASE", 101, 113], ["cardiovascular disease", "DISEASE", 115, 137], ["chronic lung disease", "DISEASE", 143, 163], ["lung", "ORGAN", 151, 155], ["non-communicable comorbidities", "PROBLEM", 49, 79], ["diabetes", "PROBLEM", 91, 99], ["hypertension", "PROBLEM", 101, 113], ["cardiovascular disease", "PROBLEM", 115, 137], ["chronic lung disease", "PROBLEM", 143, 163], ["non-communicable comorbidities", "OBSERVATION", 49, 79], ["hypertension", "OBSERVATION", 101, 113], ["cardiovascular", "ANATOMY", 115, 129], ["disease", "OBSERVATION", 130, 137], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["lung", "ANATOMY", 151, 155], ["disease", "OBSERVATION", 156, 163]]], ["Putative mechanisms for these comorbidities include aging itself and chronic inflammation caused by HIV and/or ART [26] .", [["inflammation", "DISEASE", 77, 89], ["HIV", "SPECIES", 100, 103], ["these comorbidities", "PROBLEM", 24, 43], ["chronic inflammation", "PROBLEM", 69, 89], ["HIV", "PROBLEM", 100, 103], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["inflammation", "OBSERVATION", 77, 89]]], ["Epidemiologic evidence suggests that both older age and a number of comorbidities, including hypertension, diabetes, and chronic obstructive lung disease, are risk factors for severe COVID-19 disease [27] .", [["lung", "ANATOMY", 141, 145], ["hypertension", "DISEASE", 93, 105], ["diabetes", "DISEASE", 107, 115], ["chronic obstructive lung disease", "DISEASE", 121, 153], ["COVID", "DISEASE", 183, 188], ["lung", "ORGAN", 141, 145], ["comorbidities", "PROBLEM", 68, 81], ["hypertension", "PROBLEM", 93, 105], ["diabetes", "PROBLEM", 107, 115], ["chronic obstructive lung disease", "PROBLEM", 121, 153], ["risk factors", "PROBLEM", 159, 171], ["severe COVID-19 disease", "PROBLEM", 176, 199], ["hypertension", "OBSERVATION", 93, 105], ["diabetes", "OBSERVATION", 107, 115], ["chronic", "OBSERVATION_MODIFIER", 121, 128], ["obstructive", "OBSERVATION_MODIFIER", 129, 140], ["lung", "ANATOMY", 141, 145], ["disease", "OBSERVATION", 146, 153]]], ["While limited data are available on COVID-19 and HIV-coinfection as of early April 2020 [28] [29] [30] , and on the potential protective effects of HIV antivirals [1, 30] , the interaction between these comorbidities nonetheless lends itself to an understanding through a syndemic framework [31] .", [["HIV-coinfection", "DISEASE", 49, 64], ["COVID-19", "GENE_OR_GENE_PRODUCT", 36, 44], ["HIV", "ORGANISM", 49, 52], ["HIV", "ORGANISM", 148, 151], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 148, 151], ["COVID", "TEST", 36, 41], ["HIV-coinfection", "PROBLEM", 49, 64], ["HIV antivirals", "TREATMENT", 148, 162], ["these comorbidities", "PROBLEM", 197, 216]]], ["Expression of the angiotensin-converting enzyme 2 (ACE2), identified as a crucial factor that facilitates SARS-CoV-2 virus to bind and enter host cells, is substantially increased in patients with diabetes and hypertension, who are often treated with ACE inhibitors and angiotensin II type-I receptor blockers [32] .", [["cells", "ANATOMY", 146, 151], ["angiotensin", "CHEMICAL", 18, 29], ["diabetes", "DISEASE", 197, 205], ["hypertension", "DISEASE", 210, 222], ["angiotensin II type-I receptor blockers", "CHEMICAL", 270, 309], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 18, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["SARS-CoV-2 virus", "ORGANISM", 106, 122], ["host cells", "CELL", 141, 151], ["patients", "ORGANISM", 183, 191], ["ACE", "GENE_OR_GENE_PRODUCT", 251, 254], ["angiotensin II type-I receptor", "GENE_OR_GENE_PRODUCT", 270, 300], ["angiotensin-converting enzyme 2", "PROTEIN", 18, 49], ["ACE2", "PROTEIN", 51, 55], ["host cells", "CELL_TYPE", 141, 151], ["patients", "SPECIES", 183, 191], ["SARS-CoV-2 virus", "SPECIES", 106, 122], ["the angiotensin-converting enzyme", "TEST", 14, 47], ["a crucial factor", "PROBLEM", 72, 88], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["diabetes", "PROBLEM", 197, 205], ["hypertension", "PROBLEM", 210, 222], ["ACE inhibitors", "TREATMENT", 251, 265], ["angiotensin II type-I receptor blockers", "TREATMENT", 270, 309], ["host cells", "OBSERVATION", 141, 151], ["substantially", "OBSERVATION_MODIFIER", 156, 169], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["hypertension", "OBSERVATION", 210, 222]]], ["Further, there is a concern that individuals with severe immunodeficiencies, such as HIV, may be at risk for a severe course of COVID-19 disease.Comorbidities and COVID-19 in People Living with HIVOlder PLWH may not be the only members of the HIV seropositive population at risk for the negative health sequelae of COVID-19.", [["immunodeficiencies", "DISEASE", 57, 75], ["COVID", "DISEASE", 128, 133], ["COVID-19", "CHEMICAL", 315, 323], ["People", "ORGANISM", 175, 181], ["HIV", "ORGANISM", 243, 246], ["HIV", "SPECIES", 85, 88], ["People", "SPECIES", 175, 181], ["HIV", "SPECIES", 85, 88], ["HIV", "SPECIES", 243, 246], ["severe immunodeficiencies", "PROBLEM", 50, 75], ["HIV", "PROBLEM", 85, 88], ["COVID-19 disease", "PROBLEM", 128, 144], ["Comorbidities", "PROBLEM", 145, 158], ["COVID", "TEST", 163, 168], ["the HIV seropositive population", "PROBLEM", 239, 270], ["COVID", "TEST", 315, 320], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["immunodeficiencies", "OBSERVATION", 57, 75], ["severe", "OBSERVATION_MODIFIER", 111, 117]]], ["Given recent developments that have shown the vulnerability of those ages 18-49 to COVID-19 [33] , younger PLWH may also be at heightened risk for mortality due to COVID-19 complications.", [["COVID", "DISEASE", 164, 169], ["PLWH", "CANCER", 107, 111], ["COVID", "TEST", 83, 88], ["COVID-19 complications", "PROBLEM", 164, 186]]], ["Such risk is predicated on the fact that PLWH under age 50 are both less likely to be diagnosed (and in effect more likely to be immunocompromised) and also less likely to access and be retained in care, yielding viral suppression of a mere 37% on those age 25-34 [34] .Psychosocial Conditions and COVID-19 in People Living with HIVThe psychosocial conditions which fuel these interlocking health epidemics [35] are central for both understanding the drivers of severe COVID-19 infection in PLWH and for developing effective medical and public health interventions as shown in Fig. 1 .", [["infection", "DISEASE", 478, 487], ["PLWH", "DISEASE", 491, 495], ["People", "ORGANISM", 310, 316], ["PLWH", "CANCER", 491, 495], ["People", "SPECIES", 310, 316], ["immunocompromised", "PROBLEM", 129, 146], ["viral suppression", "TEST", 213, 230], ["severe COVID-19 infection", "PROBLEM", 462, 487], ["public health interventions", "TREATMENT", 537, 564], ["infection", "OBSERVATION", 478, 487]]], ["PLWH have an increased likelihood of mental health burden, illicit drug use, and other STIs [36] [37] [38] , all catalyzed by psychosocial burdens experienced at elevated rates in marginalized populations including sexual and gender minorities, racial and ethnic minorities, and/or the poor and underserved.", [["STIs", "DISEASE", 87, 91], ["mental health burden", "PROBLEM", 37, 57], ["psychosocial burdens", "PROBLEM", 126, 146], ["elevated rates", "PROBLEM", 162, 176], ["marginalized populations", "PROBLEM", 180, 204], ["racial and ethnic minorities", "PROBLEM", 245, 273], ["increased", "OBSERVATION_MODIFIER", 13, 22]]], ["While there is no standard set of psychosocial factors that are prescribed [13, 39] , burdens such as medical mistrust, loneliness [4, 40] , stigma [41] , and hopelessness [42] have been implicated in the propagation of disease.", [["loneliness", "DISEASE", 120, 130], ["hopelessness", "DISEASE", 159, 171], ["disease", "PROBLEM", 220, 227], ["no", "UNCERTAINTY", 15, 17], ["disease", "OBSERVATION", 220, 227]]], ["In fact, at the Infectious Diseases Practice (IDP) at the New Jersey Medical School in Newark, where we collaborate, clinical staff who are managing patients via telephone conversations amidst the COVID-19 pandemic indicate many individuals are extremely stressed, anxious, and unable to sleep.Psychosocial Conditions and COVID-19 in People Living with HIVPhysical distancing or social isolation recommended by the CDC to reduce the spread of COVID-19 may add additional burden to already highly burdened lives.", [["COVID-19", "CHEMICAL", 443, 451], ["patients", "ORGANISM", 149, 157], ["individuals", "ORGANISM", 229, 240], ["People", "ORGANISM", 334, 340], ["patients", "SPECIES", 149, 157], ["People", "SPECIES", 334, 340], ["anxious", "PROBLEM", 265, 272], ["social isolation", "TREATMENT", 379, 395], ["Infectious", "OBSERVATION_MODIFIER", 16, 26]]], ["Physical distancing is described as avoiding crowds, canceling large events, closing schools, staying at and working from home; these measures have been shown to reduce the rate of new COVID-19 infections.", [["infections", "DISEASE", 194, 204], ["new COVID-19 infections", "PROBLEM", 181, 204]]], ["However, we know very little about how physical distancing enforced by a pandemic such as COVID-19 continues to impact PLWH.", [["COVID-19", "CHEMICAL", 90, 98], ["COVID-19", "CHEMICAL", 90, 98], ["PLWH", "CANCER", 119, 123], ["COVID", "TEST", 90, 95], ["PLWH", "OBSERVATION", 119, 123]]], ["Older PLWH already experience heightened rates of loneliness and social isolation [43, 44] , compromising their social and emotional well-being and health in light of social distancing efforts [45] , albeit sound epidemiological principles inform such efforts.", [["loneliness", "DISEASE", 50, 60]]], ["Diminished neurocognitive functioning and heightened mental health burden evidence in older PLWH may impede effective self-care [46] .", [["Diminished neurocognitive functioning", "PROBLEM", 0, 37], ["heightened mental health burden", "PROBLEM", 42, 73]]], ["Moreover, for individuals from underserved communities and communities of color who constitute the majority of patients we see at the IDP, physical distancing may not be possible due to financial conditions or work circumstances.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["Economic disparities, associated with worse health conditions and underlying health conditions [47] , likely explain higher death rates due to COVID-19 noted in communities of color [48] .Psychosocial Conditions and COVID-19 in People Living with HIVThese and other conditions are those internally-produced states imparted by social conditions of social injustice and health inequity.", [["death", "DISEASE", 124, 129], ["People", "ORGANISM", 228, 234], ["People", "SPECIES", 228, 234], ["Economic disparities", "PROBLEM", 0, 20], ["worse health conditions", "PROBLEM", 38, 61], ["underlying health conditions", "PROBLEM", 66, 94], ["higher death rates", "PROBLEM", 117, 135], ["COVID", "TEST", 143, 148]]], ["In this view, societal conditions such as discrimination, poverty, and homophobia drive the development of these internalized states that interfere with the ability for both people and populations to address their health [39] .", [["poverty", "DISEASE", 58, 65], ["people", "ORGANISM", 174, 180], ["people", "SPECIES", 174, 180]]], ["Thus, if we are to address COVID-19 infection for vulnerable populations including PLWH effectively, these matters must be brought to bear.", [["infection", "DISEASE", 36, 45], ["COVID-19", "ORGANISM", 27, 35], ["PLWH", "CANCER", 83, 87], ["COVID", "TEST", 27, 32], ["infection", "PROBLEM", 36, 45], ["vulnerable populations", "PROBLEM", 50, 72]]], ["Such drivers may include political and human rights determinants [49] , including but not limited to state-sanctioned discrimination [4] .", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44]]], ["These factors are deemed to create the biological vulnerabilities that are noted in communities of color, particularly those populations where the experience of such stressors is heightened.", [["the biological vulnerabilities", "PROBLEM", 35, 65], ["such stressors", "PROBLEM", 161, 175]]], ["In this view, it is understandable why migrants, people with criminal justice histories, the poor, and those who do not identify as White, heterosexual, or cisgender are more susceptible to disease states.", [["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["disease states", "PROBLEM", 190, 204]]], ["Additionally, food insecurity is a factor that contributes to this syndemic [5] .", [["food insecurity", "DISEASE", 14, 29]]], ["Food insecurity has been associated with increased HIV transmission risk, poor clinic attendance, poor ART adherence, poor immunological and virologic responses, lower efficacy of ART, and high mortality [50] .", [["HIV", "SPECIES", 51, 54], ["increased HIV transmission risk", "PROBLEM", 41, 72], ["poor ART adherence", "PROBLEM", 98, 116], ["poor immunological and virologic responses", "PROBLEM", 118, 160], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["HIV", "OBSERVATION", 51, 54]]], ["The COVID-19 pandemic has created more heightened food insecure states for all populations, including PLWH, therefore exacerbating these burdens.Healthcare Access and COVID-19 in People Living with HIVPLWH require regular engagement with the healthcare system to maintain viral suppression, which provides optimal clinical benefits and drastic reductions in HIV transmission [51, 52] .", [["HIV transmission", "DISEASE", 358, 374], ["People", "ORGANISM", 179, 185], ["HIV", "ORGANISM", 358, 361], ["People", "SPECIES", 179, 185], ["HIV", "SPECIES", 358, 361], ["The COVID", "TEST", 0, 9], ["PLWH", "PROBLEM", 102, 106], ["COVID", "TREATMENT", 167, 172], ["viral suppression", "TREATMENT", 272, 289], ["HIV transmission", "TEST", 358, 374], ["viral suppression", "OBSERVATION", 272, 289]]], ["At the IDP in Newark, NJ, adherence to appointment visits has been associated with a higher likelihood of viral suppression.", [["viral suppression", "PROBLEM", 106, 123], ["viral suppression", "OBSERVATION", 106, 123]]], ["ART implementation and consistent adherence have improved the long-term health outcomes among PLWH, but they are vulnerable if interruptions in treatment occur due to the COVID-19 pandemic.", [["ART implementation", "TREATMENT", 0, 18], ["treatment", "TREATMENT", 144, 153], ["the COVID", "TEST", 167, 176], ["pandemic", "PROBLEM", 180, 188], ["improved", "OBSERVATION_MODIFIER", 49, 57]]], ["Interactions with health providers, access to medications, and adherence are undermined by physical distancing imposed by many states and municipalities.", [["medications", "TREATMENT", 46, 57]]], ["Findings drawn from 9/11 indicate that in times of crisis, adherence to ART may be severely compromised for PLWH, creating an additional level of concern [53] .", [["crisis", "PROBLEM", 51, 57], ["severely compromised", "PROBLEM", 83, 103], ["PLWH", "PROBLEM", 108, 112]]], ["It is unclear if telemedicine will yield the same associations between visits and viral load suppression.Healthcare Access and COVID-19 in People Living with HIVIn the Wuhan region of China, reports indicate PLWH have struggled to access ART during the COVID-19 outbreak due to the stigma and discrimination surrounding the HIV/AIDS epidemic in the country [54] .", [["HIV/AIDS", "DISEASE", 324, 332], ["People", "ORGANISM", 139, 145], ["People", "SPECIES", 139, 145], ["HIV", "SPECIES", 324, 327], ["viral load suppression", "TREATMENT", 82, 104], ["COVID", "TREATMENT", 127, 132], ["the COVID", "TREATMENT", 249, 258], ["the stigma", "PROBLEM", 278, 288]]], ["While this has not been reported to date in the United States, there are growing concerns around overall prescription drug shortages due to drop-offs in production in China and India [55] .", [["growing", "OBSERVATION_MODIFIER", 73, 80]]], ["If PLWH cannot access ART, their viremia will likely increase [56] , leading to lower CD4 T-cell counts [57] , an increased risk of developing opportunistic infections [58] , and an increased risk of HIV transmission to others.", [["CD4 T-cell", "ANATOMY", 86, 96], ["viremia", "DISEASE", 33, 40], ["opportunistic infections", "DISEASE", 143, 167], ["HIV transmission", "DISEASE", 200, 216], ["HIV", "ORGANISM", 200, 203], ["CD4", "PROTEIN", 86, 89], ["HIV", "SPECIES", 200, 203], ["their viremia", "PROBLEM", 27, 40], ["cell counts", "TEST", 92, 103], ["developing opportunistic infections", "PROBLEM", 132, 167], ["HIV transmission", "PROBLEM", 200, 216], ["viremia", "OBSERVATION", 33, 40], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["opportunistic", "OBSERVATION_MODIFIER", 143, 156], ["infections", "OBSERVATION", 157, 167], ["increased", "OBSERVATION_MODIFIER", 182, 191], ["HIV", "OBSERVATION", 200, 203]]], ["As such, it is imperative PLWH remain engaged with their primary and HIV healthcare providers amidst the COVID-19 pandemic to ensure consistent access to HIV-related care and treatment.Healthcare Access and COVID-19 in People Living with HIVOne way to ensure steady access to care is through telemedicine-a mode in which medical practitioners can provide care to their patients over the phone or through video conferencing [59, 60] .", [["PLWH", "CANCER", 26, 30], ["People", "ORGANISM", 219, 225], ["patients", "ORGANISM", 369, 377], ["People", "SPECIES", 219, 225], ["patients", "SPECIES", 369, 377], ["HIV", "SPECIES", 69, 72], ["HIV", "SPECIES", 154, 157], ["the COVID", "TREATMENT", 101, 110], ["HIV-related care", "TREATMENT", 154, 170], ["treatment", "TREATMENT", 175, 184], ["COVID", "TREATMENT", 207, 212]]], ["This healthcare delivery mode has been successful with some sub-populations of PLWH, including women and smokers [60] .", [["PLWH", "CANCER", 79, 83], ["women", "ORGANISM", 95, 100], ["women", "SPECIES", 95, 100], ["This healthcare delivery mode", "TREATMENT", 0, 29]]], ["However, in light of the COVID-19 pandemic, it is likely that economic, geographic inequities, and the digital divide will prevent some PLWH from accessing care via this route due to lack of necessary technology (e.g. computer, smartphones, etc.) or adequate internet access, especially among older PLWH [60] [61] [62] [63] .ConclusionAs COVID-19 emerges in the population of PLWH, we must contextualize the health challenges that will emerge within a syndemic framework-one that is more of a conceptualization [17] than a theory per se that prescribes specific elements of the paradigm [39] .", [["PLWH", "CHEMICAL", 299, 303], ["PLWH [60] [61] [62]", "CHEMICAL", 299, 318], ["PLWH", "CANCER", 376, 380], ["COVID-19", "DNA", 338, 346], ["the COVID", "TEST", 21, 30], ["accessing care", "TREATMENT", 146, 160], ["this route", "TREATMENT", 165, 175], ["COVID", "TEST", 338, 343], ["is likely", "UNCERTAINTY", 47, 56], ["economic", "OBSERVATION_MODIFIER", 62, 70]]], ["This framing also fully embraces the concept of pathogen-pathogen interaction, which is central to our understanding of HIV-COVID-19 co-infection [3] .", [["infection", "DISEASE", 136, 145], ["HIV-COVID-19 co-", "ORGANISM", 120, 136], ["HIV", "SPECIES", 120, 123], ["HIV-COVID-19", "SPECIES", 120, 132], ["pathogen", "PROBLEM", 48, 56], ["HIV", "PROBLEM", 120, 123], ["COVID", "TEST", 124, 129], ["co-infection", "PROBLEM", 133, 145], ["infection", "OBSERVATION", 136, 145]]], ["To protect PLWH from COVID-19 and future pandemics, programming to address COVID-19 disease in light of the multiple mutually reinforcing health burdens faced by PLWH is imperative.", [["PLWH", "DISEASE", 162, 166], ["PLWH", "CANCER", 11, 15], ["PLWH", "CANCER", 162, 166], ["COVID", "TEST", 21, 26], ["COVID-19 disease", "PROBLEM", 75, 91]]], ["While healthcare providers often attend to the biological, behavioral, and occasionally psychological drivers of health, public health focuses on the structural drivers of disease and disease surveillance, neither fully embraces the psychosocial burdens and stressors that diminish well-being as delineated in a conceptualization such as that of a syndemic [13] .", [["disease and disease surveillance", "PROBLEM", 172, 204]]], ["Effective treatment for HIV-COVID-19 coinfection must be designed to address these viral interactions as well as the psychosocial burdens that both exacerbate co-infection and increase the likelihood of mortality.ConclusionFinally, it also must be noted that antiretroviral treatments, either in the form of ART for PLWH or the form of pre-exposure prophylaxis (PrEP), may bestow some protection against COVID-19 [30, 64] .", [["co-infection", "DISEASE", 159, 171], ["PLWH", "CHEMICAL", 316, 320], ["HIV-COVID-19", "ORGANISM", 24, 36], ["HIV", "SPECIES", 24, 27], ["HIV-COVID-19", "SPECIES", 24, 36], ["Effective treatment", "TREATMENT", 0, 19], ["HIV", "PROBLEM", 24, 27], ["COVID", "TREATMENT", 28, 33], ["coinfection", "PROBLEM", 37, 48], ["these viral interactions", "PROBLEM", 77, 101], ["co-infection", "PROBLEM", 159, 171], ["antiretroviral treatments", "TREATMENT", 259, 284], ["ART", "TREATMENT", 308, 311], ["PLWH", "TREATMENT", 316, 320], ["pre-exposure prophylaxis", "TREATMENT", 336, 360], ["COVID", "TEST", 404, 409]]], ["In fact, at the IDP, many of the PLWH are not presenting with severe symptoms of COVID-19.", [["COVID", "DISEASE", 81, 86], ["COVID-19", "CHEMICAL", 81, 89], ["PLWH", "CANCER", 33, 37], ["severe symptoms", "PROBLEM", 62, 77], ["COVID", "TEST", 81, 86]]], ["If there is evidence to support this assertion, there must be ongoing vigilance to identify and treat HIV infections and actively maintain PLWH in treatment and care.", [["HIV infections", "DISEASE", 102, 116], ["PLWH", "CHEMICAL", 139, 143], ["HIV", "ORGANISM", 102, 105], ["HIV", "SPECIES", 102, 105], ["HIV", "SPECIES", 102, 105], ["HIV infections", "PROBLEM", 102, 116], ["treatment", "TREATMENT", 147, 156]]]], "PMC7471338": [["Strategy 1: Daily Multidisciplinary Meetings ::: BackgroundOur multidisciplinary team (MDT) consists of pulmonologists, infectious disease specialists, internists, rheumatologists, intensivists, nephrologists and hematologists, as well as nursing supervisors, infection control nurses, case managers, respiratory technicians, physiotherapists and clinical pharmacologists.", [["infectious disease", "DISEASE", 120, 138], ["infection", "DISEASE", 260, 269]]], ["Daily MDT meetings take place to discuss patients and formulate comprehensive management plans.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["comprehensive management plans", "TREATMENT", 64, 94]]], ["Involving physiotherapists and case managers early helps disposition planning for patients who may need rehab services upon recovery.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["This huddle also serves as an opportunity for clear and direct communication between the primary team and the critical care team for early identification and intervention for patients at high risk of deterioration.Strategy 2: Identify and Treat Co-Infections ::: BackgroundIn one case series, approximately 2% of patients presenting with COVID-19 had other respiratory infections, including influenza and bacterial pathogens.2 As the fall and winter months approach, the prevalence of co-infection is likely to increase.", [["respiratory", "ANATOMY", 357, 368], ["COVID", "DISEASE", 338, 343], ["respiratory infections", "DISEASE", 357, 379], ["influenza and bacterial pathogens", "DISEASE", 391, 424], ["co-infection", "DISEASE", 485, 497], ["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 313, 321], ["intervention", "TREATMENT", 158, 170], ["deterioration", "PROBLEM", 200, 213], ["COVID", "TEST", 338, 343], ["other respiratory infections", "PROBLEM", 351, 379], ["influenza", "PROBLEM", 391, 400], ["bacterial pathogens", "PROBLEM", 405, 424], ["co-infection", "PROBLEM", 485, 497], ["respiratory", "ANATOMY", 357, 368], ["infections", "OBSERVATION", 369, 379], ["influenza", "OBSERVATION", 391, 400], ["bacterial pathogens", "OBSERVATION", 405, 424], ["co-infection", "OBSERVATION", 485, 497], ["is likely to", "UNCERTAINTY", 498, 510], ["increase", "OBSERVATION_MODIFIER", 511, 519]]], ["Routine influenza nasopharyngeal swabs and respiratory panels on admission will identify co-infection and enable timely diagnosis and management.", [["nasopharyngeal swabs", "ANATOMY", 18, 38], ["co-infection", "DISEASE", 89, 101], ["Routine influenza nasopharyngeal swabs", "TEST", 0, 38], ["respiratory panels", "TEST", 43, 61], ["co-infection", "PROBLEM", 89, 101], ["management", "TREATMENT", 134, 144]]], ["Further, in accordance with Infectious Diseases Society of America (IDSA) viral pneumonia guidelines, empiric antibacterial therapy is given to patients presenting with severe COVID-19 pneumonia, as well as to those who either fail to improve with antiviral therapy or deteriorate after initial improvement.4 Working within the hospital\u2019s antimicrobial stewardship program will help avoid the indiscriminate use of broad-spectrum antibiotics.", [["Infectious Diseases", "DISEASE", 28, 47], ["viral pneumonia", "DISEASE", 74, 89], ["pneumonia", "DISEASE", 185, 194], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["viral pneumonia guidelines", "PROBLEM", 74, 100], ["empiric antibacterial therapy", "TREATMENT", 102, 131], ["severe COVID", "PROBLEM", 169, 181], ["pneumonia", "PROBLEM", 185, 194], ["antiviral therapy", "TREATMENT", 248, 265], ["antimicrobial stewardship program", "TREATMENT", 339, 372], ["broad-spectrum antibiotics", "TREATMENT", 415, 441], ["Infectious", "OBSERVATION_MODIFIER", 28, 38], ["pneumonia", "OBSERVATION", 80, 89], ["pneumonia", "OBSERVATION", 185, 194]]], ["It is also important to recognize that other infectious diseases may have overlapping presenting features or symptomatology with COVID-19, especially in endemic regions.", [["infectious diseases", "DISEASE", 45, 64], ["other infectious diseases", "PROBLEM", 39, 64], ["symptomatology", "PROBLEM", 109, 123], ["COVID", "TEST", 129, 134]]], ["Co-infection with tuberculosis or dengue for example may result in delayed diagnosis and treatment and can further spread infection.5 Close collaboration with infection control and infectious disease specialists can help minimize these risks.Strategy 3: Encourage Early and Frequent Prone Positioning ::: BackgroundManaging patients with acute respiratory distress syndrome (ARDS) with prone positioning has been shown to increase the number of recruited alveoli, decrease pleural pressure, and improve alveolar shunting and tidal volume.6 Other studies confirm that early prone positioning decreases mortality.7 These observations initially led to prone positioning for the management of ventilated COVID-19 patients.8 Recent literature suggests that its use in patients on high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) may decrease the need for intubation.9 Benefits of prone positioning for the non-ventilated patient include improved VQ matching to reduce hypoxia, decreased atelectasis, and improved secretion clearance.9 As such, we advise early and frequent prone positioning for all hospitalized COVID-19 patients with dyspnea, hypoxia or who require supplemental oxygen support (Table 1).", [["respiratory", "ANATOMY", 344, 355], ["alveoli", "ANATOMY", 455, 462], ["pleural", "ANATOMY", 473, 480], ["alveolar", "ANATOMY", 503, 511], ["nasal", "ANATOMY", 785, 790], ["Co-infection", "DISEASE", 0, 12], ["tuberculosis", "DISEASE", 18, 30], ["dengue", "DISEASE", 34, 40], ["infection", "DISEASE", 122, 131], ["infection", "DISEASE", 159, 168], ["infectious disease", "DISEASE", 181, 199], ["acute respiratory distress syndrome", "DISEASE", 338, 373], ["ARDS", "DISEASE", 375, 379], ["COVID", "DISEASE", 700, 705], ["hypoxia", "DISEASE", 979, 986], ["atelectasis", "DISEASE", 998, 1009], ["dyspnea", "DISEASE", 1146, 1153], ["hypoxia", "DISEASE", 1155, 1162], ["oxygen", "CHEMICAL", 1191, 1197], ["oxygen", "CHEMICAL", 1191, 1197], ["patients", "ORGANISM", 324, 332], ["alveoli", "MULTI-TISSUE_STRUCTURE", 455, 462], ["pleural", "MULTI-TISSUE_STRUCTURE", 473, 480], ["alveolar", "MULTI-TISSUE_STRUCTURE", 503, 511], ["patients", "ORGANISM", 709, 717], ["patients", "ORGANISM", 763, 771], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 785, 798], ["patient", "ORGANISM", 932, 939], ["patients", "ORGANISM", 1132, 1140], ["oxygen", "SIMPLE_CHEMICAL", 1191, 1197], ["patients", "SPECIES", 324, 332], ["patients", "SPECIES", 709, 717], ["patients", "SPECIES", 763, 771], ["patient", "SPECIES", 932, 939], ["patients", "SPECIES", 1132, 1140], ["dengue", "SPECIES", 34, 40], ["Co-infection", "PROBLEM", 0, 12], ["tuberculosis", "PROBLEM", 18, 30], ["dengue", "PROBLEM", 34, 40], ["treatment", "TREATMENT", 89, 98], ["further spread infection", "PROBLEM", 107, 131], ["infection control", "TREATMENT", 159, 176], ["acute respiratory distress syndrome", "PROBLEM", 338, 373], ["ARDS", "PROBLEM", 375, 379], ["prone positioning", "TREATMENT", 386, 403], ["pleural pressure", "TEST", 473, 489], ["alveolar shunting", "TEST", 503, 520], ["tidal volume", "TEST", 525, 537], ["Other studies", "TEST", 540, 553], ["early prone positioning decreases mortality", "PROBLEM", 567, 610], ["the management", "TREATMENT", 671, 685], ["ventilated COVID", "TREATMENT", 689, 705], ["high flow nasal cannula (HFNC", "TREATMENT", 775, 804], ["non-invasive ventilation", "TREATMENT", 809, 833], ["NIV", "TREATMENT", 835, 838], ["intubation", "TREATMENT", 866, 876], ["prone positioning", "TREATMENT", 891, 908], ["hypoxia", "PROBLEM", 979, 986], ["decreased atelectasis", "PROBLEM", 988, 1009], ["improved secretion clearance", "PROBLEM", 1015, 1043], ["frequent prone positioning", "TREATMENT", 1075, 1101], ["dyspnea", "PROBLEM", 1146, 1153], ["hypoxia", "PROBLEM", 1155, 1162], ["supplemental oxygen support", "TREATMENT", 1178, 1205], ["tuberculosis", "OBSERVATION", 18, 30], ["spread", "OBSERVATION_MODIFIER", 115, 121], ["infection", "OBSERVATION", 122, 131], ["infection", "OBSERVATION", 159, 168], ["acute", "OBSERVATION_MODIFIER", 338, 343], ["respiratory distress", "OBSERVATION", 344, 364], ["decrease", "OBSERVATION_MODIFIER", 464, 472], ["pleural", "ANATOMY", 473, 480], ["pressure", "OBSERVATION_MODIFIER", 481, 489], ["alveolar shunting", "OBSERVATION", 503, 520], ["tidal volume", "OBSERVATION", 525, 537], ["early", "OBSERVATION_MODIFIER", 567, 572], ["prone positioning", "OBSERVATION", 573, 590], ["decreases", "OBSERVATION_MODIFIER", 591, 600], ["hypoxia", "OBSERVATION", 979, 986], ["decreased", "OBSERVATION_MODIFIER", 988, 997], ["atelectasis", "OBSERVATION", 998, 1009], ["hypoxia", "OBSERVATION", 1155, 1162]]], ["Our physiotherapists and nurses have been instrumental in proning the large numbers of patients.", [["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95]]]], "95a3dd795aae98c72f31e3488f368c894edac68b": [["1 Even as academic leaders remain far more positive about traditional and blended pedagogical formats than fully online learning, the outbreak of the COVID-19 pandemic has acted as a catalyst in establishing online education as an immediate substitute for in-person classrooms.", [["a catalyst", "TREATMENT", 181, 191]]], ["This paradigm shift in education has drawn considerable attention from the media, and researchers across the globe.IntroductionHowever, any research based on the acceptance of online education during this period of disturbance is likely to be a deviation from the natural relationship between education and technology.", [["online education", "TREATMENT", 176, 192], ["disturbance", "PROBLEM", 215, 226], ["a deviation", "PROBLEM", 243, 254], ["globe", "ANATOMY", 109, 114]]], ["Instead, as institutions of higher learning integrate web-based tools into classroom instructions, we assert that it is more important to assess the attitude towards digital education and its acceptance in a state of equilibrium prior to the onset of the pandemic.", [["digital education", "TREATMENT", 166, 183], ["the pandemic", "PROBLEM", 251, 263], ["pandemic", "OBSERVATION", 255, 263]]], ["With that in mind, in this paper, we analyse public opinion on the value of online education relative to traditional education using survey data from the Pew Social Trends and Demographics Project conducted by the Princeton Survey Research Associates International in 2011.IntroductionIn the early 2000s, despite significant skepticism from academics and pushback from the public, several universities invested in and adopted Massive Open Online Course (MOOCs) as a teachinglearning format (Miller, 2014) .", [["IntroductionIn", "TREATMENT", 273, 287], ["significant", "OBSERVATION_MODIFIER", 313, 324], ["skepticism", "OBSERVATION", 325, 335], ["Massive", "OBSERVATION_MODIFIER", 426, 433]]], ["Educational institutions today are compelled to rethink their pedagogical philosophies to incorporate either hybrid or fully-online teaching-learning formats, as a consequence of the ongoing pandemic.", [["pandemic", "PROBLEM", 191, 199]]], ["Therefore, we specifically address public opinion about the value of online education and the factors that influence it vis--vis traditional classes, using a Bayesian quantile analysis.IntroductionModelling public opinion on the value of online education presents a rich area for further study.IntroductionOver the last few years, a sizeable body of literature on the demand and efficacy of online education, its scope to lower educational costs, student and faculty perceptions, and its impact on student learning outcomes have emerged (Xu and Jaggars, 2013; Goodman et al., 2019; Otter et al., 2013; Cassens, 2010; Bettinger et al., 2017; Figlio et al., 2013; Alpert et al., 2016; Joyce et al., 2015; Krieg and Henson, 2016; Kirtman, 2009 ).", [["online education", "TREATMENT", 69, 85], ["a Bayesian quantile analysis", "TEST", 156, 184], ["online education", "TREATMENT", 238, 254], ["further study", "TEST", 280, 293], ["online education", "TREATMENT", 391, 407]]], ["Analysing survey data from a community college in California, Cassens (2010) finds no significant differences in students performances in online and traditional teaching methods.", [["no", "UNCERTAINTY", 83, 85], ["significant", "OBSERVATION_MODIFIER", 86, 97]]], ["On similar lines, Otter et al. (2013) find significant differences upon comparison of faculty and student perceptions of online courses versus traditional courses at a large public university in the south-eastern United States.", [["online courses", "TREATMENT", 121, 135], ["traditional courses", "TREATMENT", 143, 162], ["similar lines", "OBSERVATION", 3, 16], ["significant", "OBSERVATION_MODIFIER", 43, 54]]], ["As such, mixed evidence found owing to the narrow focus of these papers often brings their external validity into question.", [["narrow", "OBSERVATION_MODIFIER", 43, 49]]], ["To this end, we attempt to address the educational value of online classes by utilising a nationally representative US survey data, thereby drawing conclusions for a population at large.", [["large", "OBSERVATION_MODIFIER", 180, 185]]], ["This is the first contribution of our paper to the existing literature on online education.IntroductionEvidence finds the proportion of faculty who believe in the legitimacy of online education to be relatively low.", [["online education", "TREATMENT", 74, 90]]], ["Our study is the first, of which we are aware, to offer new insights regarding the opinion on the educational value of online courses across the quantiles and latent utility scale.", [["Our study", "TEST", 0, 9], ["latent utility scale", "TEST", 159, 179]]], ["This may be interpreted as a propensity or a willingness index, where higher propensity towards online education are characterised by large positive values and vice versa.", [["large positive values", "PROBLEM", 134, 155], ["large", "OBSERVATION_MODIFIER", 134, 139], ["positive", "OBSERVATION", 140, 148]]], ["Interestingly, our findings highlight that highly educated respondents have lower willingness for online education.", [["online education", "TREATMENT", 98, 114]]], ["We also note some amount of regional differences in the propensity to value online classes.", [["some", "OBSERVATION_MODIFIER", 13, 17], ["amount", "OBSERVATION_MODIFIER", 18, 24], ["regional", "OBSERVATION_MODIFIER", 28, 36], ["differences", "OBSERVATION_MODIFIER", 37, 48]]], ["All these covariates show considerable differences in covariate effects at different quantiles.", [["considerable", "OBSERVATION_MODIFIER", 26, 38], ["differences", "OBSERVATION_MODIFIER", 39, 50]]], ["Lastly, we find no convincing evidence of race or income having an effect on the propensity for online education.IntroductionThe remainder of the paper is organised as follows.", [["online education", "TREATMENT", 96, 112], ["no convincing evidence of", "UNCERTAINTY", 16, 41]]], ["Section 2 outlines the data used for our analysis including a descriptive summary.", [["our analysis", "TEST", 37, 49]]], ["This is followed by Section 3 that outlines a model of quantile regression for binary outcomes and presents a Markov chain Monte Carlo (MCMC) algorithm for its estimation.", [["a Markov chain Monte Carlo (MCMC) algorithm", "TREATMENT", 108, 151], ["its estimation", "TEST", 156, 170]]], ["We consider a subset of variables from this survey and upon removing missing observations from our variables of interest (see Table 1 ), we are left with 1,591 observations available for the analysis.", [["the analysis", "TEST", 187, 199], ["left", "ANATOMY_MODIFIER", 144, 148]]], ["The dependent variable is the response to the question: \"In general, do you think a course taken only online provides an equal educational value compared with a course taken in person in a classroom, or not?\".", [["person", "SPECIES", 177, 183], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["variable", "OBSERVATION_MODIFIER", 14, 22]]], ["The survey also consists of information on an array of other variables, some of which we utilise as covariates (independent variable) in our analysis.", [["our analysis", "TEST", 137, 149]]], ["A sizeable proportion of the sample, therefore, have had prior exposure to online learning.", [["sizeable", "OBSERVATION_MODIFIER", 2, 10], ["proportion", "OBSERVATION_MODIFIER", 11, 21]]], ["Here, enrolment in school implies that the respondent is either attending high school, technical school, trade or vocational school, is a college undergraduate or in graduate school.DataThe sample has more females (51.23%) than males (48.77%), but both genders have approximately equal representation.", [["DataThe sample", "TEST", 182, 196], ["approximately", "OBSERVATION_MODIFIER", 266, 279], ["equal", "OBSERVATION_MODIFIER", 280, 285], ["representation", "OBSERVATION", 286, 300]]], ["With respect to employment status, about a little less than two-thirds (i.e., 62.66%) are either employed full-time or part-time, while the remaining percentage are either unemployed, students or retired individuals.DataRacial classification shows that more than two-thirds are White (71.09%), followed by African-Americans (16.15%) and all other races (12.76%).", [["DataRacial classification", "TEST", 216, 241], ["all other races", "TEST", 337, 352]]], ["Regional classification as defined by the US Census Bureau shows that the largest percentage of the sample live in the South (47.77%).", [["classification", "OBSERVATION", 9, 23], ["largest", "OBSERVATION_MODIFIER", 74, 81], ["percentage", "OBSERVATION_MODIFIER", 82, 92]]], ["To explore this association, we present a stacked bar graph in Figure 1 with four panels, each portraying the relationship between the dependent variable and a single covariate. teaching, while the remaining 67.2% (70.5%) do not agree.", [["a stacked bar graph", "TREATMENT", 40, 59], ["a single covariate", "TREATMENT", 158, 176]]], ["To this end, we regress the dependent variable on age category.", [["dependent", "OBSERVATION_MODIFIER", 28, 37], ["variable", "OBSERVATION_MODIFIER", 38, 46]]], ["To net out such effects and understand the actual impact of a covariate on the dependent variable, we next turn to some formal econometric modelling.Quantile Regression for Binary OutcomesQuantile regression, as introduced by Koenker and Bassett (1978) , looks at quantiles of the (continuous) response variable conditional on the covariates and thus provides, amongst other things, a comprehensive picture (as compared to traditional mean regression) of the effect of covariates on the response variable.", [["Binary OutcomesQuantile regression", "PROBLEM", 173, 207]]], ["Estimation involves minimizing the quantile loss function using linear programming techniques (Koenker, 2005) .", [["the quantile loss function", "PROBLEM", 31, 57], ["linear programming techniques", "TREATMENT", 64, 93]]], ["Interestingly, the quantile loss function appears in the exponent of the asymmetric Laplace (AL) distribution (Yu and Zhang, 2005) , which makes minimization of the quantile loss function equivalent to maximization of the AL likelihood.", [["the quantile loss function", "PROBLEM", 15, 41], ["the quantile loss function", "PROBLEM", 161, 187], ["quantile loss", "OBSERVATION", 19, 32], ["exponent", "OBSERVATION_MODIFIER", 57, 65], ["asymmetric", "OBSERVATION_MODIFIER", 73, 83], ["Laplace", "OBSERVATION", 84, 91], ["quantile loss", "OBSERVATION", 165, 178]]], ["With discrete outcomes, the concern is to model the latent utility differential (say, between making a choice versus not making it or occurrence of an event versus its non-occurrence) facilitated through the introduction of a latent variable (Albert and Chib, 1993; Greenberg, 2012; Rahman, 2016) .", [["discrete", "OBSERVATION_MODIFIER", 5, 13], ["outcomes", "OBSERVATION", 14, 22]]], ["This applies to both mean and quantile regressions and is useful for estimation and inference.Quantile Regression for Binary OutcomesQuantile regression for binary outcomes (or binary quantile regression 2 ) was introduced in Kordas (2006) and the Bayesian framework was presented in Benoit and Poel (2012) .", [["binary outcomes", "PROBLEM", 157, 172]]], ["The binary quantile model can be conveniently expressed using the latent variable z i as follows,Quantile Regression for Binary Outcomeswhere x i is a k\u00d71 vector of covariates, \u03b2 p is a k\u00d71 vector of unknown parameters at the p-th quantile 2 Binary quantile regression is a special of ordinal quantile regression considered in Rahman (2016) and can be linked to the random utility theory in economics (Train, 2009; Jeliazkov and Rahman, 2012) .", [["k\u00d71 vector", "DNA", 186, 196], ["a k\u00d71 vector", "TREATMENT", 184, 196]]], ["In our study, the latent variable z i can be interpreted as the latent utility differential between online learning relative to in-person classroom learning.", [["our study", "TEST", 3, 12]]], ["Similarly, when y i = 0 (i.e., the respondent answers 'No' to our question of interest), the propensity to online learning is low and z i takes a value in the negative part of the real line.Quantile Regression for Binary OutcomesWe can form a working likelihood from equation (1) and directly use it to construct the posterior distribution, but this is not convenient for MCMC sampling.", [["MCMC sampling", "TEST", 372, 385], ["negative", "OBSERVATION", 159, 167], ["posterior", "ANATOMY_MODIFIER", 317, 326]]], ["A preferred alternative is to employ the normal-exponential mixture of the AL distribution (Kozumi and Kobayashi, 2011) .", [["normal", "OBSERVATION", 41, 47]]], ["In this formulation, \u01eb i = \u03b8w i + \u03c4 \u221a w i u i , and the binary quantile model is re-expressed as,Quantile Regression for Binary Outcomeswhere \u03b8 = (1\u22122p) p(1\u2212p) and \u03c4 = 2 p(1\u2212p) are constants, and w i \u223c E(1) is independently distributed of u i \u223c N (0, 1).", [["Quantile Regression", "TEST", 97, 116], ["Binary Outcomeswhere", "TEST", 121, 141], ["p", "TEST", 153, 154], ["\u2212p", "TEST", 156, 158], ["\u03c4", "TEST", 164, 165], ["\u2212p", "TEST", 173, 175], ["constants", "TEST", 181, 190]]], ["Here, the notations E and N denote exponential and normal distributions, respectively.", [["exponential", "OBSERVATION_MODIFIER", 35, 46], ["normal", "OBSERVATION", 51, 57], ["distributions", "OBSERVATION_MODIFIER", 58, 71]]], ["It is clear from formulation (2) that the latent variable z i |\u03b2, w i \u223c N (x \u2032 i \u03b2 + \u03b8w i , \u03c4 2 w i ), thus allowing access to the properties of normal distribution.Quantile Regression for Binary OutcomesBy the Bayes' theorem, the complete data likelihood from equation (2) is combined with a normal prior distribution on \u03b2 (i.e., \u03b2 \u223c N (\u03b2 0 , B 0 )) to form the complete data posterior.", [["N", "CHEMICAL", 72, 73], ["clear", "OBSERVATION", 6, 11], ["normal", "OBSERVATION", 145, 151], ["distribution", "OBSERVATION_MODIFIER", 152, 164], ["normal", "OBSERVATION", 293, 299], ["posterior", "ANATOMY_MODIFIER", 377, 386]]], ["This Algorithm 1 (MCMC Algorithm for Binary Quantile Regression) 1.", [["This Algorithm", "TREATMENT", 0, 14]]], ["Sample \u03b2|z, w \u223c N (\u03b2,B), where,Quantile Regression for Binary Outcomes\u03c4 2 + 2 .", [["Sample", "TEST", 0, 6], ["|z", "TEST", 8, 10], ["Binary Outcomes", "TEST", 55, 70]]], ["Sample the latent variable z|y, \u03b2, w for all values of i = 1, \u00b7 \u00b7 \u00b7 , n from an univariate truncated normal (TN) distribution as follows,Quantile Regression for Binary Outcomesyields the following expression,Quantile Regression for Binary OutcomesThe full conditional posterior densities for (z, \u03b2, w) can be derived from equation (3) and the model can be estimated using the Gibbs sampler (Geman and Geman, 1984 ) \u2212 a well known MCMC technique \u2212 presented in Algorithm 1.", [["TN", "PROTEIN", 109, 111], ["Sample", "TEST", 0, 6], ["posterior", "ANATOMY_MODIFIER", 268, 277]]], ["The sampling algorithm is straightforward and involves sampling \u03b2 conditional on (z, w) from an updated normal distribution.", [["The sampling algorithm", "TEST", 0, 22], ["normal", "OBSERVATION", 104, 110]]], ["The latent weight w conditional on (\u03b2, z) is sampled from a Generalized Inverse Gaussian (GIG) distribution (Devroye, 2014) .", [["latent", "OBSERVATION_MODIFIER", 4, 10]]], ["Finally, the latent variable z conditional on (y, \u03b2, w) is sampled from a truncated normal distribution (Robert, 1995) .", [["latent", "OBSERVATION_MODIFIER", 13, 19], ["variable", "OBSERVATION_MODIFIER", 20, 28], ["normal", "OBSERVATION", 84, 90], ["distribution", "OBSERVATION_MODIFIER", 91, 103]]], ["Table 2 presents the posterior means, and standard deviations of the parameters from the Bayesian estimation of probit model (Albert and Chib, 1993) , and the binary quantile regression at the 10th, 25th, 50th, 75th and 90th quantiles.", [["posterior", "ANATOMY_MODIFIER", 21, 30]]], ["We assume the following diffuse prior distribution:Results\u03b2 \u223c N (0 k , 1000 * I k ), where N and I denote a multivariate normal distribution and an identity matrix of dimension k, respectively.", [["k", "TEST", 67, 68], ["I k )", "TEST", 78, 83], ["diffuse", "OBSERVATION_MODIFIER", 24, 31], ["normal", "OBSERVATION", 121, 127]]], ["The results are based on 20,000 MCMC iterations after a burn-in of 5,000 iterations.", [["a burn", "PROBLEM", 54, 60]]], ["The inefficiency factors were calculated using the batch-means method (Greenberg, 2012; Chib, 2013 16, 1956.33, 2058.40) .", [["The inefficiency factors", "PROBLEM", 0, 24]]], ["These are presented in Table 3 3 and are calculated marginally of the remaining covariates and the parameters (Chib and Jeliazkov, 2006; Jeliazkov et al., 2008; Jeliazkov and Rahman, 2012; Jeliazkov and Vossmeyer, 2018; Rahman and Vossmeyer, 2019; Bresson et al., 2020) .ResultsWhile many of the results are in line with extant literature, our results provide some useful insights into the differences across quantiles.", [["marginally", "OBSERVATION_MODIFIER", 52, 62]]], ["As previously noted, we are modelling the latent Higher level of educational degree, on the other hand, has a negative effect on the willingness towards online education.", [["online education", "TREATMENT", 153, 169]]], ["We also note some amount of regional variation in the propensity to favour online classes.", [["regional variation", "PROBLEM", 28, 46], ["some", "OBSERVATION_MODIFIER", 13, 17], ["amount", "OBSERVATION_MODIFIER", 18, 24], ["regional variation", "OBSERVATION", 28, 46]]], ["This is not surprising as online courses invariably attract an older demographic (Crain and Ragan, 2017) .", [["not surprising", "UNCERTAINTY", 8, 22]]], ["Goodman et al. (2019) find similar results highlighting that on average, the online applicants were 34 years of age compared to 24 years for inperson applicants in their study.", [["their study", "TEST", 164, 175]]], ["Besides, our result is perhaps indicative of midcareer professionals favouring online classes since several online courses cater to those active in the workforce, requiring professional development or retaining by employers (Kizilcec et al., 2019) .ResultsFrom the calculated covariate effects in Table 3 , we see that the covariate effect of age is between 1.7 to 2.2 percentage points across the quantiles.", [["perhaps indicative of", "UNCERTAINTY", 23, 44], ["active", "OBSERVATION_MODIFIER", 138, 144]]], ["Stronger effects are visible in the upper part of the latent index.", [["upper", "ORGANISM_SUBDIVISION", 36, 41], ["visible", "OBSERVATION_MODIFIER", 21, 28], ["upper", "ANATOMY_MODIFIER", 36, 41], ["latent", "OBSERVATION_MODIFIER", 54, 60], ["index", "OBSERVATION_MODIFIER", 61, 66]]], ["The coefficient for full-time employment, compared to the base category, is statistically positive across the quantiles.", [["the base category", "TEST", 54, 71], ["positive", "OBSERVATION", 90, 98]]], ["The coefficients for part-time employment are positive but the effects are not statistically different, implying that regardless of the latent utility for online education, part-time employment does not impact the decision.", [["online education", "TREATMENT", 155, 171]]], ["It appears to be commonplace for employers to sponsor their employees enrolment into online courses for training purposes as observed by Goodman et al. (2019) and Deming et al. (2015) .", [["training purposes", "TREATMENT", 104, 121]]], ["We find positive effects of previous exposure to online education across the quantiles of the utility scale.", [["online education", "TREATMENT", 49, 65], ["positive effects", "OBSERVATION_MODIFIER", 8, 24]]], ["A positive stance towards online education is therefore undeniably linked to previous exposure and use of technology.", [["positive stance", "OBSERVATION", 2, 17]]], ["Although the effect somewhat plateaus at the 75th quantile, our findings suggest that past online experience increases the probability of valuing online classes most for those with higher utility for online education.ResultsWe also find that females are more in favour of online education relative to males.", [["online education", "TREATMENT", 200, 216]]], ["5 Furthermore, online education allows for flexible schedules that individuals can customise around their family and job constraints more easily (Goodman et al., 2019) .", [["flexible schedules", "TREATMENT", 43, 61]]], ["Strongest effect of female is found in the 25th quantile and the effect reduces at the 90th quantile.", [["female", "OBSERVATION", 20, 26]]], ["At higher utility, females are more similar to males than at lower utility.ResultsNext, we find that the coefficient for different levels of education are consistently negative, relative to the base category (HS and below), across the quantiles.", [["more similar", "OBSERVATION_MODIFIER", 31, 43]]], ["In each quantile, the post-bachelors category shows a large negative propensity for online classes vis--vis traditional learning.", [["the post-bachelors category", "TEST", 18, 45], ["large", "OBSERVATION_MODIFIER", 54, 59], ["negative", "OBSERVATION", 60, 68]]], ["The effects are also negative for those with a bachelors degree compared to those with HS education or below.", [["HS education", "TREATMENT", 87, 99]]], ["While the effects are negative for below-bachelors degree, they are not statistically different in comparison to the base category.", [["different", "OBSERVATION_MODIFIER", 86, 95]]], ["This points to some degree of stigma towards online education as the level of educational qualification rises (Kizilcec et al., 2019) .", [["online education", "TREATMENT", 45, 61], ["some degree", "OBSERVATION_MODIFIER", 15, 26], ["stigma", "OBSERVATION", 30, 36]]], ["The decrease in utility from online classes is likely driven by greater intensity of learning and teaching at graduate or post graduate levels.", [["decrease", "OBSERVATION_MODIFIER", 4, 12]]], ["Our result finds support in Chen et al. (2013) who note more favourable student outcomes for traditional classrooms versus an online mode for advanced accounting courses, and Otter et al. (2013) who note that students believe that they must do the teaching and learning on their own in online courses in contrast to what they feel about the time and effort from faculty for traditional courses.ResultsThis perhaps reduces the value they attach to online education at higher degree levels.", [["traditional classrooms", "TREATMENT", 93, 115], ["traditional courses", "TREATMENT", 374, 393]]], ["Other studies have shown that students face difficulty in keeping up motivation in online classes.", [["Other studies", "TEST", 0, 13]]], ["This is likely to become more prominent at higher levels of education.", [["likely to become", "UNCERTAINTY", 8, 24], ["more prominent", "OBSERVATION_MODIFIER", 25, 39]]], ["6 5 The proportion of individuals with previous experiences of online education is higher for females in our sample, with 55% of females having taken an online course for credit before.Results6 Individuals prior experience with online courses and their performance likely play a role in determining the value Examining our covariate effects from Table 3 , we see that the effects are negative and vary between 13.9 to 15.1 percentage points for individuals with a post-bachelors degree.", [["a post-bachelors degree", "TREATMENT", 462, 485]]], ["The result from the 50th quantile is similar to the probit result implying a 15.1 percentage points reduction in the probability of valuing online education.", [["a 15.1 percentage points reduction", "TREATMENT", 75, 109], ["valuing online education", "TREATMENT", 132, 156], ["15.1 percentage", "OBSERVATION_MODIFIER", 77, 92]]], ["The covariate effects are slightly lower for those with a bachelors degree and range between 12.1 to 13.7 percentage point decline in their opinion about online classes.ResultsLooking at geographical locations, we note some significant regional effects in driving the opinion about online education.", [["a bachelors degree", "TEST", 56, 74], ["slightly", "OBSERVATION_MODIFIER", 26, 34], ["lower", "OBSERVATION_MODIFIER", 35, 40], ["significant", "OBSERVATION_MODIFIER", 224, 235], ["regional", "OBSERVATION_MODIFIER", 236, 244], ["effects", "OBSERVATION", 245, 252]]], ["We find negative effects for those living in the Northeast, the South, and the West relative to the Midwest (the omitted category).", [["negative", "OBSERVATION", 8, 16]]], ["The largest negative effects are seen in the Northeast across all quantiles, followed by the South in comparison to the Midwest.", [["largest", "OBSERVATION_MODIFIER", 4, 11], ["negative effects", "OBSERVATION", 12, 28], ["Northeast", "ANATOMY_MODIFIER", 45, 54]]], ["Regional differences in the popularity of online courses are likely driven by use of technology, student population, course design and support provided by the universities, as well as the philosophies of universities in the region.", [["support", "TREATMENT", 135, 142], ["differences", "OBSERVATION_MODIFIER", 9, 20], ["region", "ANATOMY_MODIFIER", 224, 230]]], ["The highest negative effect is found for those in the 90th quantile.", [["highest", "OBSERVATION_MODIFIER", 4, 11], ["negative effect", "OBSERVATION", 12, 27]]], ["Similarly, the coefficients for African-Americans across the quantiles are statistically equivalent to zero.", [["African-Americans across the quantiles", "TREATMENT", 32, 70]]], ["This likely indicates that, after controlling for different educational levels and previous exposure to online learning, individuals across racial groups seem to hold similar attitudes about the online classes as an educational tool.", [["likely indicates", "UNCERTAINTY", 5, 21]]], ["Our results fall in line with (Cotten and Jelenewicz, 2006; Odell et al., 2000; Jones et al., 2009; Bowen et al., 2014) , who note that the digital divide upheld by race may be narrowing, and in some cases negligible among college campuses in the US.", [["narrowing", "PROBLEM", 177, 186], ["narrowing", "OBSERVATION", 177, 186]]], ["7 Use of technology in the Mid-west and the South is higher compared to the East.", [["higher", "OBSERVATION", 53, 59]]], ["9 Regions with students having high levels of technological proficiency are more likely to take courses which integrate technology, major in technology-rich disciplines, and pursue technology-rich careers (Xu and Jaggars, 2013) .ResultsThe coefficient for urban areas are negative and for the suburban areas are positive compared to the base group of rural residents.", [["urban areas", "TEST", 256, 267], ["negative", "OBSERVATION", 272, 280], ["positive", "OBSERVATION", 312, 320]]], ["Interestingly, income levels have a positive effect across the quantiles but once again the effects are not statistically different from zero.", [["income levels", "TEST", 15, 28], ["positive effect", "OBSERVATION_MODIFIER", 36, 51]]], ["Although, Horrigan and Rainie (2006) find that affluent families have better access to internet, we find no convincing evidence that income plays a role in determining opinion about online classes vis--vis traditional classes.ConclusionTechnological advancements and the rising cost of higher education have rendered online education as an attractive substitute or a complementary technique for teaching and learning.", [["a complementary technique", "TREATMENT", 365, 390]]], ["With the online enrolment growth rate in the US at 9.3 percent, over 6.7 million students were estimated to have taken at least one online course in 2012 (Allen and Seaman, 2013) .", [["the online enrolment growth rate", "TEST", 5, 37], ["the US", "TEST", 41, 47]]], ["Some scholars argue that public policies should in fact be guided by public opinion, so that mass opinion and democracy is upheld (Monroe, 1998; Paletz et al., 2013) .ConclusionExtant literature points to uncertainty regarding the quality and rigour of online education.ConclusionWhile there is some degree of adaptation to specific online courses offered by traditional universities as blended learning, reservations about fully online degree programs remain.", [["online education", "TREATMENT", 253, 269], ["some", "OBSERVATION_MODIFIER", 295, 299], ["degree", "OBSERVATION_MODIFIER", 300, 306]]], ["While interesting regional variations exist, we find no evidence of race and income on the propensity for online education.ConclusionWe conclude with three main questions for future work.", [["online education", "TREATMENT", 106, 122], ["no evidence of", "UNCERTAINTY", 53, 67]]], ["First, creating an in-depth, systematic support for both faculty and students, in transitioning from traditional to online teaching-learning platforms, is not an inexpensive venture.", [["systematic support", "TREATMENT", 29, 47]]], ["With considerable fixed costs incurred in training, course creations and delivery methods for online education (Ginn and Hammond, 2012; Xu and Jaggars, 2013) , what would be the incentives to switch back to in-person classrooms or blended formats in a post-pandemic general equilibrium?", [["considerable fixed costs", "PROBLEM", 5, 29], ["considerable", "OBSERVATION_MODIFIER", 5, 17], ["fixed", "OBSERVATION_MODIFIER", 18, 23], ["costs", "OBSERVATION", 24, 29]]], ["Second, evidence suggests that online education democratises and improves access to education (Goodman et al., 2019) .", [["evidence suggests", "UNCERTAINTY", 8, 25]]], ["Given this, it may be interesting to examine the trade-off between a perceived decrease in outcomes and efficacy of online education versus the increase in the exposure of education to previously inaccessible population from a policy perspective.", [["online education", "TREATMENT", 116, 132]]], ["Finally, it is well established that upward mobility in teaching colleges are largely influenced by student feedback and evaluations (Chen and Hoshower, 2003; McClain et al., 2018; Krautmann and Sander, 1999) .", [["evaluations", "TEST", 121, 132], ["upward", "OBSERVATION_MODIFIER", 37, 43], ["mobility", "OBSERVATION_MODIFIER", 44, 52]]], ["If we consider the current health landscape across the globe as a period of deviation from the true nature of dynamics between education and technology, one ought to think about how student feedback during this phase of aberration, will contribute to upward mobility of faculty.", [["upward mobility of faculty", "PROBLEM", 251, 277], ["globe", "ANATOMY", 55, 60]]]], "PMC7402109": [["IntroductionCOVID-19 is affecting many aspects of our lives and tourism is being greatly impacted (UNWTO, 2020).", [["IntroductionCOVID", "TREATMENT", 0, 17]]], ["Therefore, becoming a Smart Tourism Destination (STD), which is an aspiration for any competitive city, will also be a solution for tourism business growth.", [["an aspiration", "PROBLEM", 64, 77], ["Smart", "OBSERVATION_MODIFIER", 22, 27], ["Tourism", "OBSERVATION", 28, 35], ["aspiration", "OBSERVATION", 67, 77]]], ["However, the path towards configurating a STD is not easy; on the contrary, it is very complex and demanding (Femenia-Serra, Neuhofer, & Ivars-Baidal, 2019).", [["STD", "DISEASE", 42, 45]]], ["Enhancing the tourist experience is the final objective of the STD and, to do so, it must maximise both the destination's competitiveness and consumer satisfaction (Del Vecchio et al., 2018).", [["tourist experience", "OBSERVATION", 14, 32]]], ["The provision of tourist information is one of the tourism management fields which should be improved when destinations become STDs (Ivars-Baidal, Celdr\u00e1n-Bernabeu, Maz\u00f3n, & Perles-Ivars, 2019).", [["STDs", "DISEASE", 127, 131], ["STDs", "PROBLEM", 127, 131], ["Ivars", "TEST", 133, 138], ["Baidal", "TREATMENT", 139, 145], ["Maz\u00f3n", "TREATMENT", 165, 170]]], ["Thus, being the main information provider is key for destination management in the efforts to become STDs.IntroductionSTDs aim to stimulate and facilitate the highest tourist satisfaction and experience.", [["STDs", "DISEASE", 101, 105], ["destination management", "TREATMENT", 53, 75], ["STDs", "PROBLEM", 101, 105]]], ["Purchasing is a way of being involved in local culture, which generates shopping-related satisfaction and pleasure (Jin, Moscardo, & Murphy, 2017; Way & Robertson, 2013).", [["local culture", "TEST", 41, 54]]], ["In this way, a well-developed STD will generate synergies through continuous improvements, which will result in a process capable of remodelling tourism destination management (Ivars-Baidal et al., 2019).", [["remodelling tourism destination management", "TREATMENT", 133, 175]]], ["Therefore, STDs have the \u201cpower\u201d to adapt the content of, and initiate, the TSJ.IntroductionWith technological advances, and the widespread use of the Internet, the number of information sources available to tourists has significantly increased (Xiang, 2018).", [["STDs", "DISEASE", 11, 15], ["increased", "OBSERVATION_MODIFIER", 235, 244]]], ["In this context, STDs must understand the main reasons tourists look for information, so that they might design tourist-centric smart tourism ecosystems (Arenas, Goh, & Urue\u00f1a, 2019).", [["STDs", "DISEASE", 17, 21]]], ["This understanding will aid the STD information sources to become preferred in the destination.IntroductionThe proliferation of new technologies, the growth of tourist shopping and destinations' aspirations to become STDs argue that there is clear value in researching these issues (Akalamkam & Mitra, 2018; Cohen, Prayag, & Moital, 2014; Xiang, 2018); but little work has been done in this area and no studies have examined these topics in conjunction.", [["STDs", "DISEASE", 217, 221], ["proliferation", "OBSERVATION_MODIFIER", 111, 124], ["new", "OBSERVATION_MODIFIER", 128, 131]]], ["In addition, in the context of COVID-19, which has created a new challenge in the tourist-destination interaction, there is an urgent need for destinations to examine efficient ways to connect with tourists.", [["COVID", "TEST", 31, 36], ["new", "OBSERVATION_MODIFIER", 61, 64]]], ["This study aims to begin to bridge this gap by identifying how STDs can enhance the TSJ through offering information sources that meet visitors' needs and preferences.", [["STDs", "DISEASE", 63, 67], ["TSJ", "CANCER", 84, 87], ["This study", "TEST", 0, 10]]], ["As far as we know, no previous works have addressed the TSJ; the present study focusses on one of the first stages of the process, thereby opening a new research line.", [["TSJ", "CANCER", 56, 59], ["a new research line", "TREATMENT", 147, 166], ["new", "OBSERVATION_MODIFIER", 149, 152], ["research line", "OBSERVATION", 153, 166]]], ["The objective of the study is to determine which factors explain intention to use information sources for purchase decision-making in a destination.", [["the study", "TEST", 17, 26]]], ["The CAN (Cognitive-Affective-Normative) model was used with a sample of tourists in the city of Logro\u00f1o (Spain), a self-styled Smart City.", [["CAN", "DISEASE", 4, 7]]], ["This three-dimensional model integrates variables used in previous studies which have proved influential in consumer behaviour and technology acceptance.", [["previous studies", "TEST", 58, 74]]], ["Given the good results it has previously achieved, and its versatility, the present study expands the scope of the model into tourist behaviour.Smart Tourism Destinations and the need for information sources ::: Theoretical foundationsThe ideal STD should provide a smart experience, which has been defined as a tourism experience mediated by technologies and ameliorated through personalisation, context-awareness and real-time monitoring (Buhalis & Amaranggana, 2015).", [["the present study", "TEST", 72, 89], ["tourist behaviour", "OBSERVATION", 126, 143]]], ["The innovation and competitiveness of STDs are based on tourism apps (Buhalis & Amaranggana, 2013; Cimbaljevi\u0107, Stankov, & Pavlukovi\u0107, 2019) which increase tourists' freedom and independence in the development of tourism activities (Jeong & Shin, 2019).", [["STDs", "DISEASE", 38, 42], ["STDs", "PROBLEM", 38, 42], ["Cimbaljevi\u0107", "TREATMENT", 99, 110], ["Shin", "ANATOMY", 241, 245]]], ["Information sources are critical elements in the tourists' overall experience as they can motivate and stimulate the travel experience at the smart destination (Jeong & Shin, 2019; Um & Chung, 2019).Smart Tourism Destinations and the need for information sources ::: Theoretical foundationsInformation sources can be internal or external (Akalamkam & Mitra, 2018; Coromina & Camprub\u00ed, 2016; Gursoy & McCleary, 2004).", [["Shin", "ANATOMY", 169, 173]]], ["Today, the channels available to search for information have been increased by the emergence of the Internet (online websites, social networks and chat) and new devices (tablets, mobile phones, wearables, smartwatches and smart televisions) (Akalamkam & Mitra, 2018).Smart Tourism Destinations and the need for information sources ::: Theoretical foundationsTourists can feel confused and overloaded by the vast amount of information available online (Zillinger, 2019).", [["new devices (tablets, mobile phones", "TREATMENT", 157, 192], ["confused", "PROBLEM", 376, 384], ["overloaded", "PROBLEM", 389, 399]]], ["This can negatively impact the tourist experience and STDs must become active players in the acquisition, utilisation, supply and sharing of tourism-related information (Um & Chung, 2019).", [["STDs", "DISEASE", 54, 58]]], ["It is also crucial for STDs to have complete control over the information exchange originated by the tourist.", [["STDs", "DISEASE", 23, 27], ["STDs", "PROBLEM", 23, 27]]], ["Shopping tourism and tourism shopping, which have distinct definitions, are two separate lines of research in tourism studies (Choi, Heo, & Law, 2016; Jin et al., 2017; Timothy, 2005; Tosun et al., 2007).", [["tourism shopping", "OBSERVATION", 21, 37], ["distinct", "OBSERVATION_MODIFIER", 50, 58]]], ["The present study focuses on shopping by tourists, or tourist shopping, a recreational activity in which tourists seek, select and buy goods during their stay in a destination (Jin et al., 2017); it constitutes a secondary, or additional, trip activity (Rabbiosi, 2011).The Tourist Shopping Journey and the search for information ::: Theoretical foundationsThrough their shopping activities tourists develop the TSJ.", [["TSJ", "DISEASE", 412, 415], ["TSJ", "CANCER", 412, 415]]], ["The TSJ can be defined as the complete purchasing process of a tourist in a destination.", [["TSJ", "CANCER", 4, 7]]], ["The TSJ begins from the moment the tourist develops the intention to shop in the destination and starts seeking for information to identify the available offers.", [["TSJ", "CANCER", 4, 7]]], ["Normally, the last step in the process is the evaluation of the service after leaving the destination.The Tourist Shopping Journey and the search for information ::: Theoretical foundationsThe search for information is one of the first stages of the purchasing process (Akalamkam & Mitra, 2018; Gursoy & McCleary, 2004).", [["the evaluation", "TEST", 42, 56]]], ["To reduce the uncertainty of purchasing at destinations tourists make significant efforts to search for information (Coromina & Camprub\u00ed, 2016; Garc\u00eda-Milon, Juaneda-Ayensa, Olarte-Pascual, & Pelegr\u00edn-Borondo, 2019; Xiang, 2018).", [["Garc\u00eda", "TEST", 144, 150]]], ["It should be emphasised that the acquisition of information is a means to an end, and not an end in itself, as purchasers want to make the best possible choices (Fodness & Murray, 1999; Jiang & Bert, 2014).Influence of the cognitive dimension on intention to use information sources ::: Conceptual model ::: Theoretical foundationsThe cognitive dimension is composed of the variables performance expectancy and effort expectancy.", [["cognitive dimension", "OBSERVATION_MODIFIER", 335, 354]]], ["It has been shown that both variables have a positive impact on the consumer's pre-purchase information search behaviour (Akalamkam & Mitra, 2018; Broilo, Espartel, & Basso, 2016).", [["positive", "OBSERVATION_MODIFIER", 45, 53]]]], "PMC6052337": [["INTRODUCTIONEpstein-Barr virus (EBV) is a human pathogen that results in lifelong persistence, with more than 90% seroconversion in the adult population (1).", [["INTRODUCTIONEpstein-Barr virus", "ORGANISM", 0, 30], ["EBV", "ORGANISM", 32, 35], ["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["INTRODUCTIONEpstein-Barr virus", "SPECIES", 0, 30], ["EBV", "SPECIES", 32, 35], ["human", "SPECIES", 42, 47], ["INTRODUCTIONEpstein", "TREATMENT", 0, 19], ["Barr virus", "PROBLEM", 20, 30], ["a human pathogen", "PROBLEM", 40, 56], ["Barr virus", "OBSERVATION", 20, 30]]], ["EBV infects epithelial cells and B-lymphocytes, maintaining a latent reservoir in circulating memory B-cells with sporadic reactivation and transmission from oral secretions (2).", [["epithelial cells", "ANATOMY", 12, 28], ["B-lymphocytes", "ANATOMY", 33, 46], ["memory B-cells", "ANATOMY", 94, 108], ["oral secretions", "ANATOMY", 158, 173], ["EBV", "ORGANISM", 0, 3], ["epithelial cells", "CELL", 12, 28], ["B-lymphocytes", "CELL", 33, 46], ["memory B-cells", "CELL", 94, 108], ["oral", "ORGANISM_SUBDIVISION", 158, 162], ["epithelial cells", "CELL_TYPE", 12, 28], ["B-lymphocytes", "CELL_TYPE", 33, 46], ["circulating memory B-cells", "CELL_TYPE", 82, 108], ["EBV", "SPECIES", 0, 3], ["EBV infects epithelial cells", "PROBLEM", 0, 28], ["B-lymphocytes", "TEST", 33, 46], ["a latent reservoir", "PROBLEM", 60, 78], ["sporadic reactivation", "PROBLEM", 114, 135], ["transmission from oral secretions", "PROBLEM", 140, 173], ["epithelial cells", "OBSERVATION", 12, 28], ["lymphocytes", "ANATOMY", 35, 46], ["latent", "OBSERVATION_MODIFIER", 62, 68], ["reservoir", "OBSERVATION_MODIFIER", 69, 78], ["sporadic", "OBSERVATION_MODIFIER", 114, 122], ["reactivation", "OBSERVATION", 123, 135]]], ["Unlicensed replication in B-cells can manifest clinically as infectious mononucleosis, while productive replication in epithelial cells can be associated with immune suppression in AIDS patients in a disease known as oral hairy leukoplakia (OHL) (3).", [["B-cells", "ANATOMY", 26, 33], ["epithelial cells", "ANATOMY", 119, 135], ["oral hairy leukoplakia", "ANATOMY", 217, 239], ["infectious mononucleosis", "DISEASE", 61, 85], ["AIDS", "DISEASE", 181, 185], ["oral hairy leukoplakia", "DISEASE", 217, 239], ["B-cells", "CELL", 26, 33], ["epithelial cells", "CELL", 119, 135], ["patients", "ORGANISM", 186, 194], ["oral hairy leukoplakia", "CANCER", 217, 239], ["B-cells", "CELL_TYPE", 26, 33], ["epithelial cells", "CELL_TYPE", 119, 135], ["patients", "SPECIES", 186, 194], ["infectious mononucleosis", "PROBLEM", 61, 85], ["epithelial cells", "PROBLEM", 119, 135], ["immune suppression", "PROBLEM", 159, 177], ["a disease known", "PROBLEM", 198, 213], ["oral hairy leukoplakia", "PROBLEM", 217, 239], ["B-cells", "OBSERVATION_MODIFIER", 26, 33], ["infectious", "OBSERVATION_MODIFIER", 61, 71], ["epithelial cells", "OBSERVATION", 119, 135]]], ["Latent infection is linked to all forms of EBV-associated cancers, including nasopharyngeal carcinoma (NPC) (1, 4, 5).", [["cancers", "ANATOMY", 58, 65], ["nasopharyngeal carcinoma", "ANATOMY", 77, 101], ["NPC", "ANATOMY", 103, 106], ["Latent infection", "DISEASE", 0, 16], ["cancers", "DISEASE", 58, 65], ["nasopharyngeal carcinoma", "DISEASE", 77, 101], ["NPC", "DISEASE", 103, 106], ["EBV", "ORGANISM", 43, 46], ["cancers", "CANCER", 58, 65], ["nasopharyngeal carcinoma", "CANCER", 77, 101], ["NPC", "CANCER", 103, 106], ["Latent infection", "PROBLEM", 0, 16], ["EBV", "PROBLEM", 43, 46], ["associated cancers", "PROBLEM", 47, 65], ["nasopharyngeal carcinoma", "PROBLEM", 77, 101], ["infection", "OBSERVATION", 7, 16], ["EBV", "OBSERVATION", 43, 46], ["cancers", "OBSERVATION", 58, 65], ["nasopharyngeal", "ANATOMY", 77, 91], ["carcinoma", "OBSERVATION", 92, 101]]], ["EBV genomes are typically not integrated in the host cell, existing as circular episomal genomes in latently infected cells or as linear genomes in lytically replicating cells (6).", [["cell", "ANATOMY", 53, 57], ["cells", "ANATOMY", 118, 123], ["cells", "ANATOMY", 170, 175], ["EBV", "ORGANISM", 0, 3], ["host cell", "CELL", 48, 57], ["cells", "CELL", 118, 123], ["cells", "CELL", 170, 175], ["EBV genomes", "DNA", 0, 11], ["circular episomal genomes", "DNA", 71, 96], ["latently infected cells", "CELL_TYPE", 100, 123], ["linear genomes", "DNA", 130, 144], ["lytically replicating cells", "CELL_TYPE", 148, 175], ["EBV", "SPECIES", 0, 3], ["EBV genomes", "PROBLEM", 0, 11], ["circular episomal genomes in latently infected cells", "PROBLEM", 71, 123], ["host cell", "OBSERVATION", 48, 57], ["circular", "OBSERVATION_MODIFIER", 71, 79], ["episomal genomes", "OBSERVATION", 80, 96], ["latently", "OBSERVATION_MODIFIER", 100, 108], ["infected cells", "OBSERVATION", 109, 123], ["linear", "OBSERVATION_MODIFIER", 130, 136], ["genomes", "OBSERVATION_MODIFIER", 137, 144], ["replicating cells", "OBSERVATION", 158, 175]]], ["During latency, the variable numbers of terminal repeats at the ends of the EBV genome fuse to produce uniquely sized BamHI-digested bands, which can be analyzed by Southern blotting in a termini assay to differentiate the states of infection (latent versus lytic and polyclonal versus monoclonal) (7).", [["infection", "DISEASE", 233, 242], ["terminal repeats", "CELLULAR_COMPONENT", 40, 56], ["EBV", "ORGANISM", 76, 79], ["BamHI", "GENE_OR_GENE_PRODUCT", 118, 123], ["EBV genome", "DNA", 76, 86], ["terminal repeats", "PROBLEM", 40, 56], ["uniquely sized BamHI-digested bands", "PROBLEM", 103, 138], ["a termini assay", "TEST", 186, 201], ["infection (latent versus lytic and polyclonal versus monoclonal)", "PROBLEM", 233, 297], ["latency", "OBSERVATION_MODIFIER", 7, 14], ["variable", "OBSERVATION_MODIFIER", 20, 28], ["numbers", "OBSERVATION_MODIFIER", 29, 36], ["terminal", "OBSERVATION_MODIFIER", 40, 48], ["digested bands", "OBSERVATION_MODIFIER", 124, 138], ["infection", "OBSERVATION", 233, 242]]], ["The state of EBV genomes in NPC tumors is latent and monoclonal, strongly supporting the hypothesis that EBV infection is present at the inception of neoplastic transformation (7, 8).", [["NPC tumors", "ANATOMY", 28, 38], ["neoplastic", "ANATOMY", 150, 160], ["NPC tumors", "DISEASE", 28, 38], ["EBV infection", "DISEASE", 105, 118], ["EBV", "ORGANISM", 13, 16], ["NPC tumors", "CANCER", 28, 38], ["EBV", "ORGANISM", 105, 108], ["EBV genomes", "DNA", 13, 24], ["EBV", "SPECIES", 105, 108], ["EBV genomes in NPC tumors", "PROBLEM", 13, 38], ["EBV infection", "PROBLEM", 105, 118], ["neoplastic transformation", "PROBLEM", 150, 175], ["EBV genomes", "OBSERVATION", 13, 24], ["NPC", "ANATOMY", 28, 31], ["tumors", "OBSERVATION", 32, 38], ["latent", "OBSERVATION_MODIFIER", 42, 48], ["monoclonal", "OBSERVATION_MODIFIER", 53, 63], ["EBV", "OBSERVATION_MODIFIER", 105, 108], ["infection", "OBSERVATION", 109, 118], ["neoplastic transformation", "OBSERVATION", 150, 175]]], ["Expression of the EBV oncoprotein latent membrane protein 1 (LMP1) in epithelial cells and rat-1 fibroblasts can promote oncogenic properties, including anchorage-independent growth and increased motility, and can also result in the formation of tumors in nude mice (8\u201312).", [["epithelial cells", "ANATOMY", 70, 86], ["rat-1 fibroblasts", "ANATOMY", 91, 108], ["tumors", "ANATOMY", 246, 252], ["tumors", "DISEASE", 246, 252], ["EBV", "ORGANISM", 18, 21], ["latent membrane protein 1", "GENE_OR_GENE_PRODUCT", 34, 59], ["LMP1", "GENE_OR_GENE_PRODUCT", 61, 65], ["epithelial cells", "CELL", 70, 86], ["rat-1 fibroblasts", "CELL", 91, 108], ["tumors", "CANCER", 246, 252], ["nude mice", "ORGANISM", 256, 265], ["EBV oncoprotein", "PROTEIN", 18, 33], ["latent membrane protein 1", "PROTEIN", 34, 59], ["LMP1", "PROTEIN", 61, 65], ["epithelial cells", "CELL_TYPE", 70, 86], ["rat-1 fibroblasts", "CELL_LINE", 91, 108], ["rat", "SPECIES", 91, 94], ["mice", "SPECIES", 261, 265], ["rat-1", "SPECIES", 91, 96], ["mice", "SPECIES", 261, 265], ["the EBV oncoprotein latent membrane protein", "TEST", 14, 57], ["LMP1", "TEST", 61, 65], ["epithelial cells", "TEST", 70, 86], ["rat", "TEST", 91, 94], ["increased motility", "PROBLEM", 186, 204], ["tumors", "PROBLEM", 246, 252], ["epithelial cells", "ANATOMY", 70, 86], ["oncogenic properties", "OBSERVATION", 121, 141], ["growth", "OBSERVATION_MODIFIER", 175, 181], ["increased motility", "OBSERVATION_MODIFIER", 186, 204], ["tumors", "OBSERVATION", 246, 252]]], ["Despite the association with oncogenic properties, it has been more difficult to elucidate the early events that lead to the establishment of latency and infection persistence in NPC (5, 13\u201315).", [["NPC", "ANATOMY", 179, 182], ["infection", "DISEASE", 154, 163], ["NPC", "DISEASE", 179, 182], ["NPC", "CANCER", 179, 182], ["the early events", "PROBLEM", 91, 107], ["latency", "PROBLEM", 142, 149], ["infection persistence in NPC", "PROBLEM", 154, 182], ["latency", "OBSERVATION_MODIFIER", 142, 149], ["infection", "OBSERVATION_MODIFIER", 154, 163], ["persistence", "OBSERVATION_MODIFIER", 164, 175]]], ["The development of a robust in vitro method to mimic differentiation-induced lytic reactivation in polarized epithelia, in primary or immortalized airway epithelial cell lines, could significantly advance our interrogation of EBV pathogenesis in preneoplastic mechanisms.INTRODUCTIONThe conventional method to reactivate EBV is by chemical induction with histone deacetylase (HDAC) inhibitors and protein kinase C inhibitors (12-O-tetradecanoylphorbol 13-acetate [TPA] and sodium butyrate) (6, 16).", [["epithelia", "ANATOMY", 109, 118], ["airway epithelial cell lines", "ANATOMY", 147, 175], ["preneoplastic", "ANATOMY", 246, 259], ["12-O-tetradecanoylphorbol 13-acetate", "CHEMICAL", 426, 462], ["TPA", "CHEMICAL", 464, 467], ["sodium butyrate", "CHEMICAL", 473, 488], ["12-O-tetradecanoylphorbol 13-acetate", "CHEMICAL", 426, 462], ["TPA", "CHEMICAL", 464, 467], ["sodium butyrate", "CHEMICAL", 473, 488], ["epithelia", "CELL", 109, 118], ["airway epithelial cell lines", "CELL", 147, 175], ["EBV", "ORGANISM", 226, 229], ["EBV", "ORGANISM", 321, 324], ["histone deacetylase", "GENE_OR_GENE_PRODUCT", 355, 374], ["HDAC", "GENE_OR_GENE_PRODUCT", 376, 380], ["protein kinase C inhibitors", "SIMPLE_CHEMICAL", 397, 424], ["12-O-tetradecanoylphorbol 13-acetate", "SIMPLE_CHEMICAL", 426, 462], ["TPA", "SIMPLE_CHEMICAL", 464, 467], ["sodium butyrate", "SIMPLE_CHEMICAL", 473, 488], ["primary or immortalized airway epithelial cell lines", "CELL_LINE", 123, 175], ["histone deacetylase", "PROTEIN", 355, 374], ["HDAC", "PROTEIN", 376, 380], ["protein kinase C", "PROTEIN", 397, 413], ["EBV", "SPECIES", 226, 229], ["EBV", "SPECIES", 321, 324], ["a robust in vitro method", "TREATMENT", 19, 43], ["lytic reactivation", "PROBLEM", 77, 95], ["polarized epithelia", "PROBLEM", 99, 118], ["immortalized airway epithelial cell lines", "PROBLEM", 134, 175], ["our interrogation", "TEST", 205, 222], ["EBV pathogenesis in preneoplastic mechanisms", "PROBLEM", 226, 270], ["histone deacetylase (HDAC) inhibitors", "TREATMENT", 355, 392], ["protein kinase C inhibitors", "TREATMENT", 397, 424], ["tetradecanoylphorbol", "TREATMENT", 431, 451], ["acetate [TPA] and sodium butyrate)", "TREATMENT", 455, 489], ["lytic", "OBSERVATION_MODIFIER", 77, 82], ["reactivation", "OBSERVATION", 83, 95], ["polarized epithelia", "OBSERVATION", 99, 118], ["immortalized", "OBSERVATION_MODIFIER", 134, 146], ["airway epithelial cell lines", "OBSERVATION", 147, 175], ["EBV", "OBSERVATION", 226, 229]]], ["Alternatively, the lytic cascade can be triggered by transfecting the immediate early gene product zebra and late glycoprotein gB (6, 17).", [["late glycoprotein gB", "GENE_OR_GENE_PRODUCT", 109, 129], ["immediate early gene product zebra and late glycoprotein gB", "PROTEIN", 70, 129], ["6, 17", "PROTEIN", 131, 136], ["the lytic cascade", "PROBLEM", 15, 32], ["lytic", "OBSERVATION_MODIFIER", 19, 24], ["product zebra", "OBSERVATION", 91, 104], ["late", "OBSERVATION_MODIFIER", 109, 113], ["glycoprotein gB", "OBSERVATION_MODIFIER", 114, 129]]], ["However, these methods do not recapitulate differentiation-induced reactivation and, depending on the cell line, can be abortive without production of progeny virus to appreciable titers (16, 18, 19).", [["cell line", "ANATOMY", 102, 111], ["cell line", "CELL", 102, 111], ["cell line", "CELL_LINE", 102, 111], ["induced reactivation", "PROBLEM", 59, 79], ["the cell line", "TREATMENT", 98, 111], ["progeny virus", "PROBLEM", 151, 164], ["reactivation", "OBSERVATION", 67, 79], ["cell line", "OBSERVATION", 102, 111]]], ["Moreover, not all cell lines are efficiently transfected and chemical induction inadvertently affects global host and viral epigenetics.", [["cell lines", "ANATOMY", 18, 28], ["cell lines", "CELL", 18, 28], ["cell lines", "CELL_LINE", 18, 28], ["all cell lines", "TREATMENT", 14, 28], ["chemical induction", "TREATMENT", 61, 79], ["cell lines", "OBSERVATION", 18, 28], ["viral epigenetics", "OBSERVATION", 118, 135]]], ["The organotypic raft culture model established for studies in human papillomavirus (HPV) replication was recently applied to trigger EBV reactivation, resulting in the efficient production of infectious progeny virus that spreads in stratified primary keratinocytes (20).", [["raft culture", "ANATOMY", 16, 28], ["primary keratinocytes", "ANATOMY", 244, 265], ["human papillomavirus (HPV) replication", "DISEASE", 62, 100], ["human", "ORGANISM", 62, 67], ["papillomavirus", "ORGANISM", 68, 82], ["HPV", "ORGANISM", 84, 87], ["EBV", "ORGANISM", 133, 136], ["infectious progeny virus", "ORGANISM", 192, 216], ["keratinocytes", "CELL", 252, 265], ["organotypic raft culture model", "CELL_LINE", 4, 34], ["primary keratinocytes", "CELL_TYPE", 244, 265], ["human", "SPECIES", 62, 67], ["human papillomavirus", "SPECIES", 62, 82], ["HPV", "SPECIES", 84, 87], ["EBV", "SPECIES", 133, 136], ["The organotypic raft culture model", "TEST", 0, 34], ["studies", "TEST", 51, 58], ["human papillomavirus (HPV) replication", "TREATMENT", 62, 100], ["EBV reactivation", "PROBLEM", 133, 149], ["infectious progeny virus", "PROBLEM", 192, 216], ["EBV reactivation", "OBSERVATION", 133, 149], ["infectious", "OBSERVATION_MODIFIER", 192, 202], ["progeny virus", "OBSERVATION", 203, 216]]], ["The organotypic raft culture can also be applied to the study of EBV infection in human telomerase reverse transcriptase (hTERT)-immortalized keratinocyte cell lines but is not always as robust a model for viral spread (21).", [["raft culture", "ANATOMY", 16, 28], ["keratinocyte cell lines", "ANATOMY", 142, 165], ["EBV infection", "DISEASE", 65, 78], ["EBV", "ORGANISM", 65, 68], ["human", "ORGANISM", 82, 87], ["telomerase reverse transcriptase", "GENE_OR_GENE_PRODUCT", 88, 120], ["hTERT", "GENE_OR_GENE_PRODUCT", 122, 127], ["keratinocyte cell lines", "CELL", 142, 165], ["organotypic raft culture", "CELL_LINE", 4, 28], ["human telomerase reverse transcriptase (hTERT)-immortalized keratinocyte cell lines", "CELL_LINE", 82, 165], ["human", "SPECIES", 82, 87], ["EBV", "SPECIES", 65, 68], ["human", "SPECIES", 82, 87], ["The organotypic raft culture", "TEST", 0, 28], ["the study", "TEST", 52, 61], ["EBV infection", "PROBLEM", 65, 78], ["transcriptase (hTERT)", "TREATMENT", 107, 128], ["immortalized keratinocyte cell lines", "TREATMENT", 129, 165], ["viral spread", "PROBLEM", 206, 218], ["infection", "OBSERVATION", 69, 78], ["keratinocyte cell lines", "OBSERVATION", 142, 165]]], ["One of the triumphs of the organotypic raft model for the study of EBV reactivation is that it is amenable to many standard DNA/RNA/protein molecular virology techniques evaluated either at the population level or at single-cell resolution by immunostaining and imaging methods (22).", [["raft", "ANATOMY", 39, 43], ["cell", "ANATOMY", 224, 228], ["EBV", "ORGANISM", 67, 70], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["cell", "CELL", 224, 228], ["the study", "TEST", 54, 63], ["EBV reactivation", "PROBLEM", 67, 83], ["immunostaining", "TEST", 243, 257], ["imaging methods", "TEST", 262, 277]]], ["Nonetheless, the organotypic raft culture method selects for keratinocytes and is not yet a widely adopted technique.", [["raft", "ANATOMY", 29, 33], ["keratinocytes", "ANATOMY", 61, 74], ["keratinocytes", "CELL", 61, 74], ["keratinocytes", "CELL_TYPE", 61, 74], ["the organotypic raft culture method", "TEST", 13, 48]]], ["A method that can be applied to additional epithelial cell types and could be readily adopted for widespread use is the air-liquid interface (ALI) culture method, which is conventionally used to polarize primary airway epithelial cells of nasal or bronchial origin (23, 24).INTRODUCTIONThe air-liquid interface (ALI) culture method establishes apical and basolateral surfaces by seeding cells on a collagen-coated (or equivalent extracellular matrix-coated) transwell membrane (25).", [["epithelial cell", "ANATOMY", 43, 58], ["primary airway epithelial cells", "ANATOMY", 204, 235], ["nasal", "ANATOMY", 239, 244], ["bronchial", "ANATOMY", 248, 257], ["apical", "ANATOMY", 344, 350], ["basolateral surfaces", "ANATOMY", 355, 375], ["cells", "ANATOMY", 387, 392], ["extracellular matrix", "ANATOMY", 429, 449], ["transwell membrane", "ANATOMY", 458, 476], ["ALI", "DISEASE", 142, 145], ["epithelial cell", "CELL", 43, 58], ["airway epithelial cells", "CELL", 212, 235], ["nasal", "ORGAN", 239, 244], ["apical", "MULTI-TISSUE_STRUCTURE", 344, 350], ["basolateral surfaces", "CELLULAR_COMPONENT", 355, 375], ["cells", "CELL", 387, 392], ["collagen", "GENE_OR_GENE_PRODUCT", 398, 406], ["extracellular matrix", "CELLULAR_COMPONENT", 429, 449], ["epithelial cell types", "CELL_TYPE", 43, 64], ["primary airway epithelial cells", "CELL_TYPE", 204, 235], ["collagen", "PROTEIN", 398, 406], ["A method", "TREATMENT", 0, 8], ["culture method", "TEST", 147, 161], ["INTRODUCTIONThe air-liquid interface (ALI) culture method", "TEST", 274, 331], ["seeding cells", "PROBLEM", 379, 392], ["a collagen-coated (or equivalent extracellular matrix", "TREATMENT", 396, 449], ["epithelial cell types", "OBSERVATION", 43, 64], ["airway epithelial cells", "OBSERVATION", 212, 235], ["nasal", "ANATOMY", 239, 244], ["bronchial", "ANATOMY", 248, 257], ["origin", "ANATOMY_MODIFIER", 258, 264], ["air-liquid interface", "OBSERVATION", 290, 310], ["apical", "ANATOMY_MODIFIER", 344, 350], ["basolateral", "ANATOMY_MODIFIER", 355, 366], ["surfaces", "ANATOMY_MODIFIER", 367, 375], ["seeding cells", "OBSERVATION", 379, 392]]], ["Once an intact epithelium is established, the apical medium is removed and cells are fed through a porous membrane from the basolateral surface (Fig. 1A).", [["epithelium", "ANATOMY", 15, 25], ["cells", "ANATOMY", 75, 80], ["membrane", "ANATOMY", 106, 114], ["basolateral surface", "ANATOMY", 124, 143], ["epithelium", "TISSUE", 15, 25], ["cells", "CELL", 75, 80], ["membrane", "CELLULAR_COMPONENT", 106, 114], ["basolateral surface", "CELLULAR_COMPONENT", 124, 143], ["a porous membrane", "TREATMENT", 97, 114], ["intact", "OBSERVATION_MODIFIER", 8, 14], ["epithelium", "OBSERVATION", 15, 25], ["apical", "ANATOMY_MODIFIER", 46, 52], ["medium", "OBSERVATION_MODIFIER", 53, 59], ["removed", "OBSERVATION", 63, 70], ["porous membrane", "OBSERVATION", 99, 114], ["basolateral", "ANATOMY_MODIFIER", 124, 135], ["surface", "ANATOMY_MODIFIER", 136, 143]]], ["Originally, the ALI method was used to establish pseudostratified cultures of primary airway epithelial cells with apical cilia and basolateral nuclei, which can preserve the diversity of cell types resembling native airway epithelium (23, 24).", [["primary airway epithelial cells", "ANATOMY", 78, 109], ["apical cilia", "ANATOMY", 115, 127], ["basolateral nuclei", "ANATOMY", 132, 150], ["cell", "ANATOMY", 188, 192], ["airway epithelium", "ANATOMY", 217, 234], ["airway epithelial cells", "CELL", 86, 109], ["apical cilia", "CELLULAR_COMPONENT", 115, 127], ["basolateral nuclei", "CELLULAR_COMPONENT", 132, 150], ["cell", "CELL", 188, 192], ["airway epithelium", "TISSUE", 217, 234], ["primary airway epithelial cells", "CELL_TYPE", 78, 109], ["the ALI method", "TREATMENT", 12, 26], ["pseudostratified cultures", "TEST", 49, 74], ["primary airway epithelial cells", "PROBLEM", 78, 109], ["apical cilia and basolateral nuclei", "PROBLEM", 115, 150], ["primary airway epithelial cells", "OBSERVATION", 78, 109], ["apical", "ANATOMY_MODIFIER", 115, 121], ["cilia", "ANATOMY_MODIFIER", 122, 127], ["basolateral nuclei", "ANATOMY", 132, 150], ["diversity", "OBSERVATION_MODIFIER", 175, 184], ["cell types", "OBSERVATION", 188, 198], ["native", "ANATOMY_MODIFIER", 210, 216], ["airway", "ANATOMY", 217, 223], ["epithelium", "ANATOMY_MODIFIER", 224, 234]]], ["The ALI method can also be applied to immortalized cell lines (26, 27).", [["cell lines", "ANATOMY", 51, 61], ["ALI", "DISEASE", 4, 7], ["cell lines", "CELL", 51, 61], ["immortalized cell lines", "CELL_LINE", 38, 61], ["The ALI method", "TREATMENT", 0, 14], ["immortalized cell lines", "TREATMENT", 38, 61], ["ALI", "OBSERVATION", 4, 7], ["immortalized cell lines", "OBSERVATION", 38, 61]]], ["ALI culture conditions have been routinely used for both primary and immortalized cells to study the pathogenesis of airway microbial pathogens (27, 28).", [["primary", "ANATOMY", 57, 64], ["cells", "ANATOMY", 82, 87], ["airway", "ANATOMY", 117, 123], ["ALI", "DISEASE", 0, 3], ["airway microbial pathogens", "DISEASE", 117, 143], ["cells", "CELL", 82, 87], ["airway", "MULTI-TISSUE_STRUCTURE", 117, 123], ["primary and immortalized cells", "CELL_TYPE", 57, 87], ["ALI culture conditions", "TEST", 0, 22], ["airway microbial pathogens", "PROBLEM", 117, 143], ["airway", "ANATOMY", 117, 123]]], ["Several studies have used the ALI method to define EBV infection parameters in polarized epithelia (26, 29, 30).", [["epithelia", "ANATOMY", 89, 98], ["infection", "DISEASE", 55, 64], ["EBV", "ORGANISM", 51, 54], ["epithelia", "TISSUE", 89, 98], ["EBV", "SPECIES", 51, 54], ["Several studies", "TEST", 0, 15], ["the ALI method", "TREATMENT", 26, 40], ["EBV infection parameters", "PROBLEM", 51, 75], ["infection", "OBSERVATION", 55, 64], ["polarized epithelia", "OBSERVATION_MODIFIER", 79, 98]]], ["However, only the organotypic raft culture has undeniably demonstrated that infection of stratified keratinocytes yields a permissive and productive infection (18, 20).", [["raft culture", "ANATOMY", 30, 42], ["keratinocytes", "ANATOMY", 100, 113], ["infection", "DISEASE", 76, 85], ["infection", "DISEASE", 149, 158], ["keratinocytes", "CELL", 100, 113], ["organotypic raft culture", "CELL_LINE", 18, 42], ["stratified keratinocytes", "CELL_TYPE", 89, 113], ["the organotypic raft culture", "TEST", 14, 42], ["infection", "PROBLEM", 76, 85], ["stratified keratinocytes", "PROBLEM", 89, 113], ["a permissive and productive infection", "PROBLEM", 121, 158], ["infection", "OBSERVATION", 76, 85], ["permissive", "OBSERVATION_MODIFIER", 123, 133], ["productive", "OBSERVATION_MODIFIER", 138, 148], ["infection", "OBSERVATION", 149, 158]]], ["While those few studies have been recognized as crucial and complementary, these intricate culture methods have yet to be widely adopted (31\u201333).INTRODUCTIONThere are a limited number of authenticated NPC cell lines that continue to harbor latent EBV in culture (14, 34\u201336).", [["NPC cell lines", "ANATOMY", 201, 215], ["NPC cell lines", "CELL", 201, 215], ["EBV", "ORGANISM", 247, 250], ["NPC cell lines", "CELL_LINE", 201, 215], ["those few studies", "TEST", 6, 23], ["these intricate culture methods", "TEST", 75, 106], ["authenticated NPC cell lines", "TREATMENT", 187, 215], ["latent EBV in culture", "TEST", 240, 261], ["NPC cell lines", "OBSERVATION", 201, 215]]], ["In the present study, the ALI culture method was evaluated for induction of the EBV lytic cascade and production of progeny virus in EBV-infected nasopharyngeal and NPC-derived cell lines that are ordinarily latent in monolayer culture (37\u201339).", [["nasopharyngeal", "ANATOMY", 146, 160], ["NPC-derived cell lines", "ANATOMY", 165, 187], ["monolayer culture", "ANATOMY", 218, 235], ["ALI", "DISEASE", 26, 29], ["EBV", "ORGANISM", 80, 83], ["progeny virus", "ORGANISM", 116, 129], ["EBV", "ORGANISM", 133, 136], ["nasopharyngeal", "CELL", 146, 160], ["NPC-derived cell lines", "CELL", 165, 187], ["monolayer culture", "CELL", 218, 235], ["EBV-infected nasopharyngeal and NPC-derived cell lines", "CELL_LINE", 133, 187], ["EBV", "SPECIES", 80, 83], ["EBV", "SPECIES", 133, 136], ["the present study", "TEST", 3, 20], ["the ALI culture method", "TEST", 22, 44], ["the EBV lytic cascade", "PROBLEM", 76, 97], ["progeny virus", "PROBLEM", 116, 129], ["EBV", "PROBLEM", 133, 136], ["infected nasopharyngeal and NPC", "PROBLEM", 137, 168], ["derived cell lines", "TREATMENT", 169, 187], ["monolayer culture", "TEST", 218, 235], ["ALI", "ANATOMY", 26, 29], ["progeny virus", "OBSERVATION", 116, 129], ["infected", "OBSERVATION_MODIFIER", 137, 145], ["nasopharyngeal", "ANATOMY", 146, 160], ["NPC", "ANATOMY", 165, 168], ["cell lines", "OBSERVATION", 177, 187]]], ["The HK1 cell line, described as having originated from a differentiated NPC tumor biopsy specimen and infected with a recombinant (Akata) EBV strain, was amenable to ALI-induced culture conditions (38, 40).", [["HK1 cell line", "ANATOMY", 4, 17], ["NPC tumor biopsy specimen", "ANATOMY", 72, 97], ["tumor", "DISEASE", 76, 81], ["ALI", "DISEASE", 166, 169], ["HK1 cell line", "CELL", 4, 17], ["NPC tumor biopsy specimen", "TISSUE", 72, 97], ["EBV", "ORGANISM", 138, 141], ["HK1 cell line", "CELL_LINE", 4, 17], ["The HK1 cell line", "PROBLEM", 0, 17], ["a differentiated NPC tumor biopsy specimen", "PROBLEM", 55, 97], ["a recombinant (Akata) EBV strain", "PROBLEM", 116, 148], ["ALI", "PROBLEM", 166, 169], ["culture conditions", "TEST", 178, 196], ["cell line", "OBSERVATION", 8, 17], ["differentiated", "OBSERVATION_MODIFIER", 57, 71], ["NPC", "ANATOMY", 72, 75], ["tumor", "OBSERVATION", 76, 81], ["infected", "OBSERVATION_MODIFIER", 102, 110]]], ["Lytic reactivation was then monitored by assessing lytic gene induction, EBV genome replication, and the production of infectious progeny virus.", [["EBV", "ORGANISM", 73, 76], ["infectious progeny virus", "ORGANISM", 119, 143], ["EBV genome", "DNA", 73, 83], ["EBV", "SPECIES", 73, 76], ["Lytic reactivation", "PROBLEM", 0, 18], ["lytic gene induction", "TREATMENT", 51, 71], ["EBV genome replication", "TREATMENT", 73, 95], ["infectious progeny virus", "PROBLEM", 119, 143], ["infectious", "OBSERVATION_MODIFIER", 119, 129], ["progeny virus", "OBSERVATION", 130, 143]]], ["The results of this study demonstrate that the ALI method is proficient at reactivating EBV from the established HK1-EBV cell line, yielding high titers (~106 packaged genome equivalents per ALI culture [1.12 cm2]) that are secreted and infectious, thus providing an alternative method to interrogate EBV permissive replication from polarized epithelia in an established NPC-derived cell line and allowing the elucidation of EBV pathogenesis in nasal epithelia.Induction of the EBV lytic cascade. ::: RESULTS AND DISCUSSIONThe NPC HK1 cell line is derived from a squamous carcinoma of the nasopharynx (40).", [["HK1-EBV cell line", "ANATOMY", 113, 130], ["epithelia", "ANATOMY", 343, 352], ["NPC", "ANATOMY", 371, 374], ["cell line", "ANATOMY", 383, 392], ["nasal epithelia", "ANATOMY", 445, 460], ["NPC HK1 cell line", "ANATOMY", 527, 544], ["squamous carcinoma", "ANATOMY", 563, 581], ["nasopharynx", "ANATOMY", 589, 600], ["ALI", "DISEASE", 47, 50], ["squamous carcinoma of the nasopharynx", "DISEASE", 563, 600], ["EBV", "ORGANISM", 88, 91], ["HK1-EBV cell line", "CELL", 113, 130], ["EBV", "ORGANISM", 301, 304], ["epithelia", "TISSUE", 343, 352], ["NPC-derived cell line", "CELL", 371, 392], ["EBV", "ORGANISM", 425, 428], ["nasal epithelia", "TISSUE", 445, 460], ["EBV", "ORGANISM", 478, 481], ["NPC HK1 cell line", "CELL", 527, 544], ["squamous carcinoma", "CANCER", 563, 581], ["nasopharynx", "ORGAN", 589, 600], ["HK1-EBV cell line", "CELL_LINE", 113, 130], ["NPC-derived cell line", "CELL_LINE", 371, 392], ["NPC HK1 cell line", "CELL_LINE", 527, 544], ["EBV", "SPECIES", 88, 91], ["EBV", "SPECIES", 301, 304], ["EBV", "SPECIES", 425, 428], ["this study", "TEST", 15, 25], ["the ALI method", "PROBLEM", 43, 57], ["high titers", "PROBLEM", 141, 152], ["ALI culture", "TEST", 191, 202], ["infectious", "PROBLEM", 237, 247], ["an alternative method", "TREATMENT", 264, 285], ["EBV permissive replication", "TREATMENT", 301, 327], ["polarized epithelia", "PROBLEM", 333, 352], ["derived cell line", "TREATMENT", 375, 392], ["EBV pathogenesis in nasal epithelia", "PROBLEM", 425, 460], ["the EBV lytic cascade", "TREATMENT", 474, 495], ["NPC HK1 cell line", "TREATMENT", 527, 544], ["a squamous carcinoma of the nasopharynx", "PROBLEM", 561, 600], ["EBV cell line", "OBSERVATION", 117, 130], ["high", "OBSERVATION_MODIFIER", 141, 145], ["titers", "OBSERVATION_MODIFIER", 146, 152], ["ALI", "ANATOMY", 191, 194], ["infectious", "OBSERVATION", 237, 247], ["polarized epithelia", "OBSERVATION", 333, 352], ["cell line", "OBSERVATION", 383, 392], ["EBV", "OBSERVATION", 425, 428], ["nasal epithelia", "ANATOMY", 445, 460], ["lytic", "OBSERVATION_MODIFIER", 482, 487], ["cell line", "OBSERVATION", 535, 544], ["squamous carcinoma", "OBSERVATION", 563, 581], ["nasopharynx", "ANATOMY", 589, 600]]], ["The primary biopsy specimen was too small for EBV DNA analysis, but the outgrowing HK1 cell line did not show evidence of EBV infection as determined by staining for EBNA1 or by imaging of virus particles (40).", [["primary biopsy specimen", "ANATOMY", 4, 27], ["HK1 cell line", "ANATOMY", 83, 96], ["EBV infection", "DISEASE", 122, 135], ["biopsy specimen", "CANCER", 12, 27], ["EBV", "ORGANISM", 46, 49], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["HK1 cell line", "CELL", 83, 96], ["EBV", "ORGANISM", 122, 125], ["EBNA1", "GENE_OR_GENE_PRODUCT", 166, 171], ["HK1 cell line", "CELL_LINE", 83, 96], ["EBNA1", "PROTEIN", 166, 171], ["EBV", "SPECIES", 46, 49], ["EBV", "SPECIES", 122, 125], ["The primary biopsy specimen", "TEST", 0, 27], ["EBV DNA analysis", "TEST", 46, 62], ["the outgrowing HK1 cell line", "TEST", 68, 96], ["EBV infection", "PROBLEM", 122, 135], ["EBNA1", "PROBLEM", 166, 171], ["imaging of virus particles", "TEST", 178, 204], ["cell line", "OBSERVATION", 87, 96], ["not show evidence of", "UNCERTAINTY", 101, 121], ["EBV", "OBSERVATION_MODIFIER", 122, 125], ["infection", "OBSERVATION", 126, 135]]], ["The HK1-EBV cell line was established by in vitro infection of a recombinant EBV originating from the EBV Akata strain (38).", [["HK1-EBV cell line", "ANATOMY", 4, 21], ["infection", "DISEASE", 50, 59], ["HK1-EBV cell line", "CELL", 4, 21], ["EBV", "ORGANISM", 77, 80], ["EBV", "ORGANISM", 102, 105], ["HK1-EBV cell line", "CELL_LINE", 4, 21], ["EBV", "SPECIES", 77, 80], ["The HK1-EBV cell line", "TEST", 0, 21], ["vitro infection", "PROBLEM", 44, 59], ["a recombinant EBV", "PROBLEM", 63, 80], ["EBV cell line", "OBSERVATION", 8, 21], ["infection", "OBSERVATION", 50, 59], ["recombinant", "OBSERVATION_MODIFIER", 65, 76], ["EBV", "OBSERVATION", 77, 80]]], ["In proliferating monolayer cultures, the EBV-infected HK1 cell line does not show induction of the lytic cascade and expresses a type II latency profile characterized by the expression of EBNA1, EBER1/2, LMP1, LMP2A, LMP2B, and BART transcripts (38).", [["monolayer cultures", "ANATOMY", 17, 35], ["HK1 cell line", "ANATOMY", 54, 67], ["monolayer cultures", "CELL", 17, 35], ["EBV", "ORGANISM", 41, 44], ["HK1 cell line", "CELL", 54, 67], ["EBNA1", "GENE_OR_GENE_PRODUCT", 188, 193], ["EBER1", "GENE_OR_GENE_PRODUCT", 195, 200], ["2", "GENE_OR_GENE_PRODUCT", 201, 202], ["LMP1", "GENE_OR_GENE_PRODUCT", 204, 208], ["LMP2A", "GENE_OR_GENE_PRODUCT", 210, 215], ["LMP2B", "GENE_OR_GENE_PRODUCT", 217, 222], ["BART", "GENE_OR_GENE_PRODUCT", 228, 232], ["proliferating monolayer cultures", "CELL_LINE", 3, 35], ["EBV-infected HK1 cell line", "CELL_LINE", 41, 67], ["EBNA1, EBER1/2, LMP1, LMP2A, LMP2B, and BART transcripts", "RNA", 188, 244], ["proliferating monolayer cultures", "TEST", 3, 35], ["the EBV", "TEST", 37, 44], ["infected HK1 cell line", "PROBLEM", 45, 67], ["the lytic cascade", "PROBLEM", 95, 112], ["a type II latency profile", "PROBLEM", 127, 152], ["EBNA1", "TEST", 188, 193], ["EBER1", "TEST", 195, 200], ["LMP1", "TEST", 204, 208], ["LMP2A", "TEST", 210, 215], ["LMP2B", "TEST", 217, 222], ["infected", "OBSERVATION_MODIFIER", 45, 53], ["HK1 cell line", "OBSERVATION", 54, 67], ["lytic", "OBSERVATION_MODIFIER", 99, 104], ["LMP1", "ANATOMY", 204, 208], ["LMP2A", "ANATOMY", 210, 215]]], ["In this cell line, expression of lytic genes can be induced by the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) but is primarily abortive and does not yield progeny virus (16).", [["cell line", "ANATOMY", 8, 17], ["suberoylanilide hydroxamic acid", "CHEMICAL", 82, 113], ["SAHA", "CHEMICAL", 115, 119], ["suberoylanilide hydroxamic acid", "CHEMICAL", 82, 113], ["SAHA", "CHEMICAL", 115, 119], ["cell line", "CELL", 8, 17], ["HDAC", "GENE_OR_GENE_PRODUCT", 67, 71], ["suberoylanilide hydroxamic acid", "SIMPLE_CHEMICAL", 82, 113], ["SAHA", "SIMPLE_CHEMICAL", 115, 119], ["lytic genes", "DNA", 33, 44], ["this cell line", "TREATMENT", 3, 17], ["lytic genes", "PROBLEM", 33, 44], ["the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA", "TREATMENT", 63, 119], ["cell line", "OBSERVATION", 8, 17], ["lytic", "OBSERVATION_MODIFIER", 33, 38]]], ["Epithelial differentiation is a physiological trigger for EBV reactivation and can be induced by culturing cells at the air-liquid interface (32).", [["Epithelial", "ANATOMY", 0, 10], ["cells", "ANATOMY", 107, 112], ["Epithelial", "CELL", 0, 10], ["EBV", "ORGANISM", 58, 61], ["cells", "CELL", 107, 112], ["EBV", "SPECIES", 58, 61], ["Epithelial differentiation", "PROBLEM", 0, 26], ["EBV reactivation", "PROBLEM", 58, 74], ["culturing cells", "TEST", 97, 112]]], ["Therefore, the HK1-EBV cell line was tested using the ALI epithelial cell polarization method for EBV reactivation and the timeline presented in Fig. 1B.", [["HK1-EBV cell line", "ANATOMY", 15, 32], ["epithelial cell", "ANATOMY", 58, 73], ["1B.", "CHEMICAL", 150, 153], ["HK1", "GENE_OR_GENE_PRODUCT", 15, 18], ["EBV", "ORGANISM", 19, 22], ["cell line", "CELL", 23, 32], ["ALI epithelial cell", "CELL", 54, 73], ["EBV", "ORGANISM", 98, 101], ["HK1-EBV cell line", "CELL_LINE", 15, 32], ["EBV", "SPECIES", 98, 101], ["1B.", "SPECIES", 150, 153], ["the HK1-EBV cell line", "TEST", 11, 32], ["the ALI epithelial cell polarization method", "TREATMENT", 50, 93], ["EBV reactivation", "PROBLEM", 98, 114], ["EBV cell line", "OBSERVATION", 19, 32], ["ALI epithelial cell polarization", "OBSERVATION", 54, 86], ["EBV reactivation", "OBSERVATION", 98, 114]]], ["Upon removal of apical media, harvest time points begin 1 day after lifting to the air-liquid interface (denoted week 0) and at weekly intervals for a total of 3 weeks.", [["removal", "TREATMENT", 5, 12], ["apical media", "TREATMENT", 16, 28], ["apical", "ANATOMY_MODIFIER", 16, 22], ["media", "ANATOMY", 23, 28]]], ["One additional hTERT-immortalized nasopharyngeal cell line (NP460hTERT-EBV) and one natively infected NPC cell line (C666-1) were also evaluated (37\u201339), but only the HK1-EBV cell line could be maintained under ALI growth conditions and could preserve an intact epithelium under polarized conditions (data not shown).Induction of the EBV lytic cascade. ::: RESULTS AND DISCUSSIONTo assess the induction of EBV lytic proteins, HK1 uninfected and EBV-infected cell lysates were harvested at weekly intervals for 3 weeks after lifting to the air-liquid interface.", [["nasopharyngeal cell line", "ANATOMY", 34, 58], ["NP460hTERT-EBV", "ANATOMY", 60, 74], ["NPC cell line", "ANATOMY", 102, 115], ["C666-1", "ANATOMY", 117, 123], ["HK1-EBV cell line", "ANATOMY", 167, 184], ["epithelium", "ANATOMY", 262, 272], ["cell lysates", "ANATOMY", 458, 470], ["ALI", "DISEASE", 211, 214], ["hTERT", "GENE_OR_GENE_PRODUCT", 15, 20], ["nasopharyngeal cell line", "CELL", 34, 58], ["NP460hTERT-EBV", "CELL", 60, 74], ["NPC cell line", "CELL", 102, 115], ["C666-1", "CELL", 117, 123], ["HK1", "GENE_OR_GENE_PRODUCT", 167, 170], ["EBV", "ORGANISM", 171, 174], ["cell line", "CELL", 175, 184], ["epithelium", "TISSUE", 262, 272], ["EBV", "ORGANISM", 334, 337], ["EBV", "ORGANISM", 406, 409], ["HK1", "GENE_OR_GENE_PRODUCT", 426, 429], ["EBV", "ORGANISM", 445, 448], ["cell lysates", "CELL", 458, 470], ["hTERT", "PROTEIN", 15, 20], ["immortalized nasopharyngeal cell line", "CELL_LINE", 21, 58], ["NP460hTERT", "CELL_LINE", 60, 70], ["NPC cell line", "CELL_LINE", 102, 115], ["C666-1", "CELL_LINE", 117, 123], ["HK1-EBV cell line", "CELL_LINE", 167, 184], ["EBV lytic proteins", "PROTEIN", 406, 424], ["EBV", "SPECIES", 406, 409], ["EBV", "SPECIES", 445, 448], ["immortalized nasopharyngeal cell line", "TREATMENT", 21, 58], ["one natively infected NPC cell line", "PROBLEM", 80, 115], ["the HK1", "TEST", 163, 170], ["EBV cell line", "TREATMENT", 171, 184], ["ALI growth conditions", "PROBLEM", 211, 232], ["the EBV lytic cascade", "TREATMENT", 330, 351], ["EBV lytic proteins", "PROBLEM", 406, 424], ["HK1", "PROBLEM", 426, 429], ["EBV", "PROBLEM", 445, 448], ["infected cell lysates", "PROBLEM", 449, 470], ["nasopharyngeal", "ANATOMY", 34, 48], ["cell line", "OBSERVATION", 49, 58], ["infected", "OBSERVATION_MODIFIER", 93, 101], ["NPC cell line", "OBSERVATION", 102, 115], ["EBV cell line", "OBSERVATION", 171, 184], ["ALI growth", "OBSERVATION", 211, 221], ["intact epithelium", "OBSERVATION", 255, 272], ["lytic", "OBSERVATION_MODIFIER", 338, 343], ["infected cell lysates", "OBSERVATION", 449, 470], ["air-liquid interface", "OBSERVATION", 539, 559]]], ["Lysates were analyzed by immunoblotting for expression of immediate early protein zebra, early protein EaD, and the late viral capsid antigen (VCA) p18 protein, as well as the cellular differentiation markers involucrin, keratin 10, and filaggrin (Fig. 2A).", [["Lysates", "ANATOMY", 0, 7], ["cellular", "ANATOMY", 176, 184], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["zebra", "GENE_OR_GENE_PRODUCT", 82, 87], ["EaD", "GENE_OR_GENE_PRODUCT", 103, 106], ["viral capsid antigen", "GENE_OR_GENE_PRODUCT", 121, 141], ["VCA", "GENE_OR_GENE_PRODUCT", 143, 146], ["p18", "GENE_OR_GENE_PRODUCT", 148, 151], ["cellular", "CELL", 176, 184], ["involucrin", "GENE_OR_GENE_PRODUCT", 209, 219], ["keratin 10", "GENE_OR_GENE_PRODUCT", 221, 231], ["filaggrin", "GENE_OR_GENE_PRODUCT", 237, 246], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 248, 255], ["immediate early protein zebra, early protein", "PROTEIN", 58, 102], ["EaD", "PROTEIN", 103, 106], ["late viral capsid antigen", "PROTEIN", 116, 141], ["VCA", "PROTEIN", 143, 146], ["p18 protein", "PROTEIN", 148, 159], ["cellular differentiation markers", "PROTEIN", 176, 208], ["involucrin", "PROTEIN", 209, 219], ["keratin 10", "PROTEIN", 221, 231], ["filaggrin", "PROTEIN", 237, 246], ["Fig. 2A", "PROTEIN", 248, 255], ["Lysates", "TEST", 0, 7], ["immediate early protein zebra", "PROBLEM", 58, 87], ["early protein EaD", "PROBLEM", 89, 106], ["the late viral capsid antigen", "TEST", 112, 141], ["involucrin", "TEST", 209, 219], ["keratin", "TEST", 221, 228], ["protein zebra", "OBSERVATION", 74, 87]]], ["Although the HK1 cell line is described as having originated from a differentiated squamous carcinoma biopsy, involucrin was not evident in monolayer culture but was robustly induced in ALI culture, consistent with the hypothesis that the ALI method triggers terminal differentiation.", [["HK1 cell line", "ANATOMY", 13, 26], ["squamous carcinoma biopsy", "ANATOMY", 83, 108], ["monolayer culture", "ANATOMY", 140, 157], ["squamous carcinoma", "DISEASE", 83, 101], ["ALI", "DISEASE", 186, 189], ["ALI", "DISEASE", 239, 242], ["HK1 cell line", "CELL", 13, 26], ["squamous carcinoma biopsy", "CANCER", 83, 108], ["involucrin", "GENE_OR_GENE_PRODUCT", 110, 120], ["monolayer culture", "CELL", 140, 157], ["HK1 cell line", "CELL_LINE", 13, 26], ["involucrin", "PROTEIN", 110, 120], ["monolayer culture", "CELL_LINE", 140, 157], ["the HK1 cell line", "PROBLEM", 9, 26], ["a differentiated squamous carcinoma biopsy", "PROBLEM", 66, 108], ["monolayer culture", "TEST", 140, 157], ["ALI culture", "TEST", 186, 197], ["the hypothesis", "PROBLEM", 215, 229], ["the ALI method", "PROBLEM", 235, 249], ["cell line", "OBSERVATION", 17, 26], ["differentiated", "OBSERVATION_MODIFIER", 68, 82], ["squamous carcinoma", "OBSERVATION", 83, 101], ["not evident", "UNCERTAINTY", 125, 136], ["consistent with", "UNCERTAINTY", 199, 214], ["terminal", "OBSERVATION_MODIFIER", 259, 267], ["differentiation", "OBSERVATION_MODIFIER", 268, 283]]], ["At early time points, involucrin and keratin 10 levels were induced as early as day 1, corresponding to induction of the EBV immediate early switch protein zebra (Fig. 2A).", [["involucrin", "GENE_OR_GENE_PRODUCT", 22, 32], ["keratin 10", "GENE_OR_GENE_PRODUCT", 37, 47], ["EBV", "ORGANISM", 121, 124], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 163, 170], ["involucrin", "PROTEIN", 22, 32], ["keratin 10", "PROTEIN", 37, 47], ["EBV immediate early switch protein zebra", "PROTEIN", 121, 161], ["Fig. 2A", "PROTEIN", 163, 170], ["involucrin and keratin 10 levels", "TEST", 22, 54], ["the EBV immediate early switch protein zebra", "TREATMENT", 117, 161]]], ["Processed filaggrin levels were not affected and were weak, requiring long exposures, which may reflect the low abundance and variable detection in nasal mucosa (41, 42).", [["nasal mucosa", "ANATOMY", 148, 160], ["filaggrin", "GENE_OR_GENE_PRODUCT", 10, 19], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 148, 160], ["filaggrin", "PROTEIN", 10, 19], ["Processed filaggrin levels", "TEST", 0, 26], ["the low abundance", "PROBLEM", 104, 121], ["variable detection in nasal mucosa", "PROBLEM", 126, 160], ["weak", "OBSERVATION_MODIFIER", 54, 58], ["may reflect", "UNCERTAINTY", 92, 103], ["low abundance", "OBSERVATION_MODIFIER", 108, 121], ["variable", "OBSERVATION_MODIFIER", 126, 134], ["nasal mucosa", "ANATOMY", 148, 160]]], ["The induction of involucrin was strongest in EBV-infected HK1 cells compared to uninfected cells, but both the infected and uninfected cell lines displayed consistent induction of involucrin and keratin 10, supporting the idea that ALI culture triggers differentiation (Fig. 2A).", [["HK1 cells", "ANATOMY", 58, 67], ["cells", "ANATOMY", 91, 96], ["cell lines", "ANATOMY", 135, 145], ["ALI", "DISEASE", 232, 235], ["involucrin", "GENE_OR_GENE_PRODUCT", 17, 27], ["EBV", "ORGANISM", 45, 48], ["HK1 cells", "CELL", 58, 67], ["cells", "CELL", 91, 96], ["cell lines", "CELL", 135, 145], ["involucrin", "GENE_OR_GENE_PRODUCT", 180, 190], ["keratin 10", "GENE_OR_GENE_PRODUCT", 195, 205], ["involucrin", "PROTEIN", 17, 27], ["HK1 cells", "CELL_LINE", 58, 67], ["uninfected cells", "CELL_TYPE", 80, 96], ["uninfected cell lines", "CELL_LINE", 124, 145], ["involucrin", "PROTEIN", 180, 190], ["keratin 10", "PROTEIN", 195, 205], ["EBV", "SPECIES", 45, 48], ["EBV", "PROBLEM", 45, 48], ["infected HK1 cells", "PROBLEM", 49, 67], ["uninfected cells", "PROBLEM", 80, 96], ["uninfected cell lines", "TREATMENT", 124, 145], ["involucrin and keratin", "TREATMENT", 180, 202], ["ALI culture", "TEST", 232, 243], ["uninfected cells", "OBSERVATION", 80, 96], ["infected", "OBSERVATION_MODIFIER", 111, 119], ["uninfected cell lines", "OBSERVATION", 124, 145], ["ALI", "ANATOMY", 232, 235]]], ["In comparison to the undetectable levels in monolayer culture, the EBV zebra, EaD, and VCA p18 proteins were induced beginning at week 1 to week 2 post-ALI culture (Fig. 2A).", [["monolayer culture", "ANATOMY", 44, 61], ["ALI", "DISEASE", 152, 155], ["monolayer culture", "CELL", 44, 61], ["EBV", "ORGANISM", 67, 70], ["zebra", "GENE_OR_GENE_PRODUCT", 71, 76], ["EaD", "GENE_OR_GENE_PRODUCT", 78, 81], ["VCA p18", "GENE_OR_GENE_PRODUCT", 87, 94], ["EBV zebra, EaD, and VCA p18 proteins", "PROTEIN", 67, 103], ["EBV zebra", "SPECIES", 67, 76], ["monolayer culture", "TEST", 44, 61], ["the EBV zebra", "TEST", 63, 76], ["EaD", "TEST", 78, 81], ["VCA p18 proteins", "TREATMENT", 87, 103], ["ALI culture", "TEST", 152, 163]]], ["Moreover, chemical induction by treatment with TPA and sodium butyrate in monolayer culture triggered lytic reactivation but did not result in the production of progeny virus as determined by the green Raji unit (GRU) assay (Fig. 2A; see also Table S1 in the supplemental material).", [["monolayer culture", "ANATOMY", 74, 91], ["TPA", "CHEMICAL", 47, 50], ["sodium butyrate", "CHEMICAL", 55, 70], ["TPA", "CHEMICAL", 47, 50], ["sodium butyrate", "CHEMICAL", 55, 70], ["TPA", "SIMPLE_CHEMICAL", 47, 50], ["sodium butyrate", "SIMPLE_CHEMICAL", 55, 70], ["monolayer culture", "CELL", 74, 91], ["monolayer culture", "CELL_LINE", 74, 91], ["chemical induction", "TREATMENT", 10, 28], ["TPA", "TREATMENT", 47, 50], ["sodium butyrate", "TREATMENT", 55, 70], ["monolayer culture", "TEST", 74, 91], ["lytic reactivation", "PROBLEM", 102, 120], ["progeny virus", "PROBLEM", 161, 174]]], ["Late lytic proteins, particularly glycoproteins, are notoriously difficult to probe by immunoblotting; therefore, expression of EBV zebra and EaD and of an additional late glycoprotein, gp350, was also analyzed by immunofluorescence staining.", [["EBV", "ORGANISM", 128, 131], ["zebra", "ORGANISM", 132, 137], ["EaD", "GENE_OR_GENE_PRODUCT", 142, 145], ["gp350", "GENE_OR_GENE_PRODUCT", 186, 191], ["Late lytic proteins", "PROTEIN", 0, 19], ["glycoproteins", "PROTEIN", 34, 47], ["EBV zebra", "PROTEIN", 128, 137], ["EaD", "PROTEIN", 142, 145], ["glycoprotein", "PROTEIN", 172, 184], ["gp350", "PROTEIN", 186, 191], ["EBV zebra", "SPECIES", 128, 137], ["Late lytic proteins", "PROBLEM", 0, 19], ["immunoblotting", "TEST", 87, 101], ["EBV zebra", "PROBLEM", 128, 137], ["an additional late glycoprotein", "TREATMENT", 153, 184], ["immunofluorescence staining", "TEST", 214, 241], ["lytic", "OBSERVATION_MODIFIER", 5, 10]]], ["Nuclear staining of EBV zebra and EaD proteins and the cytoplasmic staining of gp350 further support the induction of the lytic cascade (Fig. 2B).", [["Nuclear", "ANATOMY", 0, 7], ["cytoplasmic", "ANATOMY", 55, 66], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["EBV", "ORGANISM", 20, 23], ["zebra", "ORGANISM", 24, 29], ["EaD", "GENE_OR_GENE_PRODUCT", 34, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 55, 66], ["gp350", "GENE_OR_GENE_PRODUCT", 79, 84], ["EBV zebra and EaD proteins", "PROTEIN", 20, 46], ["gp350", "PROTEIN", 79, 84], ["EBV zebra", "SPECIES", 20, 29], ["Nuclear staining", "TEST", 0, 16], ["EBV zebra", "TEST", 20, 29], ["EaD proteins", "TEST", 34, 46], ["the cytoplasmic staining", "TEST", 51, 75], ["the lytic cascade", "TREATMENT", 118, 135], ["EBV zebra", "OBSERVATION", 20, 29]]], ["Cells that stain positively for gp350 represent cells that have completed induction of the lytic cascade.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 48, 53], ["Cells", "CELL", 0, 5], ["gp350", "GENE_OR_GENE_PRODUCT", 32, 37], ["cells", "CELL", 48, 53], ["gp350", "PROTEIN", 32, 37], ["Cells that stain", "TEST", 0, 16], ["cells", "PROBLEM", 48, 53], ["the lytic cascade", "TREATMENT", 87, 104], ["lytic", "OBSERVATION_MODIFIER", 91, 96]]], ["Only sporadic cells stained positively for gp350 in monolayer culture when reactivated with TPA and sodium butyrate (Fig. 2C).", [["cells", "ANATOMY", 14, 19], ["monolayer culture", "ANATOMY", 52, 69], ["TPA", "CHEMICAL", 92, 95], ["sodium butyrate", "CHEMICAL", 100, 115], ["TPA", "CHEMICAL", 92, 95], ["sodium butyrate", "CHEMICAL", 100, 115], ["cells", "CELL", 14, 19], ["gp350", "GENE_OR_GENE_PRODUCT", 43, 48], ["monolayer", "CELL", 52, 61], ["TPA", "SIMPLE_CHEMICAL", 92, 95], ["sodium butyrate", "SIMPLE_CHEMICAL", 100, 115], ["sporadic cells", "CELL_TYPE", 5, 19], ["gp350", "PROTEIN", 43, 48], ["monolayer culture", "CELL_LINE", 52, 69], ["sporadic cells", "PROBLEM", 5, 19], ["monolayer culture", "TEST", 52, 69], ["TPA", "TREATMENT", 92, 95], ["sodium butyrate", "TREATMENT", 100, 115], ["sporadic cells", "OBSERVATION", 5, 19]]], ["However, gp350-positive cells were much more frequently detected in ALI-cultured cells (~25% to 40%) and were often detected as a group of cells in focal areas of staining (Fig. 2C).", [["gp350-positive cells", "ANATOMY", 9, 29], ["cells", "ANATOMY", 81, 86], ["cells", "ANATOMY", 139, 144], ["focal areas", "ANATOMY", 148, 159], ["ALI", "DISEASE", 68, 71], ["gp350", "GENE_OR_GENE_PRODUCT", 9, 14], ["ALI-cultured cells", "CELL", 68, 86], ["cells", "CELL", 139, 144], ["gp350-positive cells", "CELL_LINE", 9, 29], ["ALI-cultured cells", "CELL_LINE", 68, 86], ["gp350", "TEST", 9, 14], ["positive cells", "PROBLEM", 15, 29], ["ALI", "TEST", 68, 71], ["cells", "TEST", 81, 86], ["positive cells", "OBSERVATION", 15, 29], ["focal", "OBSERVATION_MODIFIER", 148, 153], ["areas", "OBSERVATION_MODIFIER", 154, 159]]], ["These data support the idea that the ALI culture method is more efficient at completing induction of the lytic cascade than chemical reactivation in monolayer culture.Induction of the EBV lytic cascade. ::: RESULTS AND DISCUSSIONIn addition to analysis of protein levels, RNA sequencing (RNA-seq) was performed to assess the global induction of EBV lytic transcripts.", [["monolayer culture", "ANATOMY", 149, 166], ["ALI", "DISEASE", 37, 40], ["monolayer culture", "CELL", 149, 166], ["EBV", "ORGANISM", 184, 187], ["EBV", "ORGANISM", 345, 348], ["monolayer culture", "CELL_LINE", 149, 166], ["EBV lytic transcripts", "RNA", 345, 366], ["the ALI culture method", "TEST", 33, 55], ["the lytic cascade", "TREATMENT", 101, 118], ["chemical reactivation", "PROBLEM", 124, 145], ["monolayer culture", "TEST", 149, 166], ["the EBV lytic cascade", "TREATMENT", 180, 201], ["protein levels", "TEST", 256, 270], ["RNA sequencing", "TEST", 272, 286], ["EBV lytic transcripts", "TREATMENT", 345, 366], ["lytic", "OBSERVATION_MODIFIER", 105, 110], ["lytic", "OBSERVATION_MODIFIER", 188, 193]]], ["Of the 78 open reading frames (ORFs) annotated in the NCBI database, 65 were analyzed (Table S2) and 62 were represented as a heat map (Fig. 3A).", [["78 open reading frames", "DNA", 7, 29], ["ORFs", "DNA", 31, 35], ["NCBI database", "DNA", 54, 67], ["heat map", "DNA", 126, 134], ["the NCBI database", "TEST", 50, 67], ["a heat map", "TEST", 124, 134]]], ["Three ORFs, EBER1, EBER2, and BNLF2A, had extremely high numbers of reads and were not represented on the heat map but are illustrated in Table S2.", [["EBER1", "GENE_OR_GENE_PRODUCT", 12, 17], ["EBER2", "GENE_OR_GENE_PRODUCT", 19, 24], ["BNLF2A", "GENE_OR_GENE_PRODUCT", 30, 36], ["ORFs", "DNA", 6, 10], ["EBER1", "DNA", 12, 17], ["EBER2", "DNA", 19, 24], ["BNLF2A", "DNA", 30, 36], ["Three ORFs", "TEST", 0, 10], ["EBER1", "TEST", 12, 17], ["EBER2", "TEST", 19, 24], ["the heat map", "TEST", 102, 114]]], ["The lytic genes were globally induced by week 2 to 3 in ALI culture, except for LMP1, LMP2B, EBER1/2, and BNLF2a, which showed a consistently decreasing trend overall (Fig. 3A).", [["ALI", "DISEASE", 56, 59], ["LMP1", "GENE_OR_GENE_PRODUCT", 80, 84], ["LMP2B", "GENE_OR_GENE_PRODUCT", 86, 91], ["EBER1/2", "GENE_OR_GENE_PRODUCT", 93, 100], ["BNLF2a", "GENE_OR_GENE_PRODUCT", 106, 112], ["lytic genes", "DNA", 4, 15], ["LMP1", "PROTEIN", 80, 84], ["LMP2B", "PROTEIN", 86, 91], ["EBER1", "PROTEIN", 93, 98], ["BNLF2a", "PROTEIN", 106, 112], ["ALI culture", "TEST", 56, 67], ["LMP1", "TEST", 80, 84], ["LMP2B", "TEST", 86, 91], ["EBER1", "TEST", 93, 98], ["BNLF2a", "TEST", 106, 112], ["lytic", "OBSERVATION_MODIFIER", 4, 9], ["consistently", "OBSERVATION_MODIFIER", 129, 141], ["decreasing", "OBSERVATION_MODIFIER", 142, 152]]], ["By comparison, host genes that were differentially regulated by at least 2-fold did not show an overall increase but a decrease in transcript levels which likely represented host shutoff (Fig. 3B; see also Table S3).Induction of the EBV lytic cascade. ::: RESULTS AND DISCUSSIONThe majority of EBV transcripts are expressed at up to 104 fragments per kilobase of transcript per million mappable reads (FPKM), but the abundant expression of EBERs at 106 to 107 FPKM is intriguing (Table S2).", [["EBV", "ORGANISM", 233, 236], ["EBV", "ORGANISM", 294, 297], ["EBERs", "GENE_OR_GENE_PRODUCT", 440, 445], ["host genes", "DNA", 15, 25], ["EBV transcripts", "RNA", 294, 309], ["EBERs", "PROTEIN", 440, 445], ["EBV", "SPECIES", 294, 297], ["a decrease in transcript levels", "PROBLEM", 117, 148], ["host shutoff", "PROBLEM", 174, 186], ["the EBV lytic cascade", "TREATMENT", 229, 250], ["EBV transcripts", "TREATMENT", 294, 309], ["EBERs", "TEST", 440, 445], ["overall", "OBSERVATION_MODIFIER", 96, 103], ["increase", "OBSERVATION", 104, 112], ["decrease", "OBSERVATION_MODIFIER", 119, 127], ["likely represented", "UNCERTAINTY", 155, 173], ["host shutoff", "OBSERVATION", 174, 186], ["lytic", "OBSERVATION_MODIFIER", 237, 242]]], ["EBERs are noncoding nuclear transcripts that are abundantly expressed in all EBV-associated cancers and latencies, with up to 106 copies per cell in B-cell infections (43).", [["nuclear", "ANATOMY", 20, 27], ["cancers", "ANATOMY", 92, 99], ["cell", "ANATOMY", 141, 145], ["B-cell", "ANATOMY", 149, 155], ["cancers", "DISEASE", 92, 99], ["infections", "DISEASE", 156, 166], ["EBERs", "GENE_OR_GENE_PRODUCT", 0, 5], ["nuclear", "CELLULAR_COMPONENT", 20, 27], ["EBV", "ORGANISM", 77, 80], ["cancers", "CANCER", 92, 99], ["cell", "CELL", 141, 145], ["B-cell", "CELL", 149, 155], ["EBERs", "PROTEIN", 0, 5], ["noncoding nuclear transcripts", "PROBLEM", 10, 39], ["associated cancers", "PROBLEM", 81, 99], ["latencies", "PROBLEM", 104, 113], ["nuclear transcripts", "OBSERVATION", 20, 39], ["cancers", "OBSERVATION", 92, 99]]], ["Therefore, the abundant expression of EBERs is exploited for the diagnosis of EBV-associated cancers and diseases by EBER in situ hybridization (EBER-ISH) (44).", [["cancers", "ANATOMY", 93, 100], ["cancers", "DISEASE", 93, 100], ["EBERs", "GENE_OR_GENE_PRODUCT", 38, 43], ["EBV", "ORGANISM", 78, 81], ["cancers", "CANCER", 93, 100], ["EBERs", "PROTEIN", 38, 43], ["EBV-associated cancers", "PROBLEM", 78, 100], ["diseases", "PROBLEM", 105, 113], ["EBV", "OBSERVATION", 78, 81], ["cancers", "OBSERVATION", 93, 100]]], ["One understanding of EBER function is that EBER2 can serve as a ribonucleoprotein complex to recruit DNA binding proteins to the terminal repeats on the EBV genome (45).", [["EBER", "GENE_OR_GENE_PRODUCT", 21, 25], ["EBER2", "GENE_OR_GENE_PRODUCT", 43, 48], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["terminal repeats", "CELLULAR_COMPONENT", 129, 145], ["EBV", "ORGANISM", 153, 156], ["EBER2", "PROTEIN", 43, 48], ["ribonucleoprotein complex", "PROTEIN", 64, 89], ["DNA binding proteins", "PROTEIN", 101, 121], ["terminal repeats", "DNA", 129, 145], ["EBV genome", "DNA", 153, 163], ["a ribonucleoprotein complex", "PROBLEM", 62, 89], ["DNA binding proteins", "PROBLEM", 101, 121], ["EBER function", "OBSERVATION", 21, 34]]], ["The only disease pathology known to be associated with permissive replication in epithelial infection is the AIDS-associated nonmalignant lesion known as OHL that manifests on tongue and gingival tissues (3, 32, 44).", [["epithelial", "ANATOMY", 81, 91], ["nonmalignant lesion", "ANATOMY", 125, 144], ["tongue", "ANATOMY", 176, 182], ["gingival tissues", "ANATOMY", 187, 203], ["epithelial infection", "DISEASE", 81, 101], ["AIDS", "DISEASE", 109, 113], ["epithelial", "TISSUE", 81, 91], ["nonmalignant lesion", "CANCER", 125, 144], ["tongue", "ORGAN", 176, 182], ["gingival tissues", "TISSUE", 187, 203], ["The only disease pathology", "PROBLEM", 0, 26], ["permissive replication", "PROBLEM", 55, 77], ["epithelial infection", "PROBLEM", 81, 101], ["nonmalignant lesion", "PROBLEM", 125, 144], ["disease", "OBSERVATION", 9, 16], ["permissive", "OBSERVATION_MODIFIER", 55, 65], ["replication", "OBSERVATION", 66, 77], ["epithelial", "ANATOMY_MODIFIER", 81, 91], ["infection", "OBSERVATION", 92, 101], ["nonmalignant", "OBSERVATION_MODIFIER", 125, 137], ["lesion", "OBSERVATION", 138, 144], ["tongue", "ANATOMY", 176, 182], ["gingival tissues", "ANATOMY", 187, 203]]], ["Paradoxically, EBER transcripts are suppressed and sometimes not detected in OHL formalin-fixed paraffin-embedded tissues, which has called into question the function of EBERs during EBV reactivation (46, 47).", [["tissues", "ANATOMY", 114, 121], ["OHL formalin", "CHEMICAL", 77, 89], ["formalin", "CHEMICAL", 81, 89], ["paraffin", "CHEMICAL", 96, 104], ["EBER", "GENE_OR_GENE_PRODUCT", 15, 19], ["tissues", "TISSUE", 114, 121], ["EBERs", "GENE_OR_GENE_PRODUCT", 170, 175], ["EBV", "ORGANISM", 183, 186], ["EBER transcripts", "RNA", 15, 31], ["EBERs", "PROTEIN", 170, 175], ["EBV", "SPECIES", 183, 186], ["Paradoxically, EBER transcripts", "PROBLEM", 0, 31], ["OHL formalin", "TEST", 77, 89], ["fixed paraffin-embedded tissues", "PROBLEM", 90, 121], ["EBV reactivation", "PROBLEM", 183, 199], ["EBER transcripts", "OBSERVATION", 15, 31]]], ["The diagnosis of OHL may require secondary confirmation by staining for zebra (48).", [["OHL", "DISEASE", 17, 20], ["OHL", "CANCER", 17, 20], ["OHL", "PROBLEM", 17, 20], ["secondary confirmation", "TEST", 33, 55]]], ["The presence of highly abundant EBER transcripts detected in the ALI culture method is consistent with the recent discovery that EBER transcripts are also detected by EBER-ISH throughout the layers of the stratified epithelium in organotypic raft cultures, which would suggest that EBERs are indeed expressed during EBV reactivation in the differentiated apical layers (20).", [["epithelium", "ANATOMY", 216, 226], ["raft cultures", "ANATOMY", 242, 255], ["apical layers", "ANATOMY", 355, 368], ["ALI", "DISEASE", 65, 68], ["EBER", "GENE_OR_GENE_PRODUCT", 32, 36], ["EBER", "GENE_OR_GENE_PRODUCT", 129, 133], ["EBER-ISH", "GENE_OR_GENE_PRODUCT", 167, 175], ["epithelium", "TISSUE", 216, 226], ["organotypic raft cultures", "CELL", 230, 255], ["EBERs", "GENE_OR_GENE_PRODUCT", 282, 287], ["EBV", "ORGANISM", 316, 319], ["apical layers", "MULTI-TISSUE_STRUCTURE", 355, 368], ["EBER transcripts", "RNA", 32, 48], ["EBER transcripts", "RNA", 129, 145], ["organotypic raft cultures", "CELL_LINE", 230, 255], ["EBERs", "PROTEIN", 282, 287], ["EBV", "SPECIES", 316, 319], ["highly abundant EBER transcripts", "PROBLEM", 16, 48], ["the ALI culture method", "TEST", 61, 83], ["EBER transcripts", "PROBLEM", 129, 145], ["organotypic raft cultures", "TEST", 230, 255], ["EBV reactivation", "PROBLEM", 316, 332], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["abundant", "OBSERVATION_MODIFIER", 23, 31], ["EBER transcripts", "OBSERVATION", 32, 48], ["ALI", "ANATOMY", 65, 68], ["consistent with", "UNCERTAINTY", 87, 102], ["EBER transcripts", "OBSERVATION", 129, 145], ["differentiated", "OBSERVATION_MODIFIER", 340, 354], ["apical", "OBSERVATION_MODIFIER", 355, 361], ["layers", "OBSERVATION_MODIFIER", 362, 368]]], ["These findings, combined with observations from the present study, would seem to imply that the suppression of EBERs may be unique to OHL.EBV genome replication and amplification. ::: RESULTS AND DISCUSSIONEBV genome amplification and replication were assessed by quantitative PCR (qPCR) and Southern blot analyses.", [["EBERs", "DISEASE", 111, 116], ["EBERs", "GENE_OR_GENE_PRODUCT", 111, 116], ["OHL", "CANCER", 134, 137], ["EBV", "ORGANISM", 138, 141], ["EBERs", "PROTEIN", 111, 116], ["EBV genome", "DNA", 138, 148], ["EBV", "SPECIES", 138, 141], ["the present study", "TEST", 48, 65], ["the suppression of EBERs", "PROBLEM", 92, 116], ["EBV genome replication", "TREATMENT", 138, 160], ["quantitative PCR", "TEST", 264, 280], ["Southern blot analyses", "TEST", 292, 314], ["genome replication", "OBSERVATION", 142, 160]]], ["Encapsidated genomes from DNase-resistant Hirt-purified extrachromosomal DNA were measured by qPCR.", [["DNase", "GENE_OR_GENE_PRODUCT", 26, 31], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["Encapsidated genomes", "DNA", 0, 20], ["DNase-resistant Hirt-purified extrachromosomal DNA", "DNA", 26, 76], ["DNase", "TEST", 26, 31], ["purified extrachromosomal DNA", "PROBLEM", 47, 76], ["genomes", "OBSERVATION", 13, 20], ["resistant", "OBSERVATION_MODIFIER", 32, 41], ["extrachromosomal DNA", "OBSERVATION", 56, 76]]], ["Total (encapsidated and nonencapsidated) EBV genomes increased more than 2 log10, beginning at 6.1 \u00d7 104 EBV genomes per ALI culture at week 0 and reaching 2.5 \u00d7 107 EBV genomes per ALI culture at week 3 (Fig. 4A).", [["ALI", "DISEASE", 121, 124], ["ALI", "DISEASE", 182, 185], ["EBV", "ORGANISM", 41, 44], ["EBV", "ORGANISM", 105, 108], ["EBV", "ORGANISM", 166, 169], ["EBV genomes", "DNA", 41, 52], ["EBV genomes", "DNA", 166, 177], ["Total (encapsidated", "PROBLEM", 0, 19], ["EBV genomes", "TEST", 41, 52], ["EBV genomes", "TEST", 105, 116], ["ALI culture", "TEST", 121, 132], ["EBV genomes", "TEST", 166, 177], ["ALI culture", "TEST", 182, 193]]], ["The majority of genomes were encapsidated with less than 1 log10 difference, starting at 1.1 \u00d7 104 EBV genomes per ALI culture at week 0 and reaching 3.0 \u00d7 106 EBV genomes per ALI culture at week 3 (Fig. 4A).EBV genome replication and amplification. ::: RESULTS AND DISCUSSIONEBV latent genomes are circular and are detected as a single band (>10 kb) by Southern blotting (7).", [["ALI", "DISEASE", 115, 118], ["ALI", "DISEASE", 176, 179], ["EBV", "ORGANISM", 99, 102], ["EBV", "ORGANISM", 160, 163], ["EBV", "ORGANISM", 208, 211], ["EBV genomes", "DNA", 160, 171], ["EBV genome", "DNA", 208, 218], ["EBV", "SPECIES", 208, 211], ["EBV genomes", "TEST", 99, 110], ["ALI culture", "TEST", 115, 126], ["EBV genomes", "TEST", 160, 171], ["ALI culture", "TEST", 176, 187], ["EBV genome replication", "TREATMENT", 208, 230], ["genome replication", "OBSERVATION", 212, 230], ["circular", "OBSERVATION_MODIFIER", 299, 307]]], ["Replicating EBV genomes are linear and differ by 500-bp increments corresponding to the number of tandem terminal repeats (7, 48).", [["EBV", "ORGANISM", 12, 15], ["EBV genomes", "DNA", 12, 23], ["tandem terminal repeats", "DNA", 98, 121], ["EBV genomes", "OBSERVATION", 12, 23], ["linear", "OBSERVATION_MODIFIER", 28, 34]]], ["At week 0 and week 1, a single band indicative of latent genomes greater than 10 kb in size was detected (Fig. 4B).", [["latent genomes", "DNA", 50, 64], ["a single band", "PROBLEM", 22, 35], ["latent genomes", "PROBLEM", 50, 64], ["latent", "OBSERVATION_MODIFIER", 50, 56], ["genomes", "OBSERVATION", 57, 64], ["greater", "OBSERVATION_MODIFIER", 65, 72], ["size", "OBSERVATION_MODIFIER", 87, 91]]], ["In comparison at weeks 2 and 3, multiple bands smaller than 10 kb in size were detected with an overall increase in hybridization intensity for all detected bands, indicative of amplified replicating genomes (Fig. 4B).", [["amplified replicating genomes", "DNA", 178, 207], ["multiple bands smaller than 10 kb in size", "PROBLEM", 32, 73], ["an overall increase in hybridization intensity", "PROBLEM", 93, 139], ["all detected bands", "PROBLEM", 144, 162], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["bands", "OBSERVATION_MODIFIER", 41, 46], ["smaller", "OBSERVATION_MODIFIER", 47, 54], ["size", "OBSERVATION_MODIFIER", 69, 73], ["overall", "OBSERVATION_MODIFIER", 96, 103], ["increase", "OBSERVATION_MODIFIER", 104, 112], ["hybridization intensity", "OBSERVATION", 116, 139], ["indicative of", "UNCERTAINTY", 164, 177]]], ["However, only one band associated with latent genomes was detected in monolayer culture and there was no appreciable increase in band intensity, indicating that EBV genomes were not replicating as efficiently as in ALI culture (Fig. 4B).Production of EBV progeny virus. ::: RESULTS AND DISCUSSIONProduction of EBV progeny virus was analyzed by determining the titers of infectious virus with the GRU assay and by imaging with transmission electron microscopy (TEM).", [["monolayer culture", "ANATOMY", 70, 87], ["ALI", "DISEASE", 215, 218], ["monolayer culture", "CELL", 70, 87], ["EBV", "ORGANISM", 161, 164], ["EBV progeny virus", "ORGANISM", 251, 268], ["EBV", "ORGANISM", 310, 313], ["monolayer culture", "CELL_LINE", 70, 87], ["EBV genomes", "DNA", 161, 172], ["latent genomes", "PROBLEM", 39, 53], ["monolayer culture", "TEST", 70, 87], ["appreciable increase in band intensity", "PROBLEM", 105, 143], ["EBV genomes", "PROBLEM", 161, 172], ["ALI culture", "TEST", 215, 226], ["EBV progeny virus", "PROBLEM", 251, 268], ["EBV progeny virus", "PROBLEM", 310, 327], ["infectious virus", "PROBLEM", 370, 386], ["the GRU assay", "TEST", 392, 405], ["imaging", "TEST", 413, 420], ["transmission electron microscopy", "TEST", 426, 458], ["one band", "OBSERVATION_MODIFIER", 14, 22], ["latent", "OBSERVATION_MODIFIER", 39, 45], ["genomes", "OBSERVATION", 46, 53], ["no", "UNCERTAINTY", 102, 104], ["appreciable", "OBSERVATION_MODIFIER", 105, 116], ["increase", "OBSERVATION_MODIFIER", 117, 125], ["band intensity", "OBSERVATION", 129, 143], ["EBV genomes", "OBSERVATION", 161, 172], ["EBV progeny virus", "OBSERVATION", 251, 268]]], ["Raji cells are a Burkitt lymphoma cell line that can be readily superinfected with EBV, but the endogenous EBV genome is truncated and will not replicate, thus enabling the determination of the titers of ALI culture-derived green fluorescent protein (GFP)-expressing virus (49, 50).", [["Raji cells", "ANATOMY", 0, 10], ["Burkitt lymphoma cell line", "ANATOMY", 17, 43], ["Burkitt lymphoma", "DISEASE", 17, 33], ["ALI", "DISEASE", 204, 207], ["Raji cells", "CELL", 0, 10], ["Burkitt lymphoma cell line", "CELL", 17, 43], ["EBV", "ORGANISM", 83, 86], ["EBV", "ORGANISM", 107, 110], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 224, 249], ["GFP", "GENE_OR_GENE_PRODUCT", 251, 254], ["Raji cells", "CELL_LINE", 0, 10], ["Burkitt lymphoma cell line", "CELL_LINE", 17, 43], ["endogenous EBV genome", "DNA", 96, 117], ["green fluorescent protein", "PROTEIN", 224, 249], ["GFP", "PROTEIN", 251, 254], ["EBV", "SPECIES", 83, 86], ["EBV", "SPECIES", 107, 110], ["Raji cells", "TREATMENT", 0, 10], ["a Burkitt lymphoma cell line", "TREATMENT", 15, 43], ["EBV", "PROBLEM", 83, 86], ["the endogenous EBV genome", "PROBLEM", 92, 117], ["ALI culture", "TEST", 204, 215], ["green fluorescent protein", "TEST", 224, 249], ["expressing virus", "PROBLEM", 256, 272], ["Burkitt lymphoma", "OBSERVATION", 17, 33], ["cell line", "OBSERVATION", 34, 43], ["EBV genome", "OBSERVATION", 107, 117]]], ["Overall titers, including extracellular and cell-associated virus titers, increased from week 0 to week 3.", [["extracellular", "ANATOMY", 26, 39], ["cell", "ANATOMY", 44, 48], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 39], ["cell", "CELL", 44, 48], ["Overall titers", "TEST", 0, 14], ["extracellular and cell-associated virus titers", "PROBLEM", 26, 72], ["virus titers", "OBSERVATION", 60, 72], ["increased", "OBSERVATION_MODIFIER", 74, 83]]], ["Extracellular virus titers were consistently 2 log10 higher than cell-associated virus titers, as would be expected from immature cell-associated virions.", [["cell", "ANATOMY", 65, 69], ["cell", "ANATOMY", 130, 134], ["virions", "ANATOMY", 146, 153], ["Extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["cell", "CELL", 65, 69], ["cell", "CELL", 130, 134], ["virions", "CELL", 146, 153], ["immature cell", "CELL_TYPE", 121, 134], ["Extracellular virus titers", "TEST", 0, 26], ["cell-associated virus titers", "PROBLEM", 65, 93], ["virus", "OBSERVATION", 14, 19], ["virus titers", "OBSERVATION", 81, 93], ["immature cell", "OBSERVATION", 121, 134], ["virions", "OBSERVATION", 146, 153]]], ["By week 3, there was a total value of 1,675,933 GRUs per ALI, demonstrating that abundant and infectious EBV virions were produced (Fig. 5A).", [["ALI", "DISEASE", 57, 60], ["EBV", "ORGANISM", 105, 108], ["EBV", "SPECIES", 105, 108], ["a total value", "TEST", 21, 34], ["infectious EBV virions", "PROBLEM", 94, 116], ["abundant", "OBSERVATION_MODIFIER", 81, 89], ["infectious", "OBSERVATION_MODIFIER", 94, 104]]], ["This increase at week 3 was ~30-fold higher than the values measured at week 0, when production of progeny virus began.", [["progeny virus", "ORGANISM", 99, 112], ["progeny virus", "PROBLEM", 99, 112], ["increase", "OBSERVATION_MODIFIER", 5, 13]]], ["In comparison to the ALI culture results, no infectious units were measured in uninduced HK1-EBV monolayer-cultured cells (Table S1).", [["cells", "ANATOMY", 116, 121], ["ALI", "DISEASE", 21, 24], ["HK1-EBV monolayer-cultured cells", "CELL", 89, 121], ["uninduced HK1-EBV monolayer-cultured cells", "CELL_LINE", 79, 121], ["the ALI culture", "TEST", 17, 32], ["infectious units", "TEST", 45, 61], ["EBV monolayer", "TEST", 93, 106]]], ["Despite the expected loss of sample from Hirt purification, at week 2 to 3 of ALI culture there were 3.0 \u00d7 106 to 4.3 \u00d7 106 DNase-resistant encapsidated EBV genomes per ALI culture (1.12 cm2), which corresponds to 1.425 \u00d7 106 to 1.676 \u00d7 106 total GRUs per ALI culture (Fig. 4A and 5A).", [["sample", "ANATOMY", 29, 35], ["ALI", "DISEASE", 78, 81], ["ALI", "DISEASE", 169, 172], ["ALI", "DISEASE", 256, 259], ["DNase", "GENE_OR_GENE_PRODUCT", 124, 129], ["EBV", "ORGANISM", 153, 156], ["DNase", "PROTEIN", 124, 129], ["encapsidated EBV genomes", "DNA", 140, 164], ["the expected loss of sample", "PROBLEM", 8, 35], ["Hirt purification", "TREATMENT", 41, 58], ["ALI culture", "TEST", 78, 89], ["DNase", "TEST", 124, 129], ["resistant encapsidated EBV genomes", "PROBLEM", 130, 164], ["ALI culture", "TEST", 169, 180], ["total GRUs", "TEST", 241, 251], ["ALI culture", "TEST", 256, 267], ["EBV genomes", "OBSERVATION", 153, 164]]], ["These data support the idea that the majority of encapsidated virions produced from ALI culture are indeed infectious.Production of EBV progeny virus. ::: RESULTS AND DISCUSSIONHK1-EBV ALI cultures harvested at week 2 were imaged for evidence of EBV virions by TEM and assessed by an independent microscopist.", [["virions", "ANATOMY", 62, 69], ["ALI", "DISEASE", 84, 87], ["EBV progeny virus", "ORGANISM", 132, 149], ["EBV", "ORGANISM", 181, 184], ["EBV", "ORGANISM", 246, 249], ["EBV ALI cultures", "CELL_LINE", 181, 197], ["EBV", "SPECIES", 246, 249], ["encapsidated virions", "PROBLEM", 49, 69], ["ALI culture", "TEST", 84, 95], ["infectious", "PROBLEM", 107, 117], ["EBV progeny virus", "PROBLEM", 132, 149], ["DISCUSSIONHK1", "TEST", 167, 180], ["EBV ALI cultures", "TEST", 181, 197], ["EBV virions", "PROBLEM", 246, 257], ["encapsidated virions", "OBSERVATION", 49, 69], ["infectious", "OBSERVATION_MODIFIER", 107, 117], ["EBV progeny virus", "OBSERVATION", 132, 149], ["EBV virions", "OBSERVATION", 246, 257]]], ["Although extracellular virions are largely washed away during TEM processing, intracellular virions can be captured.", [["extracellular virions", "ANATOMY", 9, 30], ["intracellular virions", "ANATOMY", 78, 99], ["extracellular virions", "CELLULAR_COMPONENT", 9, 30], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["extracellular virions", "PROBLEM", 9, 30], ["intracellular virions", "TREATMENT", 78, 99], ["virions", "OBSERVATION", 23, 30]]], ["The TEM images show an encapsidated herpesvirus-like virion of 200 to 250 nm and two immature virions in the cytoplasm (Fig. 5B).", [["virions", "ANATOMY", 94, 101], ["cytoplasm", "ANATOMY", 109, 118], ["herpesvirus", "ORGANISM", 36, 47], ["cytoplasm", "ORGANISM_SUBSTANCE", 109, 118], ["The TEM images", "TEST", 0, 14], ["an encapsidated herpesvirus", "PROBLEM", 20, 47], ["encapsidated herpesvirus", "OBSERVATION", 23, 47], ["immature virions", "OBSERVATION", 85, 101]]], ["Additionally, 1 to 2 cells layers were observed in the TEM images, illustrating that the HK1-EBV ALI cultures were polarized but not necessarily stratified (Fig. 5B), which is representative of the pseudostratified differentiated ALI cultures of primary nasal epithelia (24).", [["cells layers", "ANATOMY", 21, 33], ["primary nasal epithelia", "ANATOMY", 246, 269], ["ALI", "DISEASE", 230, 233], ["cells layers", "CELL", 21, 33], ["HK1", "GENE_OR_GENE_PRODUCT", 89, 92], ["EBV", "ORGANISM", 93, 96], ["nasal epithelia", "TISSUE", 254, 269], ["HK1-EBV ALI cultures", "CELL_LINE", 89, 109], ["pseudostratified differentiated ALI cultures", "CELL_LINE", 198, 242], ["1 to 2 cells layers", "PROBLEM", 14, 33], ["the TEM images", "TEST", 51, 65], ["the HK1", "TEST", 85, 92], ["EBV ALI cultures", "TEST", 93, 109], ["the pseudostratified differentiated ALI cultures", "PROBLEM", 194, 242], ["primary nasal epithelia", "PROBLEM", 246, 269], ["pseudostratified", "OBSERVATION_MODIFIER", 198, 214], ["differentiated", "OBSERVATION_MODIFIER", 215, 229], ["ALI cultures", "OBSERVATION", 230, 242], ["primary", "OBSERVATION_MODIFIER", 246, 253], ["nasal epithelia", "ANATOMY", 254, 269]]], ["These data support the idea that the ALI method is a robust method for inducing fulminant EBV lytic reactivation without the need for chemical induction.", [["ALI", "DISEASE", 37, 40], ["EBV", "ORGANISM", 90, 93], ["EBV", "SPECIES", 90, 93], ["the ALI method", "TREATMENT", 33, 47], ["a robust method", "TREATMENT", 51, 66], ["fulminant EBV lytic reactivation", "PROBLEM", 80, 112], ["chemical induction", "TREATMENT", 134, 152]]], ["The outcome of this study from an NPC-derived cell line perhaps appears to contradict the observation of latent infection in NPC tumors (7).", [["NPC-derived cell line", "ANATOMY", 34, 55], ["NPC tumors", "ANATOMY", 125, 135], ["infection", "DISEASE", 112, 121], ["NPC tumors", "DISEASE", 125, 135], ["NPC-derived cell line", "CELL", 34, 55], ["NPC tumors", "CANCER", 125, 135], ["NPC-derived cell line", "CELL_LINE", 34, 55], ["this study", "TEST", 15, 25], ["an NPC-derived cell line", "TREATMENT", 31, 55], ["latent infection in NPC tumors", "PROBLEM", 105, 135], ["cell line", "OBSERVATION", 46, 55], ["latent", "OBSERVATION_MODIFIER", 105, 111], ["infection", "OBSERVATION", 112, 121], ["NPC", "ANATOMY", 125, 128], ["tumors", "OBSERVATION", 129, 135]]], ["Given that there was no evidence of EBV infection in the original NPC biopsy specimen from which HK1 cells were derived, it is plausible that the outcome of infection might differ from that seen with NPC tumor cells that have evolved to sustain latent infection in vivo (40).", [["NPC biopsy specimen", "ANATOMY", 66, 85], ["HK1 cells", "ANATOMY", 97, 106], ["NPC tumor cells", "ANATOMY", 200, 215], ["EBV infection", "DISEASE", 36, 49], ["infection", "DISEASE", 157, 166], ["tumor", "DISEASE", 204, 209], ["infection", "DISEASE", 252, 261], ["EBV", "ORGANISM", 36, 39], ["NPC biopsy specimen", "CANCER", 66, 85], ["HK1 cells", "CELL", 97, 106], ["NPC tumor cells", "CELL", 200, 215], ["HK1 cells", "CELL_LINE", 97, 106], ["NPC tumor cells", "CELL_TYPE", 200, 215], ["EBV", "SPECIES", 36, 39], ["EBV infection", "PROBLEM", 36, 49], ["the original NPC biopsy specimen", "TEST", 53, 85], ["HK1 cells", "TEST", 97, 106], ["infection", "PROBLEM", 157, 166], ["NPC tumor cells", "PROBLEM", 200, 215], ["latent infection", "PROBLEM", 245, 261], ["no evidence of", "UNCERTAINTY", 21, 35], ["EBV", "OBSERVATION_MODIFIER", 36, 39], ["infection", "OBSERVATION", 40, 49], ["infection", "OBSERVATION", 157, 166], ["latent", "OBSERVATION_MODIFIER", 245, 251], ["infection", "OBSERVATION", 252, 261]]], ["Despite the paucity of authenticated NPC cell lines, it would be interesting to test additional NPC cell lines that originate from tumors with confirmed EBV positivity (34).", [["NPC cell lines", "ANATOMY", 37, 51], ["NPC cell lines", "ANATOMY", 96, 110], ["tumors", "ANATOMY", 131, 137], ["tumors", "DISEASE", 131, 137], ["NPC cell lines", "CELL", 37, 51], ["NPC cell lines", "CELL", 96, 110], ["tumors", "CANCER", 131, 137], ["EBV", "ORGANISM", 153, 156], ["NPC cell lines", "CELL_LINE", 37, 51], ["NPC cell lines", "CELL_LINE", 96, 110], ["authenticated NPC cell lines", "TREATMENT", 23, 51], ["test additional NPC cell lines", "TREATMENT", 80, 110], ["tumors", "PROBLEM", 131, 137], ["EBV positivity", "TEST", 153, 167], ["NPC cell lines", "OBSERVATION", 37, 51], ["NPC cell lines", "OBSERVATION", 96, 110]]], ["Furthermore, since HK1 cells can be recombinantly modified and stably selected, the HK1-EBV ALI culture model offers the potential to test host and viral factors which may predispose a neoplastic cell to EBV latent infection (25, 38).", [["HK1 cells", "ANATOMY", 19, 28], ["neoplastic cell", "ANATOMY", 185, 200], ["EBV latent infection", "DISEASE", 204, 224], ["HK1 cells", "CELL", 19, 28], ["HK1", "GENE_OR_GENE_PRODUCT", 84, 87], ["EBV", "ORGANISM", 88, 91], ["neoplastic cell", "CELL", 185, 200], ["EBV", "ORGANISM", 204, 207], ["HK1 cells", "CELL_LINE", 19, 28], ["viral factors", "PROTEIN", 148, 161], ["HK1 cells", "PROBLEM", 19, 28], ["the HK1", "TEST", 80, 87], ["EBV ALI culture model", "TEST", 88, 109], ["viral factors", "PROBLEM", 148, 161], ["a neoplastic cell", "PROBLEM", 183, 200], ["EBV latent infection", "PROBLEM", 204, 224], ["neoplastic cell", "OBSERVATION", 185, 200], ["EBV", "OBSERVATION_MODIFIER", 204, 207], ["latent", "OBSERVATION_MODIFIER", 208, 214], ["infection", "OBSERVATION", 215, 224]]], ["The ALI polarization culture method has been established for primary nasal epithelial cells (24).", [["primary nasal epithelial cells", "ANATOMY", 61, 91], ["ALI", "DISEASE", 4, 7], ["nasal epithelial cells", "CELL", 69, 91], ["primary nasal epithelial cells", "CELL_TYPE", 61, 91], ["The ALI polarization culture method", "TEST", 0, 35], ["primary nasal epithelial cells", "PROBLEM", 61, 91], ["ALI", "ANATOMY", 4, 7], ["epithelial cells", "OBSERVATION", 75, 91]]], ["Furthermore, EBV infection as defined by the presence of latent or lytic markers is not detected in nasal biopsy specimens of histologically normal areas, likely reflecting rare or focal airway epithelial infections in asymptomatic carriers (51, 52).", [["nasal biopsy specimens", "ANATOMY", 100, 122], ["focal airway epithelial", "ANATOMY", 181, 204], ["EBV infection", "DISEASE", 13, 26], ["airway epithelial infections", "DISEASE", 187, 215], ["EBV", "ORGANISM", 13, 16], ["nasal biopsy specimens", "TISSUE", 100, 122], ["airway epithelial", "TISSUE", 187, 204], ["latent or lytic markers", "PROTEIN", 57, 80], ["EBV", "SPECIES", 13, 16], ["EBV infection", "PROBLEM", 13, 26], ["latent or lytic markers", "PROBLEM", 57, 80], ["nasal biopsy specimens", "TEST", 100, 122], ["focal airway epithelial infections in asymptomatic carriers", "PROBLEM", 181, 240], ["EBV", "OBSERVATION_MODIFIER", 13, 16], ["infection", "OBSERVATION", 17, 26], ["latent", "OBSERVATION_MODIFIER", 57, 63], ["lytic", "OBSERVATION_MODIFIER", 67, 72], ["not detected", "UNCERTAINTY", 84, 96], ["nasal", "ANATOMY", 100, 105], ["biopsy", "OBSERVATION", 106, 112], ["histologically", "OBSERVATION_MODIFIER", 126, 140], ["normal", "OBSERVATION", 141, 147], ["likely reflecting", "UNCERTAINTY", 155, 172], ["focal", "OBSERVATION_MODIFIER", 181, 186], ["airway epithelial infections", "OBSERVATION", 187, 215]]], ["Due to the absence of detection of EBV infection in situ from nasal biopsy specimens of healthy tissue, in theory it is possible to study de novo EBV infection in ALI-cultured primary nasal epithelial cells.", [["nasal biopsy specimens", "ANATOMY", 62, 84], ["tissue", "ANATOMY", 96, 102], ["nasal epithelial cells", "ANATOMY", 184, 206], ["EBV infection", "DISEASE", 35, 48], ["EBV infection", "DISEASE", 146, 159], ["ALI", "DISEASE", 163, 166], ["EBV", "ORGANISM", 35, 38], ["nasal biopsy specimens", "MULTI-TISSUE_STRUCTURE", 62, 84], ["tissue", "TISSUE", 96, 102], ["EBV", "ORGANISM", 146, 149], ["nasal epithelial cells", "CELL", 184, 206], ["ALI-cultured primary nasal epithelial cells", "CELL_LINE", 163, 206], ["EBV", "SPECIES", 35, 38], ["EBV", "SPECIES", 146, 149], ["EBV infection", "PROBLEM", 35, 48], ["nasal biopsy specimens", "TEST", 62, 84], ["healthy tissue", "PROBLEM", 88, 102], ["novo EBV infection", "PROBLEM", 141, 159], ["ALI", "PROBLEM", 163, 166], ["primary nasal epithelial cells", "PROBLEM", 176, 206], ["EBV", "OBSERVATION_MODIFIER", 35, 38], ["infection", "OBSERVATION", 39, 48], ["nasal", "ANATOMY", 62, 67], ["biopsy", "OBSERVATION", 68, 74], ["healthy tissue", "OBSERVATION_MODIFIER", 88, 102], ["EBV infection", "OBSERVATION", 146, 159], ["nasal epithelial cells", "OBSERVATION", 184, 206]]], ["Ultimately, the creation of an EBV infection model and analytical methods to study (widespread or focal) infection in polarized ALI cultures of primary nasal epithelial cells would be the most relevant system to evaluate EBV de novo infection in mucociliated epithelia (53).", [["nasal epithelial cells", "ANATOMY", 152, 174], ["mucociliated epithelia", "ANATOMY", 246, 268], ["infection", "DISEASE", 35, 44], ["infection", "DISEASE", 105, 114], ["ALI", "DISEASE", 128, 131], ["infection", "DISEASE", 233, 242], ["EBV", "ORGANISM", 31, 34], ["nasal epithelial cells", "CELL", 152, 174], ["EBV", "ORGANISM", 221, 224], ["mucociliated epithelia", "TISSUE", 246, 268], ["polarized ALI cultures", "CELL_LINE", 118, 140], ["primary nasal epithelial cells", "CELL_TYPE", 144, 174], ["EBV", "SPECIES", 221, 224], ["an EBV infection model", "PROBLEM", 28, 50], ["focal) infection", "PROBLEM", 98, 114], ["polarized ALI cultures", "TEST", 118, 140], ["primary nasal epithelial cells", "PROBLEM", 144, 174], ["EBV de novo infection in mucociliated epithelia", "PROBLEM", 221, 268], ["EBV infection", "OBSERVATION", 31, 44], ["focal", "OBSERVATION_MODIFIER", 98, 103], ["infection", "OBSERVATION", 105, 114], ["polarized ALI", "OBSERVATION_MODIFIER", 118, 131], ["nasal epithelial cells", "OBSERVATION", 152, 174], ["infection", "OBSERVATION", 233, 242]]], ["Given the limited availability of primary nasal cells, the ALI culture method described for the HK1-EBV cell line thus offers a widely accessible alternative for the study of EBV permissive replication in polarized epithelia.Production of EBV progeny virus. ::: RESULTS AND DISCUSSIONTo date, there have been a few exemplar studies that have explored the effect of EBV proteins on differentiation, or differentiation-induced effects on EBV infection (18, 54\u201356).", [["primary nasal cells", "ANATOMY", 34, 53], ["HK1-EBV cell line", "ANATOMY", 96, 113], ["epithelia", "ANATOMY", 215, 224], ["EBV infection", "DISEASE", 436, 449], ["nasal cells", "CELL", 42, 53], ["HK1-EBV cell line", "CELL", 96, 113], ["EBV", "ORGANISM", 175, 178], ["epithelia", "TISSUE", 215, 224], ["EBV progeny virus", "ORGANISM", 239, 256], ["EBV", "ORGANISM", 365, 368], ["EBV", "ORGANISM", 436, 439], ["primary nasal cells", "CELL_TYPE", 34, 53], ["HK1-EBV cell line", "CELL_LINE", 96, 113], ["EBV proteins", "PROTEIN", 365, 377], ["EBV", "SPECIES", 175, 178], ["EBV", "SPECIES", 436, 439], ["primary nasal cells", "PROBLEM", 34, 53], ["the ALI culture method", "TEST", 55, 77], ["the HK1", "TEST", 92, 99], ["the study", "TEST", 162, 171], ["EBV", "PROBLEM", 175, 178], ["EBV progeny virus", "PROBLEM", 239, 256], ["exemplar studies", "TEST", 315, 331], ["EBV proteins", "PROBLEM", 365, 377], ["EBV infection", "PROBLEM", 436, 449], ["nasal cells", "ANATOMY", 42, 53], ["EBV cell line", "OBSERVATION", 100, 113], ["polarized epithelia", "OBSERVATION", 205, 224], ["EBV progeny virus", "OBSERVATION", 239, 256]]], ["These experimental models include calcium-induced differentiation, suspension of cells in methylcellulose, and organotypic raft cultures (57).", [["cells", "ANATOMY", 81, 86], ["raft cultures", "ANATOMY", 123, 136], ["calcium", "CHEMICAL", 34, 41], ["methylcellulose", "CHEMICAL", 90, 105], ["calcium", "CHEMICAL", 34, 41], ["calcium", "SIMPLE_CHEMICAL", 34, 41], ["cells", "CELL", 81, 86], ["methylcellulose", "SIMPLE_CHEMICAL", 90, 105], ["organotypic raft cultures", "CELL_LINE", 111, 136], ["calcium", "TEST", 34, 41], ["cells in methylcellulose", "PROBLEM", 81, 105], ["organotypic raft cultures", "TEST", 111, 136]]], ["Keratinocytes grown in monolayer can be induced to differentiate by high levels of calcium, which has been applied to EBV studies by treatment with fetal bovine serum (FBS) and/or by the direct addition of calcium (18, 21, 56).", [["Keratinocytes", "ANATOMY", 0, 13], ["monolayer", "ANATOMY", 23, 32], ["fetal bovine serum", "ANATOMY", 148, 166], ["FBS", "ANATOMY", 168, 171], ["calcium", "CHEMICAL", 83, 90], ["calcium", "CHEMICAL", 206, 213], ["calcium", "CHEMICAL", 83, 90], ["calcium", "CHEMICAL", 206, 213], ["Keratinocytes", "CELL", 0, 13], ["monolayer", "CELL", 23, 32], ["calcium", "SIMPLE_CHEMICAL", 83, 90], ["EBV", "ORGANISM", 118, 121], ["fetal", "ORGANISM_SUBSTANCE", 148, 153], ["bovine", "ORGANISM", 154, 160], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["FBS", "ORGANISM_SUBSTANCE", 168, 171], ["calcium", "SIMPLE_CHEMICAL", 206, 213], ["Keratinocytes", "CELL_TYPE", 0, 13], ["bovine", "SPECIES", 154, 160], ["bovine", "SPECIES", 154, 160], ["Keratinocytes", "PROBLEM", 0, 13], ["high levels of calcium", "PROBLEM", 68, 90], ["EBV studies", "TEST", 118, 129], ["fetal bovine serum", "TEST", 148, 166], ["FBS", "TEST", 168, 171], ["calcium", "TEST", 206, 213]]], ["A second method to differentiate keratinocytes is by suspending cells in methylcellulose, which has been applied to the study of EBV-infected cells and of the effect of the EBV latent protein, LMP2A, on differentiation (21, 57).", [["keratinocytes", "ANATOMY", 33, 46], ["cells", "ANATOMY", 64, 69], ["cells", "ANATOMY", 142, 147], ["methylcellulose", "CHEMICAL", 73, 88], ["keratinocytes", "CELL", 33, 46], ["cells", "CELL", 64, 69], ["methylcellulose", "SIMPLE_CHEMICAL", 73, 88], ["EBV", "ORGANISM", 129, 132], ["cells", "CELL", 142, 147], ["EBV", "ORGANISM", 173, 176], ["LMP2A", "GENE_OR_GENE_PRODUCT", 193, 198], ["keratinocytes", "CELL_TYPE", 33, 46], ["EBV-infected cells", "CELL_TYPE", 129, 147], ["EBV latent protein", "PROTEIN", 173, 191], ["LMP2A", "PROTEIN", 193, 198], ["A second method", "TREATMENT", 0, 15], ["methylcellulose", "TREATMENT", 73, 88], ["the study", "TEST", 116, 125], ["EBV", "PROBLEM", 129, 132], ["infected cells", "PROBLEM", 133, 147], ["the EBV latent protein", "TEST", 169, 191], ["differentiation", "TEST", 203, 218], ["keratinocytes", "OBSERVATION", 33, 46], ["infected cells", "OBSERVATION", 133, 147], ["EBV", "OBSERVATION_MODIFIER", 173, 176], ["latent", "OBSERVATION_MODIFIER", 177, 183], ["LMP2A", "OBSERVATION", 193, 198]]], ["The methylcellulose method can recapitulate differentiation in a three-dimensional (3D) culture model, but the analysis of these cells in a semisolid matrix is often limited to protein lysates harvested from the cell population (21, 57).", [["cells", "ANATOMY", 129, 134], ["semisolid matrix", "ANATOMY", 140, 156], ["lysates", "ANATOMY", 185, 192], ["cell", "ANATOMY", 212, 216], ["methylcellulose", "CHEMICAL", 4, 19], ["cells", "CELL", 129, 134], ["cell", "CELL", 212, 216], ["three-dimensional (3D) culture model", "CELL_LINE", 65, 101], ["The methylcellulose method", "TREATMENT", 0, 26], ["culture model", "TEST", 88, 101], ["the analysis", "TEST", 107, 119], ["these cells", "PROBLEM", 123, 134], ["protein lysates", "TEST", 177, 192], ["the cell population", "TEST", 208, 227], ["methylcellulose method", "OBSERVATION", 4, 26], ["semisolid matrix", "OBSERVATION_MODIFIER", 140, 156], ["cell population", "OBSERVATION", 212, 227]]], ["Organotypic rafts provide single-cell resolution by formalin-fixed paraffin-embedding (FFPE) sectioning and staining and serve as a robust model for culturing fully stratified squamous keratinocytes, but the keratinocyte-enriching media used to establish organotypic rafts may not culture all NPC cell types (22).", [["Organotypic rafts", "ANATOMY", 0, 17], ["cell", "ANATOMY", 33, 37], ["FFPE", "ANATOMY", 87, 91], ["squamous keratinocytes", "ANATOMY", 176, 198], ["keratinocyte", "ANATOMY", 208, 220], ["organotypic rafts", "ANATOMY", 255, 272], ["NPC cell", "ANATOMY", 293, 301], ["formalin", "CHEMICAL", 52, 60], ["paraffin", "CHEMICAL", 67, 75], ["cell", "CELL", 33, 37], ["squamous keratinocytes", "CELL", 176, 198], ["keratinocyte", "CELL", 208, 220], ["NPC cell", "CELL", 293, 301], ["squamous keratinocytes", "CELL_TYPE", 176, 198], ["NPC cell types", "CELL_LINE", 293, 307], ["Organotypic rafts", "TREATMENT", 0, 17], ["single-cell resolution", "TREATMENT", 26, 48], ["fixed paraffin-embedding (FFPE) sectioning", "TREATMENT", 61, 103], ["culturing", "TEST", 149, 158], ["squamous keratinocytes", "PROBLEM", 176, 198], ["the keratinocyte-enriching media", "TREATMENT", 204, 236], ["organotypic rafts", "TREATMENT", 255, 272], ["squamous keratinocytes", "OBSERVATION", 176, 198]]], ["In principle, organotypic rafts, originally established for the study of EBV infection in oral keratinocytes, can also be developed for nasal keratinocytes (18, 20).", [["organotypic rafts", "ANATOMY", 14, 31], ["oral keratinocytes", "ANATOMY", 90, 108], ["nasal keratinocytes", "ANATOMY", 136, 155], ["EBV infection", "DISEASE", 73, 86], ["EBV", "ORGANISM", 73, 76], ["oral keratinocytes", "CELL", 90, 108], ["nasal keratinocytes", "CELL", 136, 155], ["oral keratinocytes", "CELL_TYPE", 90, 108], ["nasal keratinocytes", "CELL_TYPE", 136, 155], ["EBV", "SPECIES", 73, 76], ["the study", "TEST", 60, 69], ["EBV infection", "PROBLEM", 73, 86], ["oral keratinocytes", "PROBLEM", 90, 108], ["nasal keratinocytes", "PROBLEM", 136, 155], ["organotypic rafts", "OBSERVATION", 14, 31], ["EBV", "OBSERVATION_MODIFIER", 73, 76], ["infection", "OBSERVATION", 77, 86]]], ["The ALI culture method ultimately extends the application of polarization to other epithelial cell types.", [["epithelial cell", "ANATOMY", 83, 98], ["ALI", "DISEASE", 4, 7], ["epithelial cell", "CELL", 83, 98], ["epithelial cell types", "CELL_TYPE", 83, 104], ["The ALI culture method", "TEST", 0, 22], ["ALI", "ANATOMY", 4, 7], ["epithelial cell types", "OBSERVATION", 83, 104]]], ["When applied to primary cells, ALI culture preserves the diversity of cell types represented in airway epithelium, including ciliated, mucosecretory, and basal cells (22).", [["primary cells", "ANATOMY", 16, 29], ["cell", "ANATOMY", 70, 74], ["airway epithelium", "ANATOMY", 96, 113], ["ciliated", "ANATOMY", 125, 133], ["mucosecretory", "ANATOMY", 135, 148], ["basal cells", "ANATOMY", 154, 165], ["ALI", "DISEASE", 31, 34], ["cells", "CELL", 24, 29], ["cell", "CELL", 70, 74], ["airway epithelium", "TISSUE", 96, 113], ["basal cells", "CELL", 154, 165], ["primary cells", "CELL_TYPE", 16, 29], ["ciliated, mucosecretory, and basal cells", "CELL_TYPE", 125, 165], ["ALI culture", "TEST", 31, 42], ["cell types", "TEST", 70, 80], ["airway epithelium", "PROBLEM", 96, 113], ["ciliated, mucosecretory, and basal cells", "PROBLEM", 125, 165], ["ALI", "ANATOMY", 31, 34], ["cell types", "OBSERVATION", 70, 80], ["airway", "ANATOMY", 96, 102], ["epithelium", "ANATOMY_MODIFIER", 103, 113], ["ciliated", "ANATOMY_MODIFIER", 125, 133], ["basal cells", "ANATOMY", 154, 165]]], ["The ALI method described in this study for an NPC cell line (HK1) permits the analysis of protein expression at the population level but also with single-cell resolution (Fig. 2), demonstrating that the ALI culture method, as in the use of organotypic rafts, is amenable to a variety of molecular virology analytical techniques, including those involving DNA, RNA, protein, imaging, and the collection of infectious virus.", [["NPC cell line", "ANATOMY", 46, 59], ["HK1", "ANATOMY", 61, 64], ["cell", "ANATOMY", 154, 158], ["organotypic rafts", "ANATOMY", 240, 257], ["ALI", "DISEASE", 4, 7], ["ALI", "DISEASE", 203, 206], ["NPC cell line", "CELL", 46, 59], ["HK1", "CELL", 61, 64], ["cell", "CELL", 154, 158], ["DNA", "CELLULAR_COMPONENT", 355, 358], ["infectious virus", "ORGANISM", 405, 421], ["NPC cell line", "CELL_LINE", 46, 59], ["HK1", "CELL_LINE", 61, 64], ["The ALI method", "TREATMENT", 0, 14], ["this study", "TEST", 28, 38], ["an NPC cell line", "TREATMENT", 43, 59], ["the analysis", "TEST", 74, 86], ["protein expression", "PROBLEM", 90, 108], ["the ALI culture method", "TEST", 199, 221], ["organotypic rafts", "TREATMENT", 240, 257], ["RNA, protein", "TEST", 360, 372], ["imaging", "TEST", 374, 381], ["infectious virus", "PROBLEM", 405, 421], ["ALI", "OBSERVATION", 4, 7], ["NPC", "ANATOMY", 46, 49], ["cell line", "OBSERVATION", 50, 59], ["ALI", "ANATOMY", 203, 206], ["infectious virus", "OBSERVATION", 405, 421]]], ["Therefore, ALI culture is a method complementary to the use of organotypic rafts that can model EBV infection for the additional cell types represented in polarized airway epithelium.Setup of the ALI culture. ::: MATERIALS AND METHODSThe overall setup of the ALI culture for the HK1 cell line has been previously described (25).", [["organotypic rafts", "ANATOMY", 63, 80], ["cell", "ANATOMY", 129, 133], ["airway epithelium", "ANATOMY", 165, 182], ["HK1 cell line", "ANATOMY", 279, 292], ["ALI", "DISEASE", 11, 14], ["infection", "DISEASE", 100, 109], ["ALI", "DISEASE", 196, 199], ["ALI", "DISEASE", 259, 262], ["EBV", "ORGANISM", 96, 99], ["cell", "CELL", 129, 133], ["airway epithelium", "TISSUE", 165, 182], ["HK1 cell line", "CELL", 279, 292], ["HK1 cell line", "CELL_LINE", 279, 292], ["EBV", "SPECIES", 96, 99], ["ALI culture", "TEST", 11, 22], ["organotypic rafts", "TREATMENT", 63, 80], ["model EBV infection", "PROBLEM", 90, 109], ["the additional cell types", "PROBLEM", 114, 139], ["the ALI culture", "TEST", 192, 207], ["the ALI culture", "TEST", 255, 270], ["the HK1 cell line", "TEST", 275, 292], ["cell types", "OBSERVATION", 129, 139], ["polarized airway epithelium", "OBSERVATION", 155, 182], ["ALI", "ANATOMY", 196, 199], ["ALI", "ANATOMY", 259, 262], ["cell line", "OBSERVATION", 283, 292]]], ["A total of 0.5 \u00d7 106 cells are seeded on thin-coat collagen-coated polyester membrane transwells (Corning) (0.4 \u00b5m pore size, 12-mm diameter) in 0.5 ml apical medium.", [["cells", "ANATOMY", 21, 26], ["membrane", "ANATOMY", 77, 85], ["pore", "ANATOMY", 115, 119], ["polyester", "CHEMICAL", 67, 76], ["cells", "CELL", 21, 26], ["collagen", "GENE_OR_GENE_PRODUCT", 51, 59], ["collagen", "PROTEIN", 51, 59], ["A total of 0.5 \u00d7 106 cells", "TREATMENT", 0, 26], ["thin-coat collagen-coated polyester membrane transwells (Corning) (0.4 \u00b5m pore size", "TREATMENT", 41, 124], ["total", "OBSERVATION_MODIFIER", 2, 7], ["apical", "ANATOMY_MODIFIER", 152, 158]]], ["Cells are fed from the basolateral surface with 1 ml of media used for the propagation of HK1 cells (RPMI 1640 supplemented with 10% fetal bovine serum).", [["Cells", "ANATOMY", 0, 5], ["basolateral surface", "ANATOMY", 23, 42], ["HK1 cells", "ANATOMY", 90, 99], ["fetal bovine serum", "ANATOMY", 133, 151], ["RPMI 1640", "CHEMICAL", 101, 110], ["Cells", "CELL", 0, 5], ["basolateral surface", "CELLULAR_COMPONENT", 23, 42], ["HK1 cells", "CELL", 90, 99], ["bovine", "ORGANISM", 139, 145], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["HK1 cells", "CELL_LINE", 90, 99], ["bovine", "SPECIES", 139, 145], ["bovine", "SPECIES", 139, 145], ["media", "TREATMENT", 56, 61], ["HK1 cells", "PROBLEM", 90, 99], ["RPMI", "TEST", 101, 105], ["10% fetal bovine serum", "TREATMENT", 129, 151], ["basolateral", "ANATOMY_MODIFIER", 23, 34], ["surface", "OBSERVATION_MODIFIER", 35, 42]]], ["Thin-coat collagen is prepared by diluting 0.1 mg/ml stock of fibrous collagen (IV) from human placenta (Sigma) in water supplemented with 200 \u00b5l glacial acetic acid (100% [vol/vol]), with rocking overnight at 4\u00b0C to facilitate solubility.", [["placenta", "ANATOMY", 95, 103], ["glacial acetic acid", "CHEMICAL", 146, 165], ["acetic acid", "CHEMICAL", 154, 165], ["collagen", "GENE_OR_GENE_PRODUCT", 10, 18], ["collagen", "GENE_OR_GENE_PRODUCT", 70, 78], ["human", "ORGANISM", 89, 94], ["placenta", "ORGAN", 95, 103], ["acetic acid", "SIMPLE_CHEMICAL", 154, 165], ["Thin-coat collagen", "PROTEIN", 0, 18], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["Thin-coat collagen", "TREATMENT", 0, 18], ["fibrous collagen (IV) from human placenta (Sigma) in water supplemented", "TREATMENT", 62, 133], ["glacial acetic acid", "TREATMENT", 146, 165], ["placenta", "ANATOMY", 95, 103]]], ["The stock collagen solution is sterile filtered and further diluted 1:10 in 0.1 M Na2CO3 to a working concentration.", [["Na2CO3", "CHEMICAL", 82, 88], ["Na2CO3", "CHEMICAL", 82, 88], ["collagen", "GENE_OR_GENE_PRODUCT", 10, 18], ["The stock collagen solution", "TREATMENT", 0, 27], ["stock collagen", "OBSERVATION", 4, 18]]], ["Collagen stocks can be aliquoted and frozen at \u221220\u00b0C, but diluted stocks should be made fresh.", [["Collagen", "GENE_OR_GENE_PRODUCT", 0, 8], ["Collagen stocks", "TREATMENT", 0, 15]]], ["For a 12-well plate, 250 \u00b5l of the collagen working stock is used to coat the apical surface of the transwell at 37\u00b0C for a minimum of 30 min and up to 1 h.", [["apical surface", "ANATOMY", 78, 92], ["collagen", "GENE_OR_GENE_PRODUCT", 35, 43], ["apical surface", "CELLULAR_COMPONENT", 78, 92], ["collagen", "PROTEIN", 35, 43], ["a 12-well plate", "TREATMENT", 4, 19], ["the collagen working stock", "TREATMENT", 31, 57], ["apical", "ANATOMY_MODIFIER", 78, 84]]], ["Before the cells are seeded, the collagen solution is aspirated and gently rinsed once with phosphate-buffered saline (PBS).", [["cells", "ANATOMY", 11, 16], ["phosphate", "CHEMICAL", 92, 101], ["phosphate", "CHEMICAL", 92, 101], ["cells", "CELL", 11, 16], ["collagen", "GENE_OR_GENE_PRODUCT", 33, 41], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 92, 117], ["the collagen solution", "TREATMENT", 29, 50], ["phosphate-buffered saline (PBS", "TREATMENT", 92, 122]]], ["At 1 to 2 days postseeding, a confluent layer should form.", [["confluent", "OBSERVATION_MODIFIER", 30, 39], ["layer", "OBSERVATION_MODIFIER", 40, 45]]], ["The apical medium is removed, and the basolateral medium is replenished.", [["apical", "ANATOMY_MODIFIER", 4, 10], ["medium", "OBSERVATION_MODIFIER", 11, 17], ["removed", "OBSERVATION", 21, 28], ["basolateral", "ANATOMY_MODIFIER", 38, 49], ["medium", "OBSERVATION_MODIFIER", 50, 56], ["replenished", "OBSERVATION", 60, 71]]], ["Beginning as early as the next day, a successful ALI culture is established when there is no medium leakage into the apical surface, and that day is noted as day zero.", [["apical surface", "ANATOMY", 117, 131], ["ALI", "DISEASE", 49, 52], ["apical surface", "CELLULAR_COMPONENT", 117, 131], ["a successful ALI culture", "TEST", 36, 60], ["medium leakage into the apical surface", "PROBLEM", 93, 131], ["no", "UNCERTAINTY", 90, 92], ["medium leakage", "OBSERVATION", 93, 107], ["apical", "ANATOMY_MODIFIER", 117, 123], ["surface", "ANATOMY_MODIFIER", 124, 131]]], ["Cells at the ALI are fed twice a week from the basolateral compartment and cultured for up to 3 additional weeks.", [["Cells", "ANATOMY", 0, 5], ["basolateral compartment", "ANATOMY", 47, 70], ["ALI", "DISEASE", 13, 16], ["Cells", "CELL", 0, 5], ["basolateral compartment", "MULTI-TISSUE_STRUCTURE", 47, 70], ["ALI", "ANATOMY", 13, 16]]], ["The uninfected cells should have minimal apical leakage over the 3-week period and should be gently removed at every feeding.", [["cells", "ANATOMY", 15, 20], ["apical", "ANATOMY", 41, 47], ["cells", "CELL", 15, 20], ["apical", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 47], ["uninfected cells", "CELL_TYPE", 4, 20], ["The uninfected cells", "PROBLEM", 0, 20], ["minimal apical leakage", "PROBLEM", 33, 55], ["uninfected cells", "OBSERVATION", 4, 20], ["minimal", "OBSERVATION_MODIFIER", 33, 40], ["apical", "OBSERVATION_MODIFIER", 41, 47], ["leakage", "OBSERVATION", 48, 55]]], ["The ALI culture of EBV-infected cells increasingly disrupts the monolayer, and apical leakage is expected to increase over the 3-week period, but the integrity of the monolayer should still be apparent by visual inspection with phase microscopy.Analysis of EBV protein induction by immunoblotting, immunofluorescence, and RNA-seq. ::: MATERIALS AND METHODSThe subsequent procedures are described for a 12-well plate transwell configuration.", [["cells", "ANATOMY", 32, 37], ["monolayer", "ANATOMY", 64, 73], ["apical", "ANATOMY", 79, 85], ["monolayer", "ANATOMY", 167, 176], ["ALI", "DISEASE", 4, 7], ["EBV", "ORGANISM", 19, 22], ["cells", "CELL", 32, 37], ["monolayer", "CELL", 64, 73], ["apical", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 85], ["monolayer", "CELL", 167, 176], ["EBV", "ORGANISM", 257, 260], ["EBV-infected cells", "CELL_TYPE", 19, 37], ["EBV", "SPECIES", 19, 22], ["The ALI culture", "TEST", 0, 15], ["EBV", "PROBLEM", 19, 22], ["infected cells", "PROBLEM", 23, 37], ["apical leakage", "PROBLEM", 79, 93], ["visual inspection with phase microscopy", "TEST", 205, 244], ["EBV protein induction", "TREATMENT", 257, 278], ["immunoblotting", "TEST", 282, 296], ["immunofluorescence", "TEST", 298, 316], ["RNA", "TEST", 322, 325], ["METHODSThe subsequent procedures", "TREATMENT", 349, 381], ["ALI", "ANATOMY", 4, 7], ["infected cells", "OBSERVATION", 23, 37], ["monolayer", "OBSERVATION_MODIFIER", 64, 73], ["apical", "ANATOMY_MODIFIER", 79, 85], ["leakage", "OBSERVATION", 86, 93], ["increase", "OBSERVATION_MODIFIER", 109, 117], ["EBV protein", "OBSERVATION", 257, 268], ["transwell configuration", "OBSERVATION", 416, 439]]], ["At weekly intervals, protein lysates were harvested.", [["lysates", "ANATOMY", 29, 36], ["lysates", "ORGANISM_SUBSTANCE", 29, 36], ["protein lysates", "TEST", 21, 36], ["harvested", "OBSERVATION", 42, 51]]], ["The basolateral media and apical leakage were removed.", [["basolateral", "ANATOMY", 4, 15], ["apical", "ANATOMY", 26, 32], ["basolateral", "CELLULAR_COMPONENT", 4, 15], ["The basolateral media", "TREATMENT", 0, 21], ["apical leakage", "PROBLEM", 26, 40], ["basolateral", "ANATOMY_MODIFIER", 4, 15], ["media", "ANATOMY", 16, 21], ["apical", "ANATOMY_MODIFIER", 26, 32], ["leakage", "OBSERVATION", 33, 40]]], ["Cells were gently rinsed once in PBS and lysed in 50 \u00b5l of radioimmunoprecipitation assay (RIPA) buffer supplemented with 1 mM phenylmethylsulfonyl fluoride, 2 mM activated sodium orthovanadate, and a 1:100 dilution of protease and phosphate inhibitor cocktails (Sigma).", [["Cells", "ANATOMY", 0, 5], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 127, 156], ["sodium orthovanadate", "CHEMICAL", 173, 193], ["phosphate", "CHEMICAL", 232, 241], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 127, 156], ["sodium orthovanadate", "CHEMICAL", 173, 193], ["phosphate", "CHEMICAL", 232, 241], ["Cells", "CELL", 0, 5], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 127, 156], ["sodium orthovanadate", "SIMPLE_CHEMICAL", 173, 193], ["phosphate", "SIMPLE_CHEMICAL", 232, 241], ["protease", "PROTEIN", 219, 227], ["Cells", "TEST", 0, 5], ["PBS", "TREATMENT", 33, 36], ["radioimmunoprecipitation assay", "TEST", 59, 89], ["1 mM phenylmethylsulfonyl fluoride", "TREATMENT", 122, 156], ["2 mM activated sodium orthovanadate", "TREATMENT", 158, 193], ["protease", "TREATMENT", 219, 227], ["phosphate inhibitor cocktails", "TREATMENT", 232, 261]]], ["The cells were lysed directly in the transwell by rocking at 4\u00b0C for 30 min followed by scraping and were clarified at \u226520,000 \u00d7 g for 5 min at 4\u00b0C. Protein concentration, separation by SDS-PAGE, and immunoblotting was performed as previously described (25).", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["Protein concentration", "TEST", 149, 170], ["immunoblotting", "TEST", 200, 214]]], ["Antibodies for immunoblotting were purchased from Santa Cruz Biotechnologies (EBV zebra clone BZ1; EaD clone 0261; filaggrin clone AKH1; HSC70 clone B-6), Thermo Scientific (EBV VCA p18; keratin 10 clone Ab-2), and Sigma (involucrin clone SY5).Analysis of EBV protein induction by immunoblotting, immunofluorescence, and RNA-seq. ::: MATERIALS AND METHODSFor immunofluorescence staining, cells were fixed in 4% paraformaldehyde at room temperature and punched out of the transwell with the lid of a cryovial (or by the use of the top end of a P1000 tip cut to the size of the transwell).", [["cells", "ANATOMY", 388, 393], ["paraformaldehyde", "CHEMICAL", 411, 427], ["EBV", "ORGANISM", 78, 81], ["filaggrin", "GENE_OR_GENE_PRODUCT", 115, 124], ["EBV", "ORGANISM", 174, 177], ["p18", "GENE_OR_GENE_PRODUCT", 182, 185], ["keratin 10 clone Ab-2", "GENE_OR_GENE_PRODUCT", 187, 208], ["involucrin", "GENE_OR_GENE_PRODUCT", 222, 232], ["EBV", "ORGANISM", 256, 259], ["cells", "CELL", 388, 393], ["paraformaldehyde", "SIMPLE_CHEMICAL", 411, 427], ["Santa Cruz", "PROTEIN", 50, 60], ["EaD clone 0261", "CELL_LINE", 99, 113], ["filaggrin clone AKH1", "CELL_LINE", 115, 135], ["HSC70 clone B", "CELL_LINE", 137, 150], ["EBV VCA p18", "PROTEIN", 174, 185], ["keratin 10 clone Ab-2", "PROTEIN", 187, 208], ["Sigma", "PROTEIN", 215, 220], ["involucrin clone SY5", "PROTEIN", 222, 242], ["EBV zebra", "SPECIES", 78, 87], ["Antibodies", "TEST", 0, 10], ["immunoblotting", "TEST", 15, 29], ["EBV zebra clone BZ1", "TEST", 78, 97], ["EaD clone", "TEST", 99, 108], ["filaggrin clone AKH1", "TEST", 115, 135], ["HSC70 clone B", "TEST", 137, 150], ["EBV VCA p18", "TEST", 174, 185], ["keratin", "TEST", 187, 194], ["clone Ab", "TEST", 198, 206], ["Sigma (involucrin clone SY5", "TREATMENT", 215, 242], ["EBV protein induction", "TREATMENT", 256, 277], ["immunoblotting", "TEST", 281, 295], ["immunofluorescence", "TEST", 297, 315], ["RNA", "TEST", 321, 324], ["METHODSFor immunofluorescence staining", "TEST", 348, 386], ["a P1000 tip", "TREATMENT", 541, 552], ["EBV protein", "OBSERVATION", 256, 267], ["size", "OBSERVATION_MODIFIER", 564, 568]]], ["The use of a scalpel is not recommended since this can wrinkle the membrane and create an uneven surface for imaging.", [["membrane", "ANATOMY", 67, 75], ["surface", "ANATOMY", 97, 104], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["surface", "CELLULAR_COMPONENT", 97, 104], ["a scalpel", "TREATMENT", 11, 20], ["imaging", "TEST", 109, 116]]], ["Cells were permeabilized with 0.1% Triton X-100\u2013PBS for 5 min and washed in wash buffer (0.05% Tween 20\u2013PBS) followed by blocking with 1% bovine serum albumin\u2013PBS for 1 h at room temperature.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 145, 150], ["Triton X-100", "CHEMICAL", 35, 47], ["albumin\u2013", "CHEMICAL", 151, 159], ["Tween 20", "CHEMICAL", 95, 103], ["Cells", "CELL", 0, 5], ["Triton X-100", "SIMPLE_CHEMICAL", 35, 47], ["bovine", "ORGANISM", 138, 144], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["bovine", "SPECIES", 138, 144], ["bovine", "SPECIES", 138, 144], ["1% bovine serum albumin\u2013PBS", "TREATMENT", 135, 162]]], ["Cells were probed with primary antibody diluted in blocking buffer and incubated overnight at 4\u00b0C in a humidified chamber.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["primary antibody", "PROTEIN", 23, 39], ["primary antibody", "TREATMENT", 23, 39], ["blocking buffer", "TREATMENT", 51, 66], ["a humidified chamber", "TREATMENT", 101, 121], ["humidified chamber", "OBSERVATION", 103, 121]]], ["Following three rinses in wash buffer, cells were incubated with secondary antibody diluted in PBS for 1 h at room temperature.", [["cells", "ANATOMY", 39, 44], ["cells", "CELL", 39, 44], ["secondary antibody", "PROTEIN", 65, 83], ["wash buffer", "TREATMENT", 26, 37], ["cells", "TREATMENT", 39, 44], ["secondary antibody diluted in PBS", "TREATMENT", 65, 98]]], ["For EBV zebra (clone BZ1), EaD (clone 0261), and gp350 (clone 0221) stains, all primary antibodies (Santa Cruz Biotechnology) were diluted 1:100.", [["EBV", "ORGANISM", 4, 7], ["zebra", "ORGANISM", 8, 13], ["clone BZ1", "CELL", 15, 24], ["EaD (clone 0261", "GENE_OR_GENE_PRODUCT", 27, 42], ["gp350", "GENE_OR_GENE_PRODUCT", 49, 54], ["EBV zebra", "DNA", 4, 13], ["EaD", "PROTEIN", 27, 30], ["clone 0261", "PROTEIN", 32, 42], ["gp350", "PROTEIN", 49, 54], ["primary antibodies", "PROTEIN", 80, 98], ["Santa Cruz Biotechnology", "PROTEIN", 100, 124], ["EBV zebra", "SPECIES", 4, 13], ["EBV zebra", "TEST", 4, 13]]], ["EBV zebra and EaD were detected with Cy3-conjugated donkey anti-mouse IgG secondary antibody (Jackson ImmunoResearch) at 3.75 \u00b5g/ml.", [["EBV", "ORGANISM", 0, 3], ["zebra", "ORGANISM", 4, 9], ["EaD", "GENE_OR_GENE_PRODUCT", 14, 17], ["Cy3", "SIMPLE_CHEMICAL", 37, 40], ["EBV zebra", "DNA", 0, 9], ["EaD", "DNA", 14, 17], ["Cy3-conjugated donkey anti-mouse IgG secondary antibody", "PROTEIN", 37, 92], ["Jackson ImmunoResearch", "PROTEIN", 94, 116], ["donkey", "SPECIES", 52, 58], ["anti-mouse", "SPECIES", 59, 69], ["EBV zebra", "SPECIES", 0, 9], ["EBV zebra", "TEST", 0, 9], ["EaD", "TEST", 14, 17], ["Cy3", "TEST", 37, 40], ["conjugated donkey anti-mouse IgG secondary antibody (Jackson ImmunoResearch)", "TREATMENT", 41, 117]]], ["EBV gp350 was detected with biotin-conjugated donkey anti-mouse IgG diluted at 3 \u00b5g/ml and rhodamine red-conjugated streptavidin at 0.78 \u00b5g/ml (Jackson ImmunoResearch).", [["biotin", "CHEMICAL", 28, 34], ["rhodamine", "CHEMICAL", 91, 100], ["biotin", "CHEMICAL", 28, 34], ["rhodamine", "CHEMICAL", 91, 100], ["EBV", "ORGANISM", 0, 3], ["gp350", "GENE_OR_GENE_PRODUCT", 4, 9], ["biotin", "SIMPLE_CHEMICAL", 28, 34], ["rhodamine red-conjugated streptavidin", "SIMPLE_CHEMICAL", 91, 128], ["EBV gp350", "PROTEIN", 0, 9], ["biotin-conjugated donkey anti-mouse IgG", "PROTEIN", 28, 67], ["donkey", "SPECIES", 46, 52], ["anti-mouse", "SPECIES", 53, 63], ["EBV", "SPECIES", 0, 3], ["EBV gp350", "TEST", 0, 9], ["biotin-conjugated donkey anti-mouse IgG diluted", "TREATMENT", 28, 75], ["rhodamine red-conjugated streptavidin", "TREATMENT", 91, 128]]], ["Cells were counterstained in DAPI (4\u2032,6-diamidino-2-phenylindole) and mounted in aqueous mounting media.", [["Cells", "ANATOMY", 0, 5], ["DAPI", "CHEMICAL", 29, 33], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 35, 64], ["DAPI", "CHEMICAL", 29, 33], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 35, 64], ["Cells", "CELL", 0, 5], ["DAPI", "SIMPLE_CHEMICAL", 29, 33], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 35, 64], ["Cells", "TEST", 0, 5], ["DAPI", "TEST", 29, 33], ["diamidino", "TEST", 40, 49], ["phenylindole", "TREATMENT", 52, 64], ["aqueous mounting", "OBSERVATION", 81, 97]]], ["Epifluorescence images were acquired on an Olympus Provis microscope with Q-Capture software.", [["Epifluorescence images", "TEST", 0, 22], ["an Olympus Provis microscope", "TEST", 40, 68]]], ["All images were adjusted for equal levels of intensity and brightness.Analysis of EBV protein induction by immunoblotting, immunofluorescence, and RNA-seq. ::: MATERIALS AND METHODSTotal RNA was isolated using Trizol (Invitrogen) from HK1-EBV cells after induction of the lytic cycle at the indicated time points (week 0, week 1, week 2, and week 3).", [["HK1-EBV cells", "ANATOMY", 235, 248], ["EBV", "ORGANISM", 82, 85], ["HK1-EBV cells", "CELL", 235, 248], ["METHODSTotal RNA", "RNA", 174, 190], ["HK1-EBV cells", "CELL_LINE", 235, 248], ["All images", "TEST", 0, 10], ["EBV protein induction", "TREATMENT", 82, 103], ["immunoblotting", "TEST", 107, 121], ["immunofluorescence", "TEST", 123, 141], ["RNA", "TEST", 147, 150], ["METHODSTotal RNA", "TREATMENT", 174, 190], ["Trizol (Invitrogen", "TREATMENT", 210, 228], ["HK1-EBV cells", "TREATMENT", 235, 248], ["the lytic cycle", "TREATMENT", 268, 283], ["EBV protein", "OBSERVATION", 82, 93], ["EBV cells", "OBSERVATION", 239, 248]]], ["Briefly, cells were lysed in 1 ml of Trizol, purified with chloroform, precipitated with isopropanol followed by two washes of 75% ethanol, and resuspended in water.", [["cells", "ANATOMY", 9, 14], ["chloroform", "CHEMICAL", 59, 69], ["isopropanol", "CHEMICAL", 89, 100], ["ethanol", "CHEMICAL", 131, 138], ["chloroform", "CHEMICAL", 59, 69], ["isopropanol", "CHEMICAL", 89, 100], ["ethanol", "CHEMICAL", 131, 138], ["cells", "CELL", 9, 14], ["Trizol", "ORGANISM", 37, 43], ["chloroform", "SIMPLE_CHEMICAL", 59, 69], ["isopropanol", "SIMPLE_CHEMICAL", 89, 100], ["ethanol", "SIMPLE_CHEMICAL", 131, 138], ["Trizol", "TREATMENT", 37, 43], ["chloroform", "TREATMENT", 59, 69], ["isopropanol", "TREATMENT", 89, 100]]], ["DNase-treated RNA (Turbo DNA-free kit; Ambion) was submitted to the Health Sciences Sequencing Core at the Children\u2019s Hospital of Pittsburgh for quality assurance/quality control (QA/QC) analysis and quantitation on an Agilent TapeStation and Qubit. rRNA is susceptible to degradation during EBV reactivation; therefore, the expected RNA integrity number (RIN) can range from 2.4 to 5.5, with an expected total RNA yield in the range of 0.2 to 7 \u00b5g per ALI culture sample, decreasing as reactivation progresses.", [["sample", "ANATOMY", 465, 471], ["DNase", "CHEMICAL", 0, 5], ["ALI", "DISEASE", 453, 456], ["DNase", "GENE_OR_GENE_PRODUCT", 0, 5], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["rRNA", "CELLULAR_COMPONENT", 250, 254], ["EBV", "ORGANISM", 292, 295], ["DNase", "PROTEIN", 0, 5], ["rRNA", "RNA", 250, 254], ["Children", "SPECIES", 107, 115], ["EBV", "SPECIES", 292, 295], ["DNase", "TEST", 0, 5], ["quality assurance/quality control", "TREATMENT", 145, 178], ["QA/QC) analysis", "TEST", 180, 195], ["quantitation", "TEST", 200, 212], ["an Agilent TapeStation", "TREATMENT", 216, 238], ["EBV reactivation", "PROBLEM", 292, 308], ["ALI culture sample", "TEST", 453, 471], ["susceptible to", "UNCERTAINTY", 258, 272], ["degradation", "OBSERVATION_MODIFIER", 273, 284], ["EBV reactivation", "OBSERVATION", 292, 308], ["RNA", "OBSERVATION_MODIFIER", 334, 337], ["integrity", "OBSERVATION_MODIFIER", 338, 347]]], ["A more accurate measure of transcript integrity should be determined by the percentage of nucleotide fragments larger than 200 bp or by Northern blotting for intact EBV transcripts such as the abundant nonpolyadenylated EBERs.Analysis of EBV protein induction by immunoblotting, immunofluorescence, and RNA-seq. ::: MATERIALS AND METHODSFollowing QA/QC analysis, DNase-treated RNA samples were subjected to rRNA depletion using a Ribo-Zero Epidemiology kit (Illumina) and were converted into a deep sequencing library using Illumina\u2019s Truseq stranded total RNA kit.", [["samples", "ANATOMY", 381, 388], ["nucleotide", "CHEMICAL", 90, 100], ["EBV", "ORGANISM", 165, 168], ["EBERs", "GENE_OR_GENE_PRODUCT", 220, 225], ["EBV", "ORGANISM", 238, 241], ["DNase", "GENE_OR_GENE_PRODUCT", 363, 368], ["nucleotide fragments", "DNA", 90, 110], ["EBV transcripts", "RNA", 165, 180], ["nonpolyadenylated EBERs", "PROTEIN", 202, 225], ["DNase", "PROTEIN", 363, 368], ["deep sequencing library", "DNA", 494, 517], ["transcript integrity", "PROBLEM", 27, 47], ["nucleotide fragments", "PROBLEM", 90, 110], ["bp", "TEST", 127, 129], ["intact EBV transcripts", "TREATMENT", 158, 180], ["EBV protein induction", "TREATMENT", 238, 259], ["immunoblotting", "TEST", 263, 277], ["immunofluorescence", "TEST", 279, 297], ["RNA", "TEST", 303, 306], ["QA/QC analysis", "TEST", 347, 361], ["DNase", "TREATMENT", 363, 368], ["RNA samples", "TEST", 377, 388], ["rRNA depletion", "PROBLEM", 407, 421], ["a deep sequencing library", "TREATMENT", 492, 517], ["Illumina\u2019s Truseq stranded total RNA kit", "TREATMENT", 524, 564], ["fragments", "OBSERVATION_MODIFIER", 101, 110], ["larger", "OBSERVATION_MODIFIER", 111, 117], ["EBV transcripts", "OBSERVATION", 165, 180], ["EBV protein", "OBSERVATION", 238, 249]]], ["Deep sequencing was performed on a NextSeq500 platform using a Mid-output kit and a 2 \u00d7 75-cycle paired-end run.", [["NextSeq500 platform", "DNA", 35, 54], ["Deep sequencing", "TEST", 0, 15]]], ["We obtained 47.1, 49.4, 46.9, and 47.7 million reads for samples at week 0, week 1, week 2, and week 3, respectively.", [["samples", "ANATOMY", 57, 64]]], ["Sequence reads were trimmed by 10 nucleotides based on read quality and subsequently aligned to the EBV Akata genome (GenBank accession number KC207813.1) or to human reference genome hg38 using TopHat2 (58) and the options \u201c\u2014no-novel-juncs -r 300\u2014library-type fr-firststrand.\u201d", [["EBV", "ORGANISM", 100, 103], ["human", "ORGANISM", 161, 166], ["EBV Akata genome", "DNA", 100, 116], ["human reference genome hg38", "DNA", 161, 188], ["TopHat2 (58) and the options \u201c\u2014no-novel-juncs -r 300\u2014library-type fr-firststrand", "DNA", 195, 275], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["Sequence reads", "TEST", 0, 14]]], ["Among the total reads, 0.4%, 0.2%, 0.8%, and 0.8% aligned to the EBV genome for sample week 0, week 1, week 2, and week 3, respectively; the alignment rates for hg38 were 82.7%, 84.1%, 80.0%, and 82.2%, respectively.Analysis of EBV protein induction by immunoblotting, immunofluorescence, and RNA-seq. ::: MATERIALS AND METHODSTo generate a heat map of EBV transcript abundance, Cufflinks (59) was used to calculate FPKM values of EBV genes, which were then applied to the heatmap.2 tool in the gplots package (60).", [["EBV", "ORGANISM", 65, 68], ["EBV", "ORGANISM", 228, 231], ["EBV", "ORGANISM", 353, 356], ["EBV", "ORGANISM", 431, 434], ["EBV genome", "DNA", 65, 75], ["EBV genes", "DNA", 431, 440], ["the alignment rates", "TEST", 137, 156], ["hg38", "TEST", 161, 165], ["EBV protein induction", "TREATMENT", 228, 249], ["immunoblotting", "TEST", 253, 267], ["immunofluorescence", "TEST", 269, 287], ["RNA", "TEST", 293, 296], ["a heat map", "TEST", 339, 349], ["EBV transcript abundance", "TEST", 353, 377], ["Cufflinks", "TEST", 379, 388], ["EBV genes", "PROBLEM", 431, 440], ["EBV protein", "OBSERVATION", 228, 239], ["EBV genes", "OBSERVATION", 431, 440]]], ["For analyzing differential host gene expression, the algorithm CuffDiff2 (61) was used to compare week 0 transcriptomes and week 3 transcriptomes with the options \u201c\u2014library-type fr-firststrand\u2014compatible-hits-norm\u2014max-bundle-frags 1000000000000.\u201d", [["\u2014library", "TEST", 164, 172]]], ["Table S3 in the supplemental material includes data from host genes that exhibited a 2-fold change between the week 0 and week 3 samples.Analysis of EBV DNA genome replication by qPCR and Southern blotting. ::: MATERIALS AND METHODSCells were harvested by scraping in 100 \u00b5l of PBS followed by three cycles of rapid freezing-thawing to release virions.", [["virions", "ANATOMY", 344, 351], ["EBV", "ORGANISM", 149, 152], ["DNA", "CELLULAR_COMPONENT", 153, 156], ["host genes", "DNA", 57, 67], ["EBV DNA genome", "DNA", 149, 163], ["EBV", "SPECIES", 149, 152], ["a 2-fold change", "PROBLEM", 83, 98], ["Analysis", "TEST", 137, 145], ["EBV DNA genome replication", "TREATMENT", 149, 175], ["METHODSCells", "TREATMENT", 225, 237], ["PBS", "TREATMENT", 278, 281], ["rapid freezing", "TREATMENT", 310, 324]]], ["Cellular debris was pelleted at \u226520,000 \u00d7 g for 5 min, and the supernatant was harvested and split for subsequent experiments performed with or without DNase treatment.", [["Cellular debris", "ANATOMY", 0, 15], ["supernatant", "ANATOMY", 63, 74], ["DNase", "GENE_OR_GENE_PRODUCT", 152, 157], ["DNase", "PROTEIN", 152, 157], ["Cellular debris", "PROBLEM", 0, 15], ["subsequent experiments", "TEST", 103, 125], ["DNase treatment", "TREATMENT", 152, 167], ["debris", "OBSERVATION", 9, 15], ["harvested", "OBSERVATION", 79, 88]]], ["Half of the sample was treated with a Turbo DNA-free kit (Ambion) to isolate encapsidated genomes.", [["sample", "ANATOMY", 12, 18], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["encapsidated genomes", "DNA", 77, 97], ["a Turbo DNA", "TREATMENT", 36, 47], ["free kit (Ambion)", "TREATMENT", 48, 65], ["encapsidated genomes", "OBSERVATION", 77, 97]]], ["Both the samples subjected to DNase treatment and those left untreated were subjected to Hirt purification for isolation of extrachromosomal EBV genomes (22).", [["samples", "ANATOMY", 9, 16], ["DNase", "CHEMICAL", 30, 35], ["DNase", "GENE_OR_GENE_PRODUCT", 30, 35], ["EBV", "ORGANISM", 141, 144], ["DNase", "PROTEIN", 30, 35], ["extrachromosomal EBV genomes", "DNA", 124, 152], ["DNase treatment", "TREATMENT", 30, 45], ["Hirt purification", "TREATMENT", 89, 106], ["extrachromosomal EBV genomes", "PROBLEM", 124, 152], ["extrachromosomal EBV genomes", "OBSERVATION", 124, 152]]], ["For every 25-\u00b5l sample, 415 \u00b5l Hirt buffer, 5 \u00b5l of 20 mg/ml proteinase K, and 25 \u00b5l of 10% SDS were added and incubated for 2 h at 37\u00b0C. This was followed by phenol-chloroform extraction (470 \u00b5l phenol-chloroform-isoamyl alcohol [25:24:1]) and separation into the aqueous phase by spinning at \u226520,000 \u00d7 g for 10 min, followed by washing the aqueous layer with 470 \u00b5l of chloroform and collecting the aqueous layer by spinning at \u226520,000 \u00d7 g for 10 min.", [["aqueous layer", "ANATOMY", 401, 414], ["K", "CHEMICAL", 72, 73], ["phenol-chloroform", "CHEMICAL", 159, 176], ["phenol-chloroform-isoamyl alcohol", "CHEMICAL", 196, 229], ["chloroform", "CHEMICAL", 371, 381], ["phenol", "CHEMICAL", 159, 165], ["chloroform", "CHEMICAL", 166, 176], ["phenol-chloroform-isoamyl alcohol", "CHEMICAL", 196, 229], ["chloroform", "CHEMICAL", 371, 381], ["proteinase K", "GENE_OR_GENE_PRODUCT", 61, 73], ["phenol", "SIMPLE_CHEMICAL", 159, 165], ["chloroform", "SIMPLE_CHEMICAL", 166, 176], ["phenol-chloroform-isoamyl alcohol", "SIMPLE_CHEMICAL", 196, 229], ["chloroform", "SIMPLE_CHEMICAL", 371, 381], ["phenol-chloroform extraction", "TREATMENT", 159, 187], ["chloroform", "TREATMENT", 371, 381]]], ["DNA was precipitated with 0.1\u00d7 3 M sodium acetate and 2.5\u00d7 100% ethanol and was incubated overnight at \u221220\u00b0C. To pellet DNA, samples were spun at \u226520,000 \u00d7 g for 10 min at 4\u00b0C, washed with 300 \u00b5l 70% ethanol, and pelleted again at \u226520,000 \u00d7 g for 10 min at 4\u00b0C. The DNA pellet was air dried and resuspended in 12.5 \u00b5l of water.", [["samples", "ANATOMY", 125, 132], ["sodium acetate", "CHEMICAL", 35, 49], ["ethanol", "CHEMICAL", 64, 71], ["ethanol", "CHEMICAL", 200, 207], ["sodium acetate", "CHEMICAL", 35, 49], ["ethanol", "CHEMICAL", 64, 71], ["ethanol", "CHEMICAL", 200, 207], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["sodium acetate", "SIMPLE_CHEMICAL", 35, 49], ["ethanol", "SIMPLE_CHEMICAL", 64, 71], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["ethanol", "SIMPLE_CHEMICAL", 200, 207], ["DNA", "CELLULAR_COMPONENT", 266, 269], ["3 M sodium acetate", "TREATMENT", 31, 49], ["pellet DNA", "PROBLEM", 113, 123], ["The DNA pellet", "TREATMENT", 262, 276], ["pellet DNA", "OBSERVATION", 113, 123], ["DNA pellet", "OBSERVATION", 266, 276], ["air dried", "OBSERVATION", 281, 290]]], ["Of note, it would also be possible to perform the qPCR procedure using column-purified total genomic DNA and normalization to a cellular target but the procedure would need to be empirically optimized for sensitivity and template quantity.Analysis of EBV DNA genome replication by qPCR and Southern blotting. ::: MATERIALS AND METHODSFor qPCR, 2 \u00b5l of the Hirt-purified DNA was analyzed by the Sybr green absolute quantitation method.", [["cellular", "ANATOMY", 128, 136], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["cellular", "CELL", 128, 136], ["EBV", "ORGANISM", 251, 254], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["DNA", "CELLULAR_COMPONENT", 370, 373], ["genomic DNA", "DNA", 93, 104], ["EBV DNA genome", "DNA", 251, 265], ["Hirt-purified DNA", "DNA", 356, 373], ["EBV", "SPECIES", 251, 254], ["the qPCR procedure", "TREATMENT", 46, 64], ["column", "TREATMENT", 71, 77], ["purified total genomic DNA", "TREATMENT", 78, 104], ["a cellular target", "TREATMENT", 126, 143], ["the procedure", "TREATMENT", 148, 161], ["sensitivity and template quantity", "PROBLEM", 205, 238], ["Analysis", "TEST", 239, 247], ["EBV DNA genome replication", "TREATMENT", 251, 277], ["qPCR", "TEST", 338, 342], ["the Hirt-purified DNA", "TREATMENT", 352, 373]]], ["A standard curve was generated with 100 to 109 copies per reaction using a BALF5 plasmid (7,782 bp) as the template (62).", [["BALF5 plasmid", "DNA", 75, 88], ["7,782 bp", "DNA", 90, 98], ["A standard curve", "TREATMENT", 0, 16], ["a BALF5 plasmid", "TREATMENT", 73, 88], ["bp", "TEST", 96, 98], ["the template", "TEST", 103, 115]]], ["Reaction mixtures were assembled with a Maxima SYBR green qPCR master mix kit (Thermo Scientific) with 0.3 \u00b5M of each primer, using recommended cycle conditions with ROX as a passive reference dye in a total reaction volume of 10 \u00b5l.", [["ROX", "CHEMICAL", 166, 169], ["ROX", "SIMPLE_CHEMICAL", 166, 169], ["Reaction mixtures", "PROBLEM", 0, 17], ["a Maxima SYBR", "TEST", 38, 51], ["cycle conditions", "TREATMENT", 144, 160], ["ROX", "TREATMENT", 166, 169], ["a total reaction volume", "TEST", 200, 223]]], ["Primer sequences are as follows: for qBALF5-F, 5\u2032 GAGCGATCTTGGCAATCTCT 3\u2032; for qBALF5-R, 5\u2032 TGGTCATGGATCTGCTAAACC 3\u2032.", [["qBALF5-R", "GENE_OR_GENE_PRODUCT", 79, 87], ["Primer sequences", "DNA", 0, 16], ["qBALF5", "DNA", 37, 43], ["qBALF5", "PROTEIN", 79, 85], ["Primer sequences", "TEST", 0, 16], ["qBALF5", "TEST", 37, 43], ["GAGCGATCTTGGCAATCTCT", "TEST", 50, 70], ["qBALF5", "TEST", 79, 85]]], ["Reactions were amplified on a StepOnePlus instrument (Applied Biosystems) and analyzed with StepOne software (v2.3).", [["a StepOnePlus instrument", "TREATMENT", 28, 52]]], ["Average values and standard deviations were calculated from triplicate technical replicas and three independent experiments.", [["Average values", "TEST", 0, 14], ["standard deviations", "PROBLEM", 19, 38], ["standard deviations", "OBSERVATION", 19, 38]]], ["Water and uninfected HK1 ALI culture cells from corresponding weeks were used as negative controls.", [["HK1 ALI culture cells", "ANATOMY", 21, 42], ["HK1 ALI culture cells", "CELL", 21, 42], ["uninfected HK1 ALI culture cells", "CELL_LINE", 10, 42], ["HK1 ALI culture cells", "TEST", 21, 42]]], ["End values were represented as BALF5 copy number per ALI culture.Analysis of EBV DNA genome replication by qPCR and Southern blotting. ::: MATERIALS AND METHODSFor Southern blotting, total genomic DNA was harvested from Trizol-lysed cells or could also be harvested by column purification (GeneJET genomic DNA purification kit with RNase treatment; Thermo Scientific).", [["cells", "ANATOMY", 233, 238], ["ALI", "DISEASE", 53, 56], ["BALF5", "GENE_OR_GENE_PRODUCT", 31, 36], ["EBV", "ORGANISM", 77, 80], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["cells", "CELL", 233, 238], ["DNA", "CELLULAR_COMPONENT", 306, 309], ["RNase", "GENE_OR_GENE_PRODUCT", 332, 337], ["EBV DNA genome", "DNA", 77, 91], ["total genomic DNA", "DNA", 183, 200], ["Trizol-lysed cells", "CELL_LINE", 220, 238], ["RNase", "PROTEIN", 332, 337], ["EBV", "SPECIES", 77, 80], ["End values", "TEST", 0, 10], ["ALI culture", "TEST", 53, 64], ["Analysis", "TEST", 65, 73], ["EBV DNA genome replication", "TREATMENT", 77, 103], ["total genomic DNA", "PROBLEM", 183, 200], ["Trizol-lysed cells", "TREATMENT", 220, 238], ["column purification", "TREATMENT", 269, 288], ["GeneJET genomic DNA purification", "TREATMENT", 290, 322], ["RNase treatment", "TREATMENT", 332, 347]]], ["Total DNA was isolated from the nonaqueous phase according to manufacturer\u2019s instructions (Invitrogen).", [["DNA", "CELLULAR_COMPONENT", 6, 9], ["Total DNA", "TEST", 0, 9]]], ["The DNA harvested from each ALI culture was digested with BamHI, ethanol precipitated in the presence of 5 to 10 \u00b5g of glycogen, and loaded on an agarose gel.", [["ALI", "DISEASE", 28, 31], ["ethanol", "CHEMICAL", 65, 72], ["glycogen", "CHEMICAL", 119, 127], ["ethanol", "CHEMICAL", 65, 72], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["BamHI", "GENE_OR_GENE_PRODUCT", 58, 63], ["ethanol", "SIMPLE_CHEMICAL", 65, 72], ["glycogen", "SIMPLE_CHEMICAL", 119, 127], ["agarose", "SIMPLE_CHEMICAL", 146, 153], ["each ALI culture", "TEST", 23, 39], ["BamHI", "TREATMENT", 58, 63], ["glycogen", "TREATMENT", 119, 127], ["an agarose gel", "TREATMENT", 143, 157], ["DNA", "OBSERVATION_MODIFIER", 4, 7], ["harvested", "OBSERVATION", 8, 17]]], ["A linearized Xho1a (1.9-kb) probe was generated by random-prime synthesis, radiolabeled, and hybridized as previously described (63).Measuring EBV titers. ::: MATERIALS AND METHODSResidual media on the apical side were collected.", [["apical", "ANATOMY", 202, 208], ["Xho1a", "GENE_OR_GENE_PRODUCT", 13, 18], ["EBV", "ORGANISM", 143, 146], ["apical side", "MULTI-TISSUE_STRUCTURE", 202, 213], ["linearized Xho1a (1.9-kb) probe", "DNA", 2, 33], ["A linearized Xho1a (1.9-kb) probe", "TREATMENT", 0, 33], ["Measuring EBV titers", "TEST", 133, 153], ["METHODSResidual media", "TREATMENT", 173, 194], ["EBV titers", "OBSERVATION", 143, 153], ["METHODSResidual media", "OBSERVATION", 173, 194], ["apical", "ANATOMY_MODIFIER", 202, 208]]], ["Intracellular and extracellular virus was harvested by scraping cells in 100 \u00b5l of RPMI media followed by an additional 50-\u00b5l rinse and was collected to reach a total volume of 200 \u00b5l.", [["Intracellular", "ANATOMY", 0, 13], ["extracellular", "ANATOMY", 18, 31], ["cells", "ANATOMY", 64, 69], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["virus", "ORGANISM", 32, 37], ["cells", "CELL", 64, 69], ["Intracellular and extracellular virus", "PROBLEM", 0, 37], ["scraping cells", "TEST", 55, 69], ["RPMI media", "TREATMENT", 83, 93], ["a total volume", "TEST", 159, 173], ["extracellular", "ANATOMY_MODIFIER", 18, 31], ["virus", "OBSERVATION", 32, 37], ["scraping cells", "OBSERVATION", 55, 69]]], ["The sample was clarified by spinning at 500 \u00d7 g for 5 min, and the supernatant was collected and stored at 4\u00b0C as extracellular virus.", [["sample", "ANATOMY", 4, 10], ["supernatant", "ANATOMY", 67, 78], ["extracellular", "ANATOMY", 114, 127], ["C", "GENE_OR_GENE_PRODUCT", 109, 110], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["virus", "ORGANISM", 128, 133], ["extracellular virus", "PROBLEM", 114, 133], ["extracellular virus", "OBSERVATION", 114, 133]]], ["The cell pellet was resuspended in 200 \u00b5l of RPMI media followed by three cycles of rapid freezing-thawing to release intracellular virus.", [["cell pellet", "ANATOMY", 4, 15], ["intracellular", "ANATOMY", 118, 131], ["cell", "CELL", 4, 8], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["The cell pellet", "TREATMENT", 0, 15], ["RPMI media", "TREATMENT", 45, 55], ["rapid freezing", "TREATMENT", 84, 98], ["intracellular virus", "PROBLEM", 118, 137], ["cell pellet", "OBSERVATION", 4, 15], ["intracellular virus", "OBSERVATION", 118, 137]]], ["Disrupted cells were spun down at 500 \u00d7 g for 5 min, and the supernatant was collected and stored at 4\u00b0C as cell-associated virus.Measuring EBV titers. ::: MATERIALS AND METHODSInfectious titer was determined by the green Raji Unit (GRU) assay (50).", [["cells", "ANATOMY", 10, 15], ["supernatant", "ANATOMY", 61, 72], ["cell", "ANATOMY", 108, 112], ["cells", "CELL", 10, 15], ["C", "GENE_OR_GENE_PRODUCT", 103, 104], ["cell", "CELL", 108, 112], ["EBV", "ORGANISM", 140, 143], ["Disrupted cells", "PROBLEM", 0, 15], ["C as cell-associated virus", "PROBLEM", 103, 129], ["Measuring EBV titers", "TEST", 130, 150], ["METHODSInfectious titer", "TEST", 170, 193], ["virus", "OBSERVATION", 124, 129], ["EBV titers", "OBSERVATION", 140, 150]]], ["In a 96-well plate, 90 \u00b5l of RPMI medium was added to 10 \u00b5l of virus stock and titrated in 10-fold serial dilutions (100 to 109).", [["RPMI medium", "TREATMENT", 29, 40], ["virus stock", "TREATMENT", 63, 74]]], ["Ten thousand Raji cells in 10 \u00b5l media were added to each well and, after a 48-h inoculation period, reactivated with 200 nM TPA and 5 mM sodium butyrate overnight.", [["Raji cells", "ANATOMY", 13, 23], ["TPA", "CHEMICAL", 125, 128], ["sodium butyrate", "CHEMICAL", 138, 153], ["TPA", "CHEMICAL", 125, 128], ["sodium butyrate", "CHEMICAL", 138, 153], ["Raji cells", "CELL", 13, 23], ["TPA", "SIMPLE_CHEMICAL", 125, 128], ["sodium butyrate", "SIMPLE_CHEMICAL", 138, 153], ["Raji cells", "CELL_LINE", 13, 23], ["Ten thousand Raji cells", "TREATMENT", 0, 23], ["200 nM TPA", "TREATMENT", 118, 128], ["5 mM sodium butyrate", "TREATMENT", 133, 153], ["Raji cells", "OBSERVATION", 13, 23]]], ["A fluorescence microscope was used to count the number of GFP-positive cells in each well to determine the number of GRU per milliliter.TEM. ::: MATERIALS AND METHODSHK1 and HK1-EBV ALI cultures harvested at week 2 were fixed in cold 2.5% glutaraldehyde\u20130.01 M PBS.", [["cells", "ANATOMY", 71, 76], ["ALI", "DISEASE", 182, 185], ["glutaraldehyde", "CHEMICAL", 239, 253], ["glutaraldehyde", "CHEMICAL", 239, 253], ["GFP", "GENE_OR_GENE_PRODUCT", 58, 61], ["cells", "CELL", 71, 76], ["METHODSHK1", "GENE_OR_GENE_PRODUCT", 159, 169], ["HK1-", "CELL", 174, 178], ["EBV", "ORGANISM", 178, 181], ["glutaraldehyde", "SIMPLE_CHEMICAL", 239, 253], ["GFP-positive cells", "CELL_LINE", 58, 76], ["HK1-EBV ALI cultures", "CELL_LINE", 174, 194], ["A fluorescence microscope", "TEST", 0, 25], ["GFP", "TEST", 58, 61], ["METHODSHK1", "TEST", 159, 169], ["HK1", "TEST", 174, 177], ["EBV ALI cultures", "TEST", 178, 194], ["positive cells", "OBSERVATION", 62, 76]]], ["Specimens were rinsed in PBS, postfixed in 1% osmium tetroxide with 1% potassium ferricyanide, rinsed in PBS, dehydrated through a graded ethanol series, and embedded in Poly/Bed 812 (Luft formulations).", [["Specimens", "ANATOMY", 0, 9], ["osmium tetroxide", "CHEMICAL", 46, 62], ["potassium ferricyanide", "CHEMICAL", 71, 93], ["ethanol", "CHEMICAL", 138, 145], ["Poly/Bed 812", "CHEMICAL", 170, 182], ["osmium tetroxide", "CHEMICAL", 46, 62], ["potassium ferricyanide", "CHEMICAL", 71, 93], ["ethanol", "CHEMICAL", 138, 145], ["osmium tetroxide", "SIMPLE_CHEMICAL", 46, 62], ["potassium ferricyanide", "SIMPLE_CHEMICAL", 71, 93], ["ethanol", "SIMPLE_CHEMICAL", 138, 145], ["Poly/Bed 812", "SIMPLE_CHEMICAL", 170, 182], ["Specimens", "TEST", 0, 9], ["PBS", "TREATMENT", 25, 28], ["1% osmium tetroxide", "TREATMENT", 43, 62], ["1% potassium ferricyanide", "TREATMENT", 68, 93], ["a graded ethanol series", "TREATMENT", 129, 152], ["embedded in Poly/Bed", "TREATMENT", 158, 178], ["Luft formulations", "TREATMENT", 184, 201]]], ["Semithin (300-nm-thick) sections were cut on a Leica Reichart Ultracut ultramicrotome, stained with 0.5% toluidine blue\u20131% sodium borate, and examined under the light microscope.", [["sections", "ANATOMY", 24, 32], ["toluidine", "CHEMICAL", 105, 114], ["sodium borate", "CHEMICAL", 123, 136], ["toluidine", "CHEMICAL", 105, 114], ["sodium borate", "CHEMICAL", 123, 136], ["toluidine blue\u20131", "SIMPLE_CHEMICAL", 105, 121], ["sodium borate", "SIMPLE_CHEMICAL", 123, 136], ["Semithin (300-nm-thick) sections", "TREATMENT", 0, 32], ["a Leica Reichart Ultracut ultramicrotome", "TREATMENT", 45, 85], ["0.5% toluidine blue\u20131% sodium borate", "TREATMENT", 100, 136]]], ["Ultrathin sections (65 nm thick) were stained with uranyl acetate and Reynold\u2019s lead citrate and examined on a JEOL 1011 transmission electron microscope with a side-mount AMT 2-k digital camera (Advanced Microscopy Techniques).", [["sections", "ANATOMY", 10, 18], ["uranyl acetate", "CHEMICAL", 51, 65], ["Reynold\u2019s lead citrate", "CHEMICAL", 70, 92], ["uranyl acetate", "CHEMICAL", 51, 65], ["Reynold", "CHEMICAL", 70, 77], ["citrate", "CHEMICAL", 85, 92], ["uranyl acetate", "SIMPLE_CHEMICAL", 51, 65], ["Reynold\u2019s lead citrate", "SIMPLE_CHEMICAL", 70, 92], ["Ultrathin sections", "TEST", 0, 18], ["uranyl acetate", "TREATMENT", 51, 65], ["Reynold\u2019s lead citrate", "TREATMENT", 70, 92], ["a side-mount AMT", "TREATMENT", 159, 175]]]], "PMC2669640": [["INTRODUCTIONComputational/mathematical approaches, such as structural bioinformatics [1], structural class prediction [2, 3], molecular docking [4-9], molecular packing [10, 11], pharmacophore modelling [12], Mote Carlo simulated annealing approach [13], diffusion-controlled reaction simulation [14], graph/diagram approach [15-21], bio-macromolecular internal collective motion simulation [22], QSAR [23-25], protein subcellular location prediction [26-30], protein structural class prediction [31, 32], identification of membrane proteins and their types [33], identification of enzymes and their functional classes [34], identification of proteases and their types [35], protein cleavage site prediction [36-38], and signal peptide prediction [39, 40] can timely provide very useful information and insights for both basic research and drug design and hence are widely welcome by science community.INTRODUCTIONSeveral computational approaches aimed to the prediction of protein domain boundaries have been published during the last few years [41, 42].", [["subcellular", "ANATOMY", 419, 430], ["membrane", "ANATOMY", 524, 532], ["membrane", "CELLULAR_COMPONENT", 524, 532], ["membrane proteins", "PROTEIN", 524, 541], ["enzymes", "PROTEIN", 582, 589], ["proteases", "PROTEIN", 643, 652], ["protein domain boundaries", "PROTEIN", 974, 999], ["molecular packing", "TREATMENT", 151, 168], ["pharmacophore modelling", "TEST", 179, 202], ["Mote Carlo simulated annealing approach", "TREATMENT", 209, 248], ["graph/diagram approach", "TEST", 302, 324], ["bio-macromolecular internal collective motion simulation", "TEST", 334, 390], ["QSAR", "TEST", 397, 401], ["protein subcellular location prediction", "TEST", 411, 450], ["protein structural class prediction", "TEST", 460, 495], ["membrane proteins", "TEST", 524, 541], ["enzymes", "TEST", 582, 589], ["proteases", "TEST", 643, 652], ["protein cleavage site prediction", "TEST", 675, 707], ["signal peptide prediction", "TEST", 721, 746], ["INTRODUCTIONSeveral computational approaches", "TREATMENT", 902, 946], ["the prediction of protein domain boundaries", "TREATMENT", 956, 999]]], ["Besides their intrinsic interest in genome analysis and evolution studies, they are tools that structural biologists may use to optimize the design of the constructs of the proteins, the three-dimensional (3D) structure of which must be determined [43].", [["genome analysis", "TEST", 36, 51], ["evolution studies", "TEST", 56, 73]]], ["While this is particularly important in structural genomics (SG), where the targets have, in general, not been deeply characterized with appropriate biochemical and biophysical tools, this can be important also for traditional hypothesis-driven structural biology projects, where a fine tuning of the construct that is inserted into the experimental pipeline \u2013 cloning, expression, purification, etc. \u2013 is often necessary in order to get suitable samples [44].INTRODUCTIONSeveral information about structure prediction methods are periodically published in the framework of the CASP initiative, the main goal of which is to promote an evaluation of computational prediction methods [45].", [["traditional hypothesis", "PROBLEM", 215, 237], ["an evaluation", "TEST", 632, 645]]], ["During CASP experiment a series of protein sequences, the 3D structure of which was determined experimentally though it was not yet published, are distributed to research groups that develop computational methods for predicting protein structural features.", [["protein sequences", "TEST", 35, 52], ["computational methods", "TEST", 191, 212], ["predicting protein structural features", "PROBLEM", 217, 255]]], ["It is thus a blinded test, where several methods of \u201cin silico\u201d structural biology techniques can be compared to the reality and to each other.", [["a blinded test", "TEST", 11, 25]]], ["Nevertheless, in each CASP run, the number of targets is obviously quite limited and a prediction method that performs very well in CASP is not necessarily better than other techniques in the reality.", [["a prediction method", "TREATMENT", 85, 104], ["not necessarily", "UNCERTAINTY", 140, 155]]], ["It is necessary to make additional investigations focusing on the possibility to use these prediction methods for practical application in structural biology.INTRODUCTIONAlthough it is impossible to consider it a rule, it is generally easier to work with single-domain proteins than with multi-domain proteins, since the latter ones tend to be conformationally more flexible [46].", [["single-domain proteins", "PROTEIN", 255, 277], ["multi-domain proteins", "PROTEIN", 288, 309], ["additional investigations", "TEST", 24, 49], ["these prediction methods", "TREATMENT", 85, 109], ["practical application", "TREATMENT", 114, 135], ["single-domain proteins", "TREATMENT", 255, 277], ["multi-domain proteins", "PROBLEM", 288, 309]]], ["For example, the reciprocal orientation of the domains can vary and depend on the presence of other molecules.", [["reciprocal", "OBSERVATION_MODIFIER", 17, 27], ["orientation", "OBSERVATION_MODIFIER", 28, 39], ["molecules", "OBSERVATION", 100, 109]]], ["Multi-domain proteins may also be little prone to refold if, by chance, they had been over-expressed in cells lacking proper chaperones.", [["cells", "ANATOMY", 104, 109], ["cells", "CELL", 104, 109], ["Multi-domain proteins", "PROTEIN", 0, 21], ["chaperones", "PROTEIN", 125, 135], ["Multi-domain proteins", "PROBLEM", 0, 21], ["may also be", "UNCERTAINTY", 22, 33]]], ["This does not mean that multi-domain proteins cannot be studied but it implies that some care must be paid in structural biology experiments and that longer time and larger funding can be expected to be necessary to solve multi-domain proteins.", [["multi-domain proteins", "PROTEIN", 24, 45], ["multi-domain proteins", "PROTEIN", 222, 243], ["multi-domain proteins", "PROBLEM", 24, 45]]], ["It is thus extremely important to be able to predict, on the basis of its amino acid sequence, if a protein contains one or more structural domains.INTRODUCTIONCASP is divided into several sections, ranging from prediction of conformational disorder to tertiary structure prediction.", [["sections", "ANATOMY", 189, 197], ["amino acid", "CHEMICAL", 74, 84], ["disorder", "DISEASE", 241, 249], ["amino acid", "CHEMICAL", 74, 84], ["amino acid", "AMINO_ACID", 74, 84], ["structural domains", "PROTEIN", 129, 147], ["its amino acid sequence", "TEST", 70, 93], ["a protein", "PROBLEM", 98, 107], ["conformational disorder", "PROBLEM", 226, 249], ["conformational disorder", "OBSERVATION", 226, 249], ["tertiary structure", "OBSERVATION", 253, 271]]], ["Protein domain boundary predictions began to be included in the CASP initiative in 2004.", [["Protein domain boundary predictions", "PROBLEM", 0, 35]]], ["The dissection of a protein into separate structural domains is in fact not trivial at all [46, 47].", [["dissection", "OBSERVATION", 4, 14], ["trivial", "OBSERVATION", 76, 83]]], ["It is related to the ill-definition of what a protein domain is.", [["protein domain", "PROTEIN", 46, 60]]], ["An amino acid segment can be in fact considered to be a structural domain if i) it is a compact ensemble of atoms/residues; ii) it is an ensemble of atoms/residues that behaves as a rigid body, in the sense that it can move relative to other protein moieties without changing its shape; iii) it is a self-folding subunit; iv) it is a polypeptide segment well conserved during molecular evolution.", [["body", "ANATOMY", 188, 192], ["amino acid", "CHEMICAL", 3, 13], ["amino acid", "CHEMICAL", 3, 13], ["amino acid", "AMINO_ACID", 3, 13], ["protein moieties", "PROTEIN", 242, 258], ["self-folding subunit", "PROTEIN", 300, 320], ["polypeptide segment", "PROTEIN", 334, 353], ["An amino acid segment", "TREATMENT", 0, 21], ["a rigid body", "PROBLEM", 180, 192], ["a self-folding subunit", "TREATMENT", 298, 320], ["a polypeptide segment", "PROBLEM", 332, 353], ["molecular evolution", "OBSERVATION", 376, 395]]], ["Given the ambiguity in any quantitative definition, the real domain boundaries were defined according to the CASP7 organizers and assessors [47].", [["assessors", "TEST", 130, 139]]], ["They found a reasonable consensus definition for each investigated protein, which seems to be well suitable for a structural biology analysis.INTRODUCTIONThe present study is attempted to compare modern approaches for predicting protein domain boundaries and to define new prediction strategies.", [["protein domain boundaries", "PROTEIN", 229, 254], ["each investigated protein", "PROBLEM", 49, 74], ["a structural biology analysis", "TEST", 112, 141], ["The present study", "TEST", 154, 171], ["predicting protein domain boundaries", "PROBLEM", 218, 254], ["new prediction strategies", "TREATMENT", 269, 294]]], ["Here, we refer to the exercise named CASP7, organized in 2006, for which both predictions and experimental data are available on-line (http://www.predictioncenter.org/casp7/Casp7.html).", [["CASP7", "GENE_OR_GENE_PRODUCT", 37, 42], ["CASP7", "DNA", 37, 42]]], ["In this manuscript, several tools, designed for predicting domain boundaries on the basis of the amino acid sequence, will be compared to the real domain architecture.", [["amino acid", "CHEMICAL", 97, 107], ["amino acid", "CHEMICAL", 97, 107], ["amino acid", "AMINO_ACID", 97, 107], ["amino acid sequence", "PROTEIN", 97, 116], ["the amino acid sequence", "TEST", 93, 116]]], ["The analysis of these data allows one to answer the following basic questions: i) Is it possible to predict, with the presently available bioinformatics tools, if a protein is made by a single domain or if it contains more than one domain? ii) What is the statistical significance of the available predictions? iii) How accurately can the domain boundaries be predicted in the cases where the presently available bioinformatics predictions work well?Available Data and Tools ::: METHODSData were obtained from the CASP7 web page (http://predictioncenter.gc.ucdavis.edu/casp7/).", [["these data", "TEST", 16, 26]]], ["Table 1 shows the bioinformatics tools that are freely available and that were used in CASP7.", [["CASP7", "GENE_OR_GENE_PRODUCT", 87, 92], ["CASP7", "PROTEIN", 87, 92], ["the bioinformatics tools", "TEST", 14, 38]]], ["Protein domain prediction methods can be classified into three main categories [42]: i) homology prediction; ii) domain recognition; iii) new domain prediction methods.", [["Protein domain prediction methods", "TREATMENT", 0, 33], ["new domain prediction methods", "PROBLEM", 138, 167]]], ["The 14 prediction methods regarded in present study include all types of approaches.", [["The 14 prediction methods", "TEST", 0, 25]]], ["The homology prediction is presented by the chop [48, 49] methods that assign the query sequence to known PDB chains.", [["PDB chains", "PROTEIN", 106, 116], ["PDB chains", "OBSERVATION", 106, 116]]], ["Dsp [42] uses in addition more general properties of sequence conservation throughout the protein and it can be considered as lying between domain homology and new domain predictions.", [["Dsp [42]", "CHEMICAL", 0, 8], ["sequence conservation", "TREATMENT", 53, 74], ["new domain predictions", "TREATMENT", 160, 182]]], ["Domssea [42] belongs to the domain recognition approaches.", [["Domssea", "CHEMICAL", 0, 7]]], ["It is based on the assumption that secondary structure is a more conserved feature of proteins with similar folds than sequence.", [["secondary structure", "PROBLEM", 35, 54]]], ["Domssea aligns the secondary structure predicted for a query protein against a database of 3D domain structures and derives the domain boundaries from the known domain with the most similar secondary structure.", [["3D domain structures", "PROTEIN", 91, 111], ["secondary structure", "OBSERVATION", 19, 38], ["most similar", "OBSERVATION_MODIFIER", 177, 189], ["secondary structure", "OBSERVATION", 190, 209]]], ["Robetta [50] applies BLAST/PSI-BLAST for domain homology prediction and it uses FFAS03 and 3D-Jury to find remote homologues of known domain structure.", [["Robetta", "CHEMICAL", 0, 7], ["domain structure", "PROTEIN", 134, 150], ["BLAST/PSI", "TREATMENT", 21, 30], ["domain homology prediction", "TREATMENT", 41, 67], ["FFAS03", "TREATMENT", 80, 86], ["known domain structure", "PROBLEM", 128, 150]]], ["Hhpred [51] is a server for remote homology detection and for structure prediction using pairwise comparison of profile hidden Markov models (HMMs).", [["Hhpred", "CHEMICAL", 0, 6], ["remote homology detection", "TEST", 28, 53]]], ["In the foldpro [52] method the structural relevance of the query-template pairs is extracted from global profile-profile alignments in combination with predicted secondary structure, relative solvent accessibility, contact map and beta-strand pairing using support vector machines.", [["beta-strand pairing", "TREATMENT", 231, 250], ["support vector machines", "TREATMENT", 257, 280], ["profile alignments", "OBSERVATION", 113, 131], ["secondary structure", "OBSERVATION", 162, 181], ["solvent accessibility", "OBSERVATION", 192, 213]]], ["Distill [53] provides prediction of Contact Density defined as the Principal Eigenvector (PE) of a residue contact map.", [["a residue contact map", "PROBLEM", 97, 118], ["PE", "OBSERVATION", 90, 92]]], ["Baker generates 3D protein models using the de novo prediction algorithm Rosetta and then assigns domain boundaries using Taylor's structure-based domain identification technique.", [["the de novo prediction algorithm Rosetta", "TREATMENT", 40, 80], ["Taylor's structure", "TREATMENT", 122, 140]]], ["Maopus performs a template screening with PSI-BLAST and FFAS03.", [["FFAS03", "DNA", 56, 62], ["a template screening", "TEST", 16, 36], ["FFAS03", "TREATMENT", 56, 62]]], ["The SKELEFOLD approach implemented in Maopus is a de novo folding algorithm that uses vector representations of secondary structural elements; domain boundaries are defined with three sequence-based filters.", [["secondary structural elements", "DNA", 112, 141], ["The SKELEFOLD approach", "TREATMENT", 0, 22], ["a de novo folding algorithm", "TREATMENT", 48, 75], ["secondary structural elements", "PROBLEM", 112, 141], ["three sequence-based filters", "TREATMENT", 178, 206], ["secondary structural elements", "OBSERVATION", 112, 141], ["filters", "OBSERVATION", 199, 206]]], ["In the domfold method, the output from DomSSEA, DISOPRED and HHsearch is parsed to form a consensus.", [["HHsearch", "PROTEIN", 61, 69], ["the output", "TEST", 23, 33], ["DomSSEA", "PROBLEM", 39, 46], ["DISOPRED", "TREATMENT", 48, 56], ["output", "OBSERVATION_MODIFIER", 27, 33]]], ["In this case, only the first, which is considered to be the more reliable, was retained for further analysis.", [["further analysis", "TEST", 92, 108]]], ["Predicted domain boundaries were obtained from the CASP7 web page.", [["CASP7", "PROTEIN", 51, 56]]], ["95 proteins are considered.", [["95 proteins", "PROTEIN", 0, 11]]], ["Given that predictions were not deposited for each protein and for each prediction method, this results in a set of 1210 predictions [47].Multi-Domain Prediction Using Protein Length ::: METHODSTo predict, on the basis of the protein length, that a protein contains one domain or it is a multi-domain construct, a threshold value can be used.", [["each prediction method", "TEST", 67, 89], ["a threshold value", "TEST", 312, 329]]], ["If the protein is longer than the threshold value it consists of more than one domain.", [["the protein", "TEST", 3, 14], ["the threshold value", "TEST", 30, 49]]], ["On the contrary, a protein, smaller than this threshold value, would be predicted to contain only a single domain.", [["a protein", "TEST", 17, 26], ["this threshold value", "TEST", 41, 61], ["smaller", "OBSERVATION_MODIFIER", 28, 35]]], ["Consequently, a true positive (tp) is defined as a multi-domain protein, which is correctly predicted to be a multi-domain protein; a multi-domain protein that is predicted to contain a single domain is defined a false negative (fn); a single-domain protein predicted to be a multi-domain protein is defined a false positive (fp); and a correctly predicted single-domain protein is defined a true negative (tn).Multi-Domain Prediction Using Protein Length ::: METHODSThese four types of predictions can be used to estimate the reliability of this prediction methodology.", [["tp", "GENE_OR_GENE_PRODUCT", 31, 33], ["tp", "PROTEIN", 31, 33], ["multi-domain protein", "PROTEIN", 51, 71], ["multi-domain protein", "PROTEIN", 110, 130], ["multi-domain protein", "PROTEIN", 134, 154], ["fn", "PROTEIN", 229, 231], ["single-domain protein", "PROTEIN", 236, 257], ["multi-domain protein", "PROTEIN", 276, 296], ["fp", "PROTEIN", 326, 328], ["single-domain protein", "PROTEIN", 357, 378], ["tn", "PROTEIN", 407, 409], ["a true positive (tp)", "PROBLEM", 14, 34], ["a multi-domain protein", "TEST", 49, 71], ["a multi-domain protein", "PROBLEM", 108, 130], ["a multi-domain protein", "TEST", 132, 154], ["a single-domain protein", "TEST", 234, 257], ["a multi-domain protein", "TEST", 274, 296], ["domain protein", "TEST", 364, 378]]]]}